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Invasive Pulmonary Apsergillosis (IPA) is caused by inhalation of fungal conidia 
to the deep lung followed by germination and invasive hyphal growth in heavily 
immunosuppressed patients (e.g. those with hematologic malignancies, hematopoietic 
stem cell transplant recipients, and those undergoing solid organ transplantation).  Hyphal 
growth into pulmonary capillaries often leads to dissemination of the infection and high 
mortality rates despite current treatment and prophylactic modalities.  In addition, 
systemic antifungal therapy is often limited by drug toxicities, low and variable 
bioavailability, erratic pharmacokinetics, and drug interactions.  Although targeted drug 
delivery to the lungs has been investigated to reduce adverse events and promote drug 
efficacy, inconsistent pharmacokinetic properties following inhalation of poorly water 
soluble antifungals has prompted variable drug efficacy.  In this dissertation, inhaled 
voriconazole was investigated through in vitro and in vivo testing to evaluate 
pharmacokinetic properties, characterize drug safety and, determine drug efficacy as 
prophylaxis against IPA 
 viii
In Chapter 2, the in vitro evaluation of solution properties and aerosol 
characterization of aqueous voriconazole was evaluated.  Subsequent in vivo single and 
multiple dose pharmacokinetic studies demonstrated high drug concentrations were 
achieved in lung tissue and plasma following inhalation in contrast to previous reports of 
inhaled antifungals.  Inhaled voriconazole was then administered twice daily (BID, at 
08:00 and 16:00) in a murine model of IPA as described in Chapter 3 with significant 
improvements in animal survival over 12 days compared to both positive and negative 
control groups. 
As described in Chapter 4, voriconazole was then chronically administered BID at 
a high and low dose to rats over 21 days with a 7 day recovery period to assess dose 
tolerability through laboratory tests and histopathological changes to lung, liver, kidney, 
and spleen tissues.  Inhaled voriconazole was well tolerated through all assessments but 
with signs of mild acute histiocytosis in lung tissue without other signs of inflammation. 
Chapter 5 expanded the single inhaled dose pharmacokinetic profile in lung tissue 
and plasma with determination of additional pharmacokinetic parameters through 
compartmental modeling.  Peak and trough voriconazole concentrations were also 
evaluated in mice as well as rats following multiple doses administered over 12 hours 
(Q12H) as opposed to BID.   
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Chapter 1: Advances in the Pulmonary Delivery of Poorly Water 




Therapeutic administration of active pharmaceutical ingredients (APIs) to the 
lungs has long historical significance (1). Despite the long term use of therapeutic 
aerosols, the scientific principles governing the in vivo performance of inhaled drugs 
have only recently been probed. In the modern age of drug research and development 
focused on pulmonary drug delivery, the fate of inspired aerosols has been correlated to 
patient specific as well as formulation/device factors. The in vivo action of inhaled 
aerosols can be affected by patients through the control and regulation of the physiologic 
parameters of breathing; e.g. including respiration rate, tidal volume, inhalation air flow, 
breath holding, etc. (2).  Additionally, the formulation scientist can influence in vivo 
aerosol performance through manipulation of the interrelationships between the 
formulation and inhalation device, e.g. pressurized metered dose inhaler (pMDI), 
nebulizer, or dry powder inhaler (DPI).  These modifiable relationships govern the 
aerodynamic particle size distribution, pH, tonicity, and physiologic compatibility of the 
inspired aerosol.   
 
Traditionally, inhaled APIs have been intended for local drug action in the lungs 
for treatment of topical conditions in the airways; examples include the treatment of 
airway inflammation, lung diseases, and lung infections.  However, drug delivery to the 
lungs has recently received increased scientific attention and expansion. This renewed 
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interest coincides with advances in particle engineering technologies (3, 4), advances in 
biotechnology-derived therapeutic macromolecules (5), and new APIs with low and/or 
erratic bioavailability (6-8). Much of the expanded interest in pulmonary drug delivery 
focuses on systemic drug delivery via the lungs due to the rapid bioavailability and 
avoidance of the pH, food effects, enzymatic, and first-pass metabolic barriers following 
oral drug administration. Despite these potential advantages, inhaled drugs must 
overcome numerous barriers for adequate deposition in the lung. 
 
Several excellent reviews have explained in detail the physiologic barriers to 
inhaled drug delivery (7, 9-11).  Briefly, the lungs are a natural particle filter due to 
numerous cellular and physiological factors.  The majority of lung airway epithelium is 
ciliated with a mucous layer that can prevent drug from depositing in the deep lungs and 
promote drug ingestion through the mucociliary escalator. Additionally, the airways in 
the lung subdivide through a tortuous pathway of bifurcations throughout the lung that 
allow air communication with the gas-exchange specializing lung structures, the alveoli, 
also referred to as the deep lung.  An inspired particle must therefore, avoid contact with 
the ciliated and mucous covered epithelium to avoid ingestion, via the mucociliary 
escalator, as well as traverse numerous potential impaction sites for then deposition along 
the airways or in the deep lung.  The aerodynamic properties and particle behavior of the 
inspired particle are therefore crucial for drug delivery to the lungs, typically 1-5µm in 
size (9).  The inspired particle must also be physiologically compatible with the lung 
membranes (i.e. isotonic, iso-pH, non-immunogenic, etc.) to avoid airway hyper-
responsiveness, cough or airway spasticity, or inflammation (12).  The deposition of 
particles can also be affected by the increasing relative humidity in the lungs as a particle 
is inspired into the deep lung (13). 
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Once a particle has bypassed these pulmonary barriers and been deposited in the 
alveolar region, the API must be absorbed for systemic drug action. The ability for APIs 
to be absorbed across the alveolar membrane has not been investigated to the degree of 
gastrointestinal (GI) drug absorption. Mechanistic explanations of GI absorption have 
recently been re-reviewed and form a foundation for explaining pulmonary drug 
absorption (14, 15). The primary differences between modeling GI and pulmonary drug 
absorption focus on the fact that the lungs have different physiologic and cellular 
structures at absorption sites, have a dramatically decreased metabolic capacity, lack the 
degree of active transport sites, and have a much higher surface area and corresponding 
blood flow than the GI tract.   
 
An excellent review by Sakagami was published in 2006 and summarized 
numerous methodological approaches to investigating the mechanisms underlying 
pulmonary drug absorption and disposition (16). As with any model, control and 
evaluation of the numerous variables associated with pharmacokinetic profile and 
properties of a drug following inhalation is very difficult. As a result, researchers have 
employed ex vivo, cellular, in silico, and in vitro models to isolate and quantify the 
different variables present in whole animals when investigating the factors affecting drug 
absorption in the lungs. However, these isolated or simplified models do not adequately 
simulate the numerous factors involved with pulmonary drug delivery in a living system.  
 
To further complicate the literature describing the pharmacokinetics of inhaled 
drug delivery, researchers have used whole animal models with varying methods of 
pulmonary drug administration, i.e. intratracheal instillation of a liquid, orotracheal 
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intubation and administration of a liquid spray or powder insufflator, and natural whole-
body or nose-only exposure. The method of pulmonary drug administration can affect the 
reported results due to species-specific differences in the respiratory system between 
animals. For example, the majority of mammal species are obligate nose breathers with 
the inability to breathe through the mouth, causing airflow differences and resultant 
differences in deposition from humans (17). Although these whole animal modeling 
systems have difficulty isolating the specific contributing factors involved in drug 
absorption, they are applicable as screening mechanisms for different formulations and 
can represent a more realistic approach to understanding drug absorption in the lungs. Of 
the numerous factors that can influence drug absorption from the lungs, the effect of drug 
solubility, solubility enhancing excipient, and drug solution or solid state for poorly water 
soluble APIs has not been explained in whole animal or in isolated component systems 
for pulmonary drug administration.   
 
Poorly water soluble APIs are becoming increasingly common for new chemical 
entities (18-21).  A compound with poor aqueous solubility presents challenges and 
limitations for formulation development and the clinical utility of a dosage form, 
particularly in the lungs. The absorption would be limited by the number of dissolved 
molecules for diffusion through biological membranes.  Although there is no unified 
definition for poorly water soluble drugs, the United States Pharmacopeia (USP) uses 
descriptive terms related to quantifiable solubility ranges, i.e. very soluble (>1 g mL-1) to 
insoluble (<0.1 mg mL-1) (22).  Instead, the Center for Drug Evaluation and Research 
(CDER) describes solubility as “high” or “low” based on the ability of 250 mL of 
dissolution medium to dissolve the dose of drug by in vitro methods (23).  This 
categorical classification is intended to describe the impact of solubility on drug 
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absorption and bioavailability (24).  However, the definition of low solubility has little 
physiologic significance on absorption when applied to pulmonary drug delivery due low 
masses in inhaled drug doses and a small and dispersed fluid volume within the lungs (7, 
25, 26).  Therefore, the relationship between low solubility and observed 
pharmacokinetic properties of drugs when administered to the lungs does not fall into the 
definitions and testing parameters that are applicable for other routes of drug 
administration. 
 
Several therapeutic agents with low aqueous solubilities have been investigated 
for pulmonary drug delivery.  These agents include: corticosteroids in the management of 
asthma and inflammation; anti-infective agents to treat and prevent bacterial, fungal, and 
viral pneumonias; chemotherapeutic agents for lung cancers and tumors; and numerous 
other APIs.  The low solubility of these APIs can influence the absorption and retention 
of the drug in the lung tissue and can directly affect drug activity, side effects, and dosing 
regimens. Accordingly, this article will review the literature available describing the 
pulmonary drug administration of poorly soluble APIs where some pharmacokinetic data 
is available. Although drug absorption across membranes in the lungs is the parameter of 
interest, few researchers directly measure absorption rates across the pulmonary 
epithelium, e.g. mean absorption times (MAT) or absorption rate constants (kabs).  
Instead, proxy markers of drug absorption could include other observed pharmacokinetic 
parameters such as maximal drug concentration in the blood and in the lung tissue if 
available (Cmax), the time to reach maximal concentrations (tmax), elimination half-life 
(t1/2) and drug exposure (AUC). These proxy markers will allow comparative 
relationships to be established to evaluate the influence of formulation and solubility 
enhancements have on drug absorption.  Therefore, the influence of solubility and 
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formulation-based solubility enhancements on pharmacokinetic parameters following 
inhalation of various classes of poorly water soluble drugs, including corticosteroids, 
antifungals, oligopeptides, and opioids, will be reviewed. 
 
1.2. INHALED CORTICOSTEROIDS 
Inhaled corticosteroids are the most commonly inhaled class of poorly water 
soluble API.  They are therapeutically used to inhibit inflammatory processes in the 
lungs, primarily in management of asthma. These structurally related agents have a 
steroid backbone, some with modifications to the steroid ring, and appended functional 
groups (27).  These modifications primarily affect ligand-receptor interactions and lead to 
varied binding affinities with the glucocorticoid receptor.  Because all corticosteroids 
affect the same receptor, competitive binding assays have allowed the relative potencies 
of these agents to be stratified as fluticasone propionate > beclomethasone-17-
monopropionate > budesonide > beclomethasone dipropionate > triamcinolone acetonide 
(28). These relative potencies affect drug efficacy as well as the side effect profile and 
propensity for long-term adverse events.  However, many adverse events associated with 
inhaled corticosteroids result from systemic exposure following absorption. In addition to 
these structure-based pharmacodynamic properties, most corticosteroids remain poorly 
water soluble compounds with aqueous solubilities of 21µg mL-1 for triamcinolone 
acetonide, 16µg mL-1 for budesonide, 0.14µg mL-1 for fluticasone propionate, and 0.13µg 
mL-1 for beclomethasone dipropionate (15.5µg mL-1 for the beclomethasone-17-
monopropionate active metabolite) (29).  Reported log Po/w values also indicate these 
agents are very lipophilic with values of 3.4 for triamcinolone acetonide, 3.6 for 
budesonide, 4.5 for fluticasone propionate, and 4.9 for beclomethasone dipropionate (4.3 
for beclomethasone-17-monopropionate).  The molecular weights for these compounds 
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are 430.5 g mol-1 for budesonide, 434.5 g mol-1 for triamcinolone acetonide, 500.6 g mol-1 
for fluticasone propionate, and 521.1 g mol-1 for beclomethasone dipropionate.  These 
high log P values and small molecular weights indicate the potential for good passive 
membrane permeability, leading to dissolution-limited drug absorption following 
inhalation.   
 
Ideally, an inhaled corticosteroid would have high potency, be retained in the 
airways and lung tissue for prolonged anti-inflammatory action, and would then have low 
drug absorption leading to low systemic drug exposure with consequently, low incidence 
of adverse events.  Accordingly, several researchers have investigated the 
pharmacokinetic properties of inhaled corticosteroids to understand the mechanisms of 
drug deposition and absorption from the lungs to the systemic circulation (30-35). Some 
pharmacokinetic profiles of these agents are also influenced by the structural differences 
between the APIs, specifically the avenues of clearance and metabolic pathways between 
the various agents (36). The other pharmacokinetic properties of inhaled corticosteroids, 
including the Cmax, tmax, AUC, and t1/2, vary between the agents based, in part, on the 
physicochemical properties of the API. The interrelationship of pharmacokinetic and 
pharmacodynamic properties of this drug class defines their clinical utility. For that 
reason, many researchers have investigated adverse events of these agents through the 
biomarker of endogenous cortisol secretion suppression and corresponding 
bioavailabilities between inhaled and other routes of administration (37). However, the 
utility of a biomarker in this current investigation is limited when correlating the 
influence of drug solubility and solubilization properties of the formulation on drug 
absorption following inhalation.  Through independent evaluation of corticosteroids with 
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reported pharmacokinetic parameters, categorical relationships can describe the influence 
of solution state and formulation on pulmonary absorption of these inhaled agents.  
 
1.2.1. Fluticasone propionate 
(See Table 1.1A) The majority of systemic pharmacokinetic data on inhaled 
fluticasone propionate is with the dry powder inhaler (DPI) formulation branded as the 
Flutide®, Flovent®, or Flixotide® administered with the Diskhaler®, Diskus®, or 
Accuhaler® devices (30, 38-42).  These formulations use micronized fluticasone 
propionate blended with a lactose carrier particle and de-aggregate from the carrier via 
turbulent airflow through the device.  Some pharmacokinetic data is also available with 
the pressurized metered dose inhaled (pMDI) branded as Flovent®.  The pMDI 
formulation contained a microcrystalline suspension of fluticasone propionate in a 
propellant mixture of CFC-11 and CFC-12 with soya lecithin as a surfactant and lubricant 
for the metering valve.  Both the DPI and pMDI formulations deliver solid fluticasone 
propionate particles to the lung and rely on particle size reduction of the API to improve 
the rate of dissolution for this poorly water soluble drug. Therefore, fluticasone 
propionate has little data to describe the influence of drug solubilization and solubility 
enhancement through the formulation on drug absorption from the lungs.  However, it 
does serve as a reference and comparator for the remainder of the inhaled corticosteroids 
with a moderate aqueous solubility (0.14 µg mL-1), log P value (4.5), and molecular 
weight (500.6 g mol-1) for this class of poorly water soluble compounds. 
 
Following a single inhalation, maximal concentrations were observed after an 
average of 0.9 to 1.88 hours (54-118 minutes).  Dose normalized maximal concentrations 
ranged from 0.1 up to 0.3 pg mL-1µg-1 while dose normalized AUC values ranged from 
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0.3 to 3.0 pg hr mL-1 µg-1 with no real difference between the DPI and pMDI forms.  
Concentrations and AUC values were not controlled for the influence of oral ingestion of 
the drug through oral administration of activated charcoal and must be assumed to have 
been affected by minor, but non-trivial, oral ingestion of fluticasone propionate.  
However, despite possible oral ingestion of the inhaled product and a 3 to 10 fold 
difference in maximal drug concentrations and drug exposure, plasma fluticasone 
concentrations remained very low, in the pg to ng range, following large inhaled doses.  
The very low systemic fluticasone propionate concentrations indicate very little drug 
absorption from the inhaled particulate systems.   
 
Several researchers reported the mean residence time (MRT), the average time a 
molecule resides within the system from absorption to elimination, for fluticasone 
following inhalation.  The reported MRT values were 7.1 to 12 hours for DPIs and 5.3 
hours for the pMDI, indicating an prolonged but variable time for the drug to be retained 
in the studies population.  Additionally, Brindley et al. specifically investigated the 
absorption kinetics of fluticasone propionate following inhalation using both the DPI and 
pMDI devices (30).  Following inhalation from both DPI and pMDI devices, 50% of the 
bioavailable dose was absorbed within 1.6 to 2.4 hours (95 to 145 minutes) while 90% of 
the dose was absorbed by 11.4 to 12.3 hours.  The average time it takes for a drug 
molecule to be absorbed, the mean absorption time (MAT), was 4.3 to 4.4 hours.  The 
authors identified that fluticasone propionate is retained in the lungs for an extended 
period of time with an initial rapid phase of drug absorption followed by a period of 




(See Table 1.1B) Inhaled formulations of budesonide were more diverse than 
those for fluticasone propionate and included DPI, pMDI, and nebulizer formulations.  
The branded DPI products included the Pulmicort Turbohaler®, now referred to as the 
Flexhaler®, with only micronized budesonide in the formulation, and the Giona® 
Easyhaler® containing budesonide blended with a lactose carrier particle (31, 39-41, 43).  
The pMDI formulation, Pulmicort® (no longer available in the United States), contained 
a micronized suspension of budesonide with sorbitan trioleate as a metering valve 
lubricant , and a propellant mixture of CFC-11, CFC-12, CFC-114 (44).  Budesonide 
suspensions for nebulization were also tested and included the marketed Pulmicort 
Respules® and two different novel nano-scale suspensions (44-46).  The Pulmicort 
Respules® contained a micronized suspension of budesonide with disodium edetate, 
sodium chloride, sodium citrate, citric acid, polysorbate 80, in water for injection.  The 
first nano-suspension from Kraft et al. did not contain information on the formulation.  
However, the second nano-suspension from Shrewsbury et al. contained submicron 
budesonide in a sterile aqueous formulation containing surface modifiers, possibly 
including a cyclodextrin (47), and sodium chloride, citric acid, sodium citrate, disodium 
edentate dehydrate in water.  Despite the differences, the DPI, pMDI, and suspension for 
nebulization formulations all deliver solid budesonide particles to the lung following 
inhalation and utilize particle size reduction to improve the dissolution rate of the drug.  
The low aqueous solubility (16 µg mL-1), high log P (3.6), and low molecular weight 
(430.5 g mol-1) promote a model of solubility limiting drug absorption following 
inhalation of budesonide particles.  However, the novel nano-suspension formulations 
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contain excipients that could improve or augment drug solubility in the lung and 
subsequent drug absorption following inhalation.  
 
Following inhalation of budesonide, tmax values were achieved within 0.13 to 0.58 
hours (8 to 35 minutes) for the DPI devices, 0.15 to 0.24 hours (9 to 14 minutes) for 
micronized suspensions, and 0.051 to 0.19 hours (3 to 11 minutes) for nano-sized 
suspensions with no values reported for the pMDI. Dose normalized Cmax values for DPI 
devices, the pMDI, micronized suspensions, and nano-sized suspensions ranged from 0.9 
to 1.8 pg mL-1µg-1, 0.6 pg mL-1µg-1 (assuming a 2 hr tmax due to limited reported data), 
0.7 to 1.3 pg mL-1µg-1, and 1.8 to 2.5 pg mL-1µg-1, respectively.  These Cmax ranges 
indicate approximate equivalence for reported maximal concentrations for all methods of 
budesonide administrations except a two-fold increase in reported concentrations for 
nano-scale suspensions. However, no difference was observed for dose normalized AUC 
values between delivery methods with ranges of 2.5 to 4.5 pg hr mL-1 µg-1 for DPI 
devices, 2.1 to 3.3 pg hr mL-1 µg-1 for micronized suspensions, and 1.1 to 3.3 pg hr mL-1 
µg-1 for nano-sized suspensions with no reported value for the pMDI.  As mentioned for 
inhaled fluticasone propionate, no report was made to control for possible oral ingestion 
of budesonide following inhalation.  In a similar manner, the reported Cmax and AUC 
values could have a minor, but non-trivial, contribution of orally absorbed budesonide.  
The elimination half-life, t1/2, for inhaled budesonide also varied by the method of 
inhalation with DPIs ranging from 2.1 to 3.5 hours, the micronized suspension reporting 
2.43 hours, and the nano-scale suspension reporting 1.17 to 2.33 hours.  Of note, Kraft 
and colleagues reported much higher t1/2 values, from 5.42 to 6.62 hours for inhaled 
micro and nano-sized suspensions without corroboration from the other sources, possible 
indicating a sampling outlier.  Some researchers reported MRT values for DPI devices 
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that ranged from 0.6 to 3.9 hours, indicating varied but relatively rapid drug transit 
through and low drug retention by the patient. 
 
1.2.3. Beclomethasone dipropionate (Beclomethasone 17-monopropionate) 
(See Table 1.1C) Beclomethasone dipropionate is converted in the lungs via 
epithelial esterases from a functional pro-drug into the active and more potent 
beclomethasone 17-monopropionate.  Therefore, pharmacokinetic studies involving 
beclomethasone specify the molecule of interest and involve a metabolic process if 
results are reported for the mono-propionate metabolite.  The di- and monopropionate 
forms have different solubilities (0.13 µg mL-1 for the dipropionate and 15.5 µg mL-1 for 
the monopropionate) but similar log P values (4.9 for dipropionate and 4.3 for 
monopropionate) and molecular weights (521.1 g mol-1 for dipropionate and 465.0 g mol-
1 for monopropionate).  Although the active metabolite has a 100-fold improvement in 
aqueous solubility over the dipropionate form, absorption must take place with the pro-
drug dipropionate prior to metabolic conversion.  Despite these metabolic complications 
in assessing systemic pharmacokinetics following inhalation of beclomethasone 
dipropionate, investigators have administered beclomethasone dipropionate as a 
nebulized solution in addition to the typical DPI and pMDI devices reported by other 
researchers.   
 
Specifically, Esposito-Festen et al. generated very low dose mono-disperse 
particle sized aerosols from an alcoholic solution containing budesonide dipropionate and 
administered them to healthy volunteers (48).  This formulation delivered aerosolized 
droplets to the lung that contained beclomethasone in solution as a molecular dispersion.  
In contrast, particle size reduction of the API was utilized for pMDI and DPI 
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formulations.  A pMDI formulation containing a suspension of micronized 
beclomethasone dipropionate in CFC-11 and CFC-12 with oleic acid as a valve lubricant, 
marketed as Beclovent®, was tested in human patients with and without concomitant oral 
administration of activated charcoal to eliminate oral ingestion and absorption of the API 
following inhalation (49).  Pharmacokinetic values were also evaluated for a DPI device 
used to administer micronized beclomethasone dipropionate on lactose carrier particles, 
branded as Becodisks®, to stable human asthma patients (41). 
 
Marked differences were observed for inhaled beclomethasone dipropionate, and 
the active metabolite beclomethasone 17-monopropionate, based on the formulation.  
Tmax values for inhaled particulate formulations of beclomethasone dipropionate from 
DPI and pMDI devices were 0.8 to 2.5 hours (48 to 150 minutes).  In contrast, tmax values 
were much more rapid for inhaled alcoholic solutions with values of 0.17 to 0.33 hours 
(10 to 20 minutes).  Additionally, the dose normalized Cmax values for DPI and pMDI 
devices were 0.41 and 0.94 pg mL-1µg-1, respectively, while normalized AUC values with 
the same devices were 2.13 and 3.85 pg hr mL-1 µg-1.  However, when patients received 
oral charcoal to negate gastrointestinal absorption of the drug when administered with the 
pMDI dose, normalized Cmax and AUC values were 0.71 and 2.40 pg hr mL-1 µg-1, 
indicating substantial increases in plasma concentrations of beclomethasone  
17-monopropionate due to oral ingestion and absorption after normal inhalation with the 
pMDI.  These findings are in stark contrast with pharmacokinetic results reported 
following inhalation of a solubilized form of beclomethasone dipropionate.  When 
administered as a nebulized alcoholic solution, dose normalized Cmax values ranged from 
3.9 to 9.1 pg mL-1µg-1.  These values resulted in a 4 to 20 fold increase in maximal 
concentrations compared to inhaled particulate drug via DPI or pMDI devices.  
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Additionally, dose normalized AUC values for the inhaled alcoholic solution ranged from 
6.0 to 16.0 pg hr mL-1 µg-1, representing a 2.5 to 22.5 fold increase in drug exposure.  
The administration of an alcoholic solution of beclomethasone dipropionate promoted 
much more rapid maximal concentrations of the active metabolite as well as markedly 
elevated drug concentrations and drug exposure compared to inhalation of solid 
particulate forms of the API.  
 
1.2.4. Triamcinolone acetonide 
(See Table 1.1D) Inhaled triamcinolone acetonide was administered to human 
subjects by both DPI and pMDI devices.  The DPI device used was a breath-actuated 
inhaler, the Ultrahaler®, to optimize lung deposition of the inhaled powder containing 
micronized triamcinolone acetonide blended with lactose as a carrier particle (50).  The 
pMDI formulations included CFC and HFA formulations of triamcinolone acetonide, 
marketed as Azmacort® and developed as Azmacort® HFA (43, 51).  The CFC-based 
formulation contained a microcrystalline suspension of triamcinolone acetonide in CFC-
12 and 1% w/w dehydrated alcohol to improve drug loading of the API in the propellant.  
The Azmacort® HFA inhaler contained a microcrystalline suspension of triamcinolone 
acetonide in HFA 143-a but insufficient detail was provided to identify other excipients if 
present.  Both DPI and pMDI formulations utilized particle size reduction to improve the 
dissolution rate of the API with an insignificant contribution of the alcohol in the CFC-
pMDI formulation to alter solubility of triamcinolone acetonide after dose administration.  
Additionally, Lim et al. administered oral activated charcoal to some patients to assess 
the influence of oral ingestion and gut absorption following pMDI and DPI use (50).  
Triamcinolone acetonide has the highest aqueous solubility (21 µg mL-1) and lowest log 
P value (3.4) for these poorly water soluble inhaled corticosteroids.  However, a log P of 
 15
3.4 is still very high and suggests good membrane permeability, particularly with a mid-
range molecular weight (434.5 g mol-1).   
 
Following inhalation, tmax values for the DPI device was 0.25 hours (15 minutes) 
while pMDI formulations peaked at 0.66 to 1.74 hours (40 to 104 minutes).  Despite 
these differences in the speed to achieve maximal concentrations, dose normalized Cmax 
values were very similar for both DPI and pMDI devices.  Cmax values for the DPI inhaler 
ranged from 1.77 to 2.25 pg mL-1µg-1 while pMDI values ranged from 0.69 to  
2.52 pg mL-1µg-1.  In contrast, AUC values were more varied with a range of 6.88 to  
8.10 pg hr mL-1 µg-1 for the DPI formulation and 2.69 to 12.90 pg hr mL-1 µg-1 for the 
pMDI formulation.  This variability could be due to oral ingestion of triamcinolone 
acetonide as demonstrated by Cmax ratios between DPI and pMDI formulations of 2.44 
under typical usage and 1.56 with oral ingestion of charcoal.  A similar pattern was 
reported for AUC ratios between DPI and pMDI formulations without and with charcoal 
of 1.99 to 1.44, respectively.  No change was reported in the elimination half-life based 
on device and formulation with values ranging from 2.2 to 2.5 hours.  
 
1.2.5. Comparison of Inhaled Corticosteroids 
The reduction in inhaled corticosteroid absorption from the lungs is clinically 
relevant to minimize adverse events associated with systemic drug exposure for all 
inhaled corticosteroids.  All included studies employed a method to enhance drug 
solubility or improve the rate of drug dissolution including particle size reduction of the 
API (i.e. micronization or nano-scale particle production) or drug solubilization in a non-
aqueous solvent.  The methods of solubility enhancement demonstrated that following µg 
dose masses, normalized plasma drug concentrations were only in the pg mL-1 range with 
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low total drug exposure, as indicated by normalized AUC values, for all the formulations 
and drug deliver devices.  However, the differences in pharmacokinetic parameters 
within and in-between formulations were illustrative for solubilization effects on 
pulmonary drug absorption.  Specifically, systemic tmax values were within two hours, 
with the majority of reported values within one hour, for all reported drug-formulation 
combinations.  The fastest relative tmax values, when compared between different 
formulations of the same API, were obtained for nano-budesonide suspensions (≥3-times 
faster than other formulations) and alcoholic solutions of beclomethasone dipropionate 
(≥4-times faster than other formulations).  These values suggest that increasing the 
velocity of particle dissolution, through administration of a pre-solubilized drug or 
through extreme particle size reduction into the nano-scale range, promoted the most 
rapid drug absorption following inhalation of a poorly water soluble API (52-54).  
However, no consistent differences were observed in dose normalized Cmax and AUC 
values for DPI, pMDI, or nebulized suspensions when the formulation contained micro- 
to nano-meter range particles, suggesting total drug absorption was eventually achieved 
from the lungs.  A striking elevation in drug concentrations and drug exposure were 
observed for nebulized alcohol solutions suggesting pre-solubilized drug actually can 
improve the extent of drug absorbed from the lungs (55). 
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1.3. INHALED ANTIFUNGALS 
Most typical fungal infections are found on the skin, genitorurinary, or 
gastrointestinal tract and involve superficial infiltration of the fungi into the epithelium or 
mucosal membranes and are readily treated with topical or oral antifungal therapy (56).  
However, systemic fungal infections can involve numerous organs and systems and are 
much more difficult to treat with some causative organisms and infections associated 
with very high rates of mortality (57-59).  Many systemic fungal infections begin with 
the inhalation of fungal spores, or conidia, into the deep lung followed by the 
establishment of an infection and potential dissemination to the distal organs via the 
systemic circulation (60).  However, systemically administered antifungal agents are 
limited by poor tissue penetration into lung tissue and associated with high rates of 
adverse events and the potential for serious drug interactions (61, 62).  Therefore, 
targeted antifungal delivery to the lung could elevate and retain drug concentrations in 
the lung for improved efficacy and reduce systemic drug exposure to reduce adverse 
events and drug interactions.  Theoretically, an ideal inhaled antifungal would have 
minimal drug absorption following inhalation for optimum efficacy and minimal adverse 
events and drug interactions. 
 
Antifungal pharmacology, like that for all anti-infective agents, focuses on 
selective targeting of microbiological or biochemical differences between the pathogen 
and host.  For fungal infections, the available targets have been difficult to identify and 
optimize due to the similarities in eukaryotic cellular physiology and biochemical 
pathways between fungal and animal cells.  However, the most commonly used 
antifungals in systemic fungal infections target ergosterol, a cellular membrane stabilizer 
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and fungal equivalent to animal cholesterol.  Polyene antifungals, including  
amphotericin B, form drug-ergosterol complexes to create non-selective trans-membrane 
channels that disrupt cellular integrity.  The low aqueous solubility, log P value, and 
relatively large molecular weight (0.25 µg mL-1, 1.6, and 924 g mol-1 , respectively, for 
amphotericin B) allow the polyene to partition into fungal cell membranes for 
pharmacologic activity (63).  Triazole antifungals, including itraconazole, inhibit 
ergosterol biosynthesis through reversible antagonism of fungal cell cytochrome P450 
isomers (64).  Triazoles are also very poorly water soluble but with a much higher log P 
values indicative of better lipophilicity (approximately 0.001 µg mL-1 and 5.7 for 
itraconazole, respectively) (65, 66).  The low solubility and high lipophilicity of triazole 
antifungals as well as relatively large molecular weight (705.6 g mol-1 for itraconazole) 
allow them to be absorbed into fungal cells and be metabolized by fungal cytochrome 
P450 enzymes responsible for normal ergosterol biosynthesis.  Accordingly, the 
evaluation of antifungal pharmacokinetic parameters following inhalation will elucidate 
additional influences of drug solubilization and solubility enhancement on drug 
absorption. 
 
1.3.1. Amphotericin B 
(See Table 1.2A) The medical management of fungal infections was limited by 
poor pharmacologic selectivity between eukaryotic cellular physiology in both fungal and 
animal cells until the identification and development of amphotericin B in the  
mid-twentieth century (67).  Amphotericin B preferentially forms non-selective pore or 
channel complexes with fungal cell membrane ergosterol, a membrane stabilizer 
analogous to cholesterol in animal cell membranes, to cause a loss of osmotic integrity 
and ultimately fungal cell death (68, 69).  These ergosterol-amphotericin B complexes 
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form through nonspecific Van Der Waals forces between the hydrophobic region of the 
amphiphilic amphotericin B molecule and the lipophilic ergosterol molecule (70).  
Amphotericin B is a 38-membered cyclic lactone ring composed of a distinct lipophilic 
region, with seven conjugated ester bonds, and a separate hydrophilic region with ester 
and ether bonds, a carboxylic acid group, a primary amino group in an attached sugar 
moiety, and several hydroxyl groups.  Amphotericin B has a low aqueous solubility  
(0.25 µg mL-1), a large molecular weight (924 g mol-1), and lower than expected log P 
value (1.6) that allow the API to distribute into the membrane to be pharmacologically 
active.   
 
Accordingly, four commercially available amphotericin B formulations use 
stabilizers and/or solubilizers to produce pharmaceutically acceptable products.  
Although all have been administered in an off-label manner via inhalation for analysis of 
efficacy and tolerability, only reports with the amphotericin B deoxycholate 
(Fungizone®, hereafter referred to as AmB-d) and liposomal amphotericin B 
(AmBisome®, hereafter referred to as L-AmB) formulations have associated systemic 
pharmacokinetic parameters (71, 72).  Some investigators have also reported lung tissue 
or fluid drug concentrations to demonstrate high drug concentrations in the lung 
following inhalation (72-75).  Additionally, Diot et al. reported serum amphotericin B 
concentrations following nebulization of pure amphotericin B powder and water 
dispersions without additional excipients (76).  AmB-d is a suspension for reconstitution 
containing deoxycholate as a solubilizer and stabilizer and sodium phosphates as a buffer 
that forms a colloidal dispersion when reconstituted.  L-AmB is suspension for 
reconstitution containing a bilayered liposome of amphotericin B in lipid membranes of 
hydrogenated soy phosphatidylcholine, cholesterol, and distearoylphosphatidylglycerol 
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(2:0.5:0.8 ratio) in a 1:10 ratio.  Aerosols of both products have been inhaled using 
various nebulizers and systemic pharmacokinetic properties have varied widely. 
 
Following inhalation of all formulations, lung tmax values were approximately  
1 hour while tmax values in bronchoalveolar lavage fluid (BAL) following inhalation of 
AmB-d ranged from 0.5 to 4 hours (30 to 240 minutes).  Similarly, serum tmax values 
following inhalation of pure amphotericin B ranged from 0.5 to 3.5 hours (30 to  
210 minutes).  However, there was great variability in dose normalized Cmax and AUC 
values for lung tissue, BAL, and plasma/serum values based on the formulation.  For 
example, inhaled doses of mg masses produced concentration values in serum, lung 
tissue, and BAL fluid ranged that spanned over 3 orders of magnitude across the µg mL-1 
to ng mL-1 range.  Specifically, dose normalized Cmax values in serum following 
inhalation of pure amphotericin B ranged from 1.1 to 4.2 ng mL-1 mg-1 while plasma Cmax 
values ranged from 0.8 to 45 ng mL-1 mg-1 following inhalation of AmB-d and were  
5 ng mL-1 mg-1 for L-AmB.  In stark contrast, Cmax values ranged from 7.3 to  
2,625 ng mL-1 mg-1 for BAL fluid and from 623 to 987 ng g-1 mg-1 for lung tissue 
following inhalation of AmB-d.  The dose normalized lung tissue Cmax value was also 
379 ng g-1 mg-1 following inhalation of L-AmB.  The dose normalized AUC following 
inhalation of AmB-d in BAL fluid ranged from 40 to 96 ng hr mL-1 mg-1.  The wide 
range of observed differences in these pharmacokinetic parameters based on the 
formulation obfuscated the trends for absorption of inhaled amphotericin B.  However, 
the ratio of lung to plasma concentrations for inhaled AmB-d was over 1000:1, indicating 




(See Table 1.2B) Itraconazole must distribute into fungal cells to inhibit the 
cytochrome P450 enzymes responsible for ergosterol biosynthesis.  However, 
itraconazole has dissolution limited absorption due to the extremely low aqueous 
solubility (1 ng mL-1).  Several particle engineering technologies, including cryogenic-
based spray-freeze into liquid (SFL) (77), ultra-rapid freezing (URF) (78), and non-
cryogenic evaporative precipitation into aqueous solution (EPAS) (79) have been 
investigated with itraconazole as a model API (80).  These processes have been reviewed 
elsewhere, but briefly produce amorphous (SFL and URF) or crystalline (EPAS) nano-
structured powder agglomerates with enhanced dissolution properties (81).  These 
engineered powders have been nebulized as dispersions to rodent to evaluate the 
pharmacokinetic parameters following inhalation (80, 82-84).  Most of these manuscripts 
reported lung tissue and plasma drug concentrations allowing better evaluation of drug 
absorption from the lungs.  Additionally, these researchers have provided detailed 
formulation information allowing a more thorough comparative analysis of the 
contributing factors involved in solubility and solubilization on pulmonary drug 
absorption.  Specifically, EPAS formulations contained itraconazole and surfactant(s) 
including polysorbate 20 or polysorbate 80 and poloxamer 407.  SFL formulations 
contained polysorbate 80 with or without poloxamer 407.  In contrast, the reported URF 
formulation contained mannitol and lecithin. 
 
Following inhalation, lung tmax values ranged from 0.5 to 1.0 hours (30 to  
60 minutes) for all itraconazole formulations while plasma tmax were delayed with values 
of 5.4 hours (342 minutes) for SFL itraconazole and 2.0 hours (120 minutes) for URF 
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itraconazole.  Dose normalized lung Cmax values were 1.7 µg g-1 mg-1 for the crystalline 
EPAS formulation with polysorbate 20.  However, normalized maximal lung 
concentrations increased approximately 3-fold, to 5.4 µg g-1 mg-1, when containing 
polysorbate 80 and poloxamer 407.  This elevated lung concentration was associated with 
a low normalized plasma Cmax value of 0.44 µg mL-1 mg-1.  In comparison, the dose 
normalized lung Cmax value for amorphous SFL formulations containing only polysorbate 
80 was 0.48 µg g-1 mg-1.  The SFL formulation maximal lung concentrations also 
increased to 1.1 to 2.4 µg g-1 mg-1 when poloxamer 407 was added.  The corresponding 
SFL itraconazole, containing polysorbate 80 and poloxamer 407, produced plasma Cmax 
values from 0.1 to 0.2 µg mL-1 mg-1 and were much lower than those reported for the 
comparable EPAS formulation.  In contrast, the amorphous URF formulation contained 
only mannitol and lecithin but had a high dose normalized lung Cmax value of 3.0 µg g-1 
mg-1 but low plasma Cmax value of 0.2 µg mL-1 mg-1.  Similar trends were observed for 
dose normalized AUC values.  Namely, the addition of poloxamer 407 to EPAS 
formulations increased normalized lung AUC values from 8.7 µg hr g-1 mg-1 up to  
14.8 µg hr g-1 mg-1 and SFL formulations from 1.6 µg hr g-1 mg-1 to a range of 5.8 to  
15.1 µg hr g-1 mg-1.  The normalized lung AUC values for URF itraconazole of  
21.1 µg hr g-1 mg-1 were also the highest reported.  Dose normalized plasma AUC values 
also followed lung AUC trends with a range of 0.1 to 0.3 µg hr g-1 mg-1 for SFL 
itraconazole that contained polysorbate and poloxamer achieving while the URF 
formulation produced a normalized plasma AUC of 0.8 µg hr g-1 mg-1.  Despite these 
consistent trends in concentration and AUC values for EPAS, SFL, and URF itraconazole 
formulations, the lung elimination half-life was variable.  The t1/2 ranges for itraconazole 
were 6.7 to 7.2 hr for EPAS, 2.3 to 5.5 hr for SFL, and 7.4 for URF and indicate 
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variability independent of formulation, crystallization state, and other pharmacokinetic 
parameters.   
 
In addition to comparison of observable and dose normazlied pharmacokinetic 
properties, reported itraconazole concentrations and AUC values in lung tissue and 
plasma from the same study population allow calculation of drug ratio values and 
distribution coefficients.  Specifically, mice with a lung fungal infection had a lung to 
plasma Cmax ratio of 59 to 1 for crystalline EPAS itraconazole while mice administered 
amorphous SFL itraconazole had a ratio of 12 to 1.  In comparison, healthy mice 
administered SFL itraconazole had Cmax lung to plasma ratios of 112 to 1 while mice that 
received amorphous URF drug had a ratio of 13 to 1.  A lung to blood partition 
coefficient can also be calculated using a ratio of lung AUC and plasma AUC values.  
The calculated partition coefficients were 57 for SFL and 21 for URF. 
 
1.3.3. Comparison of Inhaled Antifungals 
Inhaled amphotericin B and itraconazole demonstrated more variable 
pharmacokinetic parameters compared to inhaled corticosteroids due in part to dose 
differences.  These differences can be attributed, in part, to the physicochemical 
differences between inhaled corticosteroids and inhaled antifungals.  Large inhaled 
antifungal doses, in the mg range, produced plasma concentrations in the µg mL-1 to  
ng mL-1 range for amphotericin B and µg mL-1 for itraconazole compared to much 
smaller doses of inhaled corticosteroids with plasma concentrations in the ng mL-1 to  
pg mL-1 range.  Although the scale of dose to effect concentrations was conserved 
between the agents, the deposition mass of inhaled antifungals was potentially several 
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orders of magnitude larger than for inhaled corticosteroids and could affect the absorption 
kinetics of the inhaled API (85).   
 
The incorporation of surface active excipients in the nebulized formulation of 
amphotericin B elevated the dose normalized plasma Cmax range from 1.1 to 4.2 µg mL-1 
for AmB dispersion to 0.8 to 45 µg mL-1 for AmB-d.  Inhaled AmB-d also produced very 
high normalized lung tissue Cmax values from 627 to 987 µg kg mL-1 mg-1.  The relative 
ratio of lung to plasma concentrations for inhaled AmB-d of 1000 to 1 suggest very low 
drug absorption despite the presence of a surface active agent, deoxycholate.  Although 
insufficient data was available for evaluation, L-AmB only elevated plasma 
concentrations by a factor of 10 and would not significantly improve drug absorption 
from the lung.   
 
Inhaled itraconazole allows a more thorough analysis of formulation effects and 
drug solubilization on pulmonary drug absorption.  For example, the addition of a second 
surface active agent, poloxamer 407, increased dose normalized lung concentrations by  
2 to 5 times and normalized lung AUC values by 2 to 9 times for both crystalline EPAS 
and amorphous SFL itraconazole formulations compared with only a polysorbate 
surfactant.  These increases suggest itraconazole improved inhaled particle deposition in 
the lung or aided in drug wetting and solubilization in lung fluid as has been suggested 
for other routes of administration (86, 87).  Inhaled URF itraconazole contained lecithin 
instead of poloxamer 407 but produced the highest dose normalized lung AUC values 
despite consistent lung Cmax values, suggesting drug wetting by a surface-active agent 
could be a probable mechanism of improved lung drug exposure and lung concentrations.  
However, elevated lung concentrations and drug exposure did not correlate to improved 
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drug absorption in the lungs.  Specifically, lung to plasma concentrations ratios suggested 
marked drug retention in the lungs with high AUC-based partition coefficients between 
lung tissue and plasma.  In addition, comparison of dose normalized Cmax and AUC 
values for formulation-matched crystalline EPAS and amorphous SFL formulations 
suggest inhalation of crystalline itraconazole dispersions led to higher drug 
concentrations and AUC values in the lung and plasma.  The authors suggest that 
physiologic factors of mucociliary clearance of amorphous particles or other 
biopharmaceutical process resulted in lower tissue concentrations of amorphous SFL 
itraconazole.  
 
1.4. INHALED OLIGOPEPTIDES 
Recent trends in biotechnology have led to a surge of protein and peptide 
candidate drug molecules (88).  However, formulation and effective non-invasive 
delivery of these APIs has been very challenging (89-91).  The pulmonary delivery of 
proteins and peptides as a route for systemic drug delivery is intended to improve 
systemic bioavailability and reduce the pharmacokinetic variability compared to oral 
administration.  Therefore, goal for most pulmonary peptide administration is typically 
systemic drug absorption instead of local action in the lungs.  However, some therapeutic 
peptides could exert local action in the lung and targeted delivery could minimize 
systemic drug exposure.  Although several manuscripts have been published that review 
inhalation of proteins and peptides (5, 6, 8, 92), examples of small molecular weight 
cyclic peptides with low aqueous solubility are pertinent to an examination of the 
influence of solubility and solubilization on pulmonary absorption.  These agents include 
the immunosuppressant cyclosporine and an investigational substance P and neurokinin 
antagonist, FK224.  Cyclosporine, a relatively small (1203 g mol-1) cyclic undecapeptide 
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is very poorly water soluble (0.03 µg mL-1) with a high log P value (2.9).  FK224 is also 
a small cyclic hexapeptide (1041 g mol-1) also has low aqueous solubility (21 µg mL-1) 
and a lower log P value (1.3).   
 
1.4.1. Cyclosporine 
(See Table 1.3A) Cyclosporine is a polypeptide immunosuppressant used 
primarily to prevent tissue rejection after organ and tissue transplants through inhibition 
of signaling pathways involved in normal T-cell activation.  Although effective following 
lung transplantation, acute rejection can occur due to delays in drug distribution into lung 
tissue following systemic drug administration.  Additionally, targeting 
immunosuppressant delivery to the lung can reduce adverse events associated with 
systemic immunosuppression.  Initial pharmacokinetic experiments with inhaled 
cyclosporine used nebulized alcoholic solutions, associated with poor patient tolerability 
and high rates of adverse events (93-95), or nebulized propylene glycol solutions (96-98).  
A nebulized suspension of cyclosporine in multi-lamellar dilauroylphosphatidylcholine 
liposomes was also investigated in dogs (99, 100).  Recently, a nano-scale amorphous 
dispersion of cyclosporine was produced by controlled precipitation (CP), a stabilized 
anti-solvent precipitation, and nebulized to mice (101).  The use of provided or estimated 
dose masses for pharmacokinetic parameter normalization produced study-dependent 
variability in calculated values.  Therefore, dose normalization of Cmax and AUC values 
were generally performed with the reported mass-based dosing (mg kg-1) rather than the 
dose mass comparisons used for earlier poorly water soluble APIs.   
 
Following inhalation of an alcoholic solution of cyclosporine, lung and whole 
blood tmax values ranged from 0.5 to 1.0 hours (30 to 60 minutes) while propylene glycol 
 27
solutions achieved more variable tmax values of 0.1 to 4.6 hours (6 to 276 minutes) in the 
lung and 0.1 to 2.0 hours (6 to 120 minutes) in the blood.  Aerosolization of the liposomal 
cyclosporine had a tmax of 0.5 hours (30 minutes) in lung tissue but was faster in the blood 
with a value of 0.25 hours (15 minutes), indicating very rapid absorption following 
inhalation.  The nebulized CP nano-scale dispersion also produced a similar lung tmax 
value, 1.0 hours (60 minutes) but with a delayed blood tmax value, 3.7 hours  
(222 minutes).  The nebulized alcoholic cyclosporine solution produced dose normalized 
Cmax values from 33 to 35 µg kg g-1 mg-1 in the lung and 0.7 to 0.8 µg kg mL-1 mg-1 in the 
blood that then decreased to trough concentration ranges from 2.2 to 4.1 µg kg g-1 mg-1 in 
the lung and 0.1 to 0.2 µg kg mL-1 mg-1 in the blood.  In contrast, nebulized propylene 
glycol solutions produced markedly lower normalized Cmax values from 1.3 to  
6.8 µg kg g-1 mg-1 in the lung and 0.04 to 0.2 µg kg mL-1 mg-1 in the blood.  Comparable 
values were observed for dose normalized Cmax values for the amorphous CP dispersion 
in the lung, 3.0 µg kg g-1 mg-1, and blood, 0.1 µg kg mL-1 mg-1.  Even lower normalized 
Cmax values were observed following inhalation of liposomal cyclosporine in lung tissue, 
0.2 to 0.3 µg kg g-1 mg-1, and blood, 0.002 to 0.01 µg kg mL-1 mg-1.   Inconsistency in 
dose normalized AUC values were observed for inhaled alcoholic solutions with values 
of 96 to 138 µg hr kg g-1 mg-1 in the lung and 5.1 to 5.5 µg hr kg mL-1 mg-1 in the blood 
when the dose was 3 to 5 mg kg-1 but 20 to 24 µg hr kg g-1 mg-1 in the lung and 25 to  
27 µg hr kg mL-1 mg-1 in the blood when the dose was increased to 10 to 25 mg kg-1.  
Similar inconsistencies were observed following inhalation of the propylene glycol 
solution with normalized AUC values of 0.05 to 0.1 µg hr kg mL-1 mg-1 in the blood at 
doses of 4.4 to 9.7 mg kg-1 (no lung tissue values reported for that dose range) and 
increasing to 11 to 46 µg hr kg g-1 mg-1 in the lung and 0.8 to 1.7 µg hr kg mL-1 mg-1 in 
the blood when the dose was increased to 8.4 to 112.6 mg kg-1.  Comparable normalized 
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values were calculated for inhaled CP cyclosporine with a lung value of  
41 µg hr kg g-1 mg-1 and blood value of 2.8 µg hr kg mL-1 mg-1.  The reported 
pharmacokinetic parameters for both lung and plasma also allow calculation of 
concentration ratios and partition coefficients for inhaled cyclosporine formulations.  
Calculated drug concentration ratios were 40-50 to 1 for alcoholic solutions,  
30-42 to 1 for propylene glycol solutions, 25-100 to 1 for liposomal suspensions, and 28 
to 1 for amorphous CP dispersions.  The corresponding partition coefficients were 1-27 




(See Table 1.3B) FK224 is an investigational cyclic hexapeptide, (L-Ser-L-Thr-L-
Leu-D-Phe-L-allo-Thr-L-Asp- NH2) used as a substance P and neurokinin antagonist 
with potential utilization in the management of conditions associated with 
neurotransmitter release, such as depression, analgesia, nociception, inflammation, and 
nausea and emesis (102-104).  However, very low bioavailability was observed following 
oral administration due to gastrointestinal proteolytic degradation as well as formulation 
difficulty prompting dose limitations due to the physicochemical properties of the drug 
(105).  Two publications have investigated systemic pharmacokinetic parameters 
following pulmonary delivery of FK224 with different mechanisms of solubility 
enhancement (105, 106).  Specifically, a micronized co-precipitate of β-cyclodextrin and 
FK224 was incorporated into a CFC-based pMDI as well as with lactose carrier particles 
for a DPI formulation. 
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The addition of β-cyclodextrin decreased plasma tmax values in rats to 0.25 hours 
(15 minutes) compared to a value of 1.0 hr (60 minutes) when no cyclodextrin was 
present.  This value was clearly different for pMDI and DPI administered formulations in 
humans with values of 2.7 to 3.0 hours (162 to 180 minutes) and 0.7 to 2.2 hours (42 to 
132 minutes), respectively.  Increasing concentrations of β-cyclodextrin also affected 
pharmacokinetic parameters in rats when administered drug via a pMDI device with dose 
normalized plasma Cmax values increasing from 0.01 µg kg mL-1 mg-1 to  
0.03 µg kg mL-1 mg-1, to 0.09 µg kg mL-1 mg-1 for API to cyclodextrin rations of 1:0, 1:1, 
and 1:7, respectively with corresponding dose normalized AUC values of  
0.06 µg hr kg mL-1 mg-1, 0.43 µg hr kg mL-1 mg-1, and 1.35 µg hr kg mL-1 mg-1.  The 
marked increase in both maximal plasma concentrations and drug exposure from FK224 
without cyclodextrin up to a 1:7 mixture of API and cyclodextrin corresponded to an 
increase in drug solubility from 21 µg mL-1 to 1 mg mL-1.  When a 1 : 1 :: FK224 :  
β-cyclodextrin pMDI was administered to humans, dose normalized Cmax values ranged 
from 0.07 to 0.09 µg kg mL-1 mg-1 but considerably increased to 0.34 to  
0.37 µg kg mL-1 mg-1 for the DPI delivered formulation.  A similar pattern was observed 
for normalized AUC values when the same formulation when administered with a pMDI 
device, 0.13 to 0.79 µg hr kg mL-1 mg-1 and  3.05 to 3.61 µg hr kg mL-1 mg-1 with a DPI 
device.  
 
4.3. Comparison of Inhaled Oligopeptides 
Numerous formulation and delivery devises have been investigated for inhaled 
poorly water soluble oligopeptides including: solutions, suspensions, particle size 
reduction, solubilizing excipients, nebulizers, DPIs and pMDIs.  Inhalation of solubilized 
cyclosporine in alcohol and propylene glycol solutions produced similar tmax values in 
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lung tissue and plasma but with very different dose normalized Cmax and AUC ranges, 
suggesting alcoholic solutions enhanced pulmonary drug absorption compared to 
propylene glycol solutions, possibly through alterations in hydrodynamics across alveolar 
membranes (107).  In addition, tissue and blood concentration ratios and partition 
coefficients for pulmonary absorption suggest alcohol solutions promote increased 
retention of cyclosporine in the lungs following inhalation compared to propylene glycol 
solutions.  Therefore, although alcohol solutions promote improved relative absorption of 
the oligopeptide, propylene glycol solutions do not promote retention of drug in lung 
tissue, possibly through non-absorptive lung clearance mechanisms.  Further studies are 
needed to elucidate possible causes of this behavior.  Inhalation of a nano-scale 
dispersion of CP cyclosporine retained drug in the lungs in a similar manner to solutions 
but had slightly improved drug absorption as evidenced by concentration ratios compared 
to solutions and could be due to enhanced absorption of nanoparticles (4).   Inhalation of 
liposomal cyclosporine seemed to inhibit systemic drug absorption and could be due to 
tissue retention of the liposome (108). 
 
The incorporation of β-cyclodextrin into FK224 formulations markedly enhanced 
the aqueous solubility of the oligopeptide resulting in better pulmonary absorption of the 
API (109).  However, incorporation of solid state micronized FK224-cyclodextrin 
powders into pMDI and DPI devices prompted divergent pharmacokinetic parameters as 
evidenced by a 3 to 4-fold increase in dose normalized plasma Cmax values and 4 to 28-
fold increase in normalized plasma AUC values following inhalation of the DPI delivered 
powder.  The authors suggested the DPI produced higher Cmax and AUC values due to 
device dependent differences in the delivered dose (106).  Ideally, a pMDI and DPI 
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would produce similar systemic pharmacokinetic parameters for equivalent inhaled 
doses. 
 
1.5. INHALED OPIOIDS 
1.5.1. Fentanyl 
(See Table 1.4) Opioid analgesics are based on the prototypical opioid, morphine, 
but structurally diverse through various ring structures and functional groups to provide 
consistent binding sites to opioid receptors.  As a result of this inconsistency in chemical 
structures, opioids have varied aqueous solubilities, molecular weights, and log P values.  
For this review, fentanyl is a poorly water soluble compounds and has been administered 
via inhalation for the treatment of breakthrough pain.  Fentanyl is a small molecule 
compound (336.5 g mol-1) with low aqueous solubility (200 µg mL-1) and high log P 
value (3.9) suggesting dissolution limited absorption and good propensity for diffusion 
controlled absorption.  The inhalation of fentanyl gained popular interest when fentanyl 
derivative was pumped into the ventilation system of a building in Moscow that held 
terrorists and more than 800 hostages (110).  Following the exposure to the inhaled 
fentanyl derivative and neutralization of the terrorists, a military operation brought the 
standoff to a close.  However, after that incident, over 80% of the hostages required 
hospitalization with a total of 16% that died as a result to the inhaled fentanyl derivative.  
Despite these negative results, the controlled and therapeutic use of inhaled fentanyl was 
investigated as a route of administration for rapid and potentially prolonged systemic 
drug action using a nebulized suspension of a 50/50 mixture of free and liposome-
encapsulated (phospholipon 90-G and cholesterol) fentanyl (FLEF) and as a pMDI 
containing micronized fentanyl base in a mixture of CFC-11 and CFC-12 propellants 
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with sorbitan trioleate as a metering valve lubricant (111-113).  A DPI formulation of 
engineered micronized fentanyl on lactose carrier particles was also administered to 
humans via the Taifun® device (114, 115).  
 
The plasma pharmacokinetic profile following inhalation of the FLEF formulation 
could be considered the summation of the inhaled encapsulated fentanyl pharmacokinetic 
profile with the pharmacokinetic profile of the inhaled free fentanyl.  However, those two 
profiles are impossible to isolate based on the available pharmacokinetic data from FLEF.  
In addition, the pMDI formulation and the DPI fentanyl-lactose system provided different 
pharmacokinetic profiles, suggesting none of the inhaled fentanyl systems provided an 
un-modified free liposomal comparator.  Specifically, the pMDI formulation used a 
solution of fentanyl in CFC propellants that volatilized on actuation to deliver particulate 
fentanyl to the lungs.  Administration of the pMDI formulation achieved very rapid 
plasma tmax values of 0.1 to 0.12 hours (6 to 7 minutes) with corresponding dose 
normalized plasma Cmax values of 9.5 to 15.0 µg kg mL-1 mg-1 and a normalized AUC 
range of 91 to 154 µg hr kg mL-1 mg-1.  The DPI formulation provided an even quicker 
tmax value, 0.017 hours (1 minute), but with a lower dose normalized Cmax of  
4.7 µg kg mL-1 mg-1.  However, when compared with the FLEF formulation, plasma tmax 
values were slightly slower and ranged from 0.25 to 0.38 hours (15 to 23 minutes) but 
with much lower dose normalized Cmax values of 0.6 to 2.5 µg kg mL-1 mg-1.  Therefore, 
a component of both the pMDI and DPI formulations enhanced pulmonary absorption 
from the lung, or the nebulized liposomal fentanyl suspension behaved in a substantially 
different manner than suggested by the pMDI formulation.  A more thorough analysis 
was not possible due to incomplete reporting of AUC values for the DPI fentanyl and 
FLEF.  However, fentanyl particle size reduction was the likely mechanism of rapid and 
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high maximal drug concentrations for both the DPI and pMDI formulations which 
occurred either in the particle manufacturing process (DPI) or following volatilization of 
the CFC propellant from the fentanyl solution which caused precipitation of discrete 
micro- to nano-sized particles (pMDI).  Further studies are needed to better elucidate this 
possible mechanism of improved drug solubilization for fentanyl. 
 
1.6. SUMMARY 
Pulmonary drug delivery is an accepted route of drug administration for lung 
condition and disease management including: asthma and other inflammatory processes, 
lung infections, immunosuppression following lung transplantation, and others.  The 
lungs were also investigated as a route of systemic drug administration to bypass oral 
barriers to absorption and avoid parenteral administration and the pain and inconvenience 
associated with injections for other APIs.  These biopharmaceutical advantages for 
interest in pulmonary drug delivery have led researchers to administer an increasingly 
wide variety of APIs to the lungs.  Although poorly water soluble drugs pose formulation 
and drug delivery limitations for typical delivery methods, an evaluation of their impact 
on pulmonary drug delivery with emphasis on in vivo pharmacokinetic effects has not 
been performed.  A sample of poorly water soluble APIs were selected from the literature 
and included for analysis where a formulation was provided or suggested, the drug was 
inhaled by an in vivo system, and some form of pharmacokinetic evaluation was 
performed such that drug concentration values were reported.  Studies that evaluated a 
biomarker or physiologic response were not included in the current evaluation.  Studies 
with non-compartmental pharmacokinetic parameters of tmax, Cmax, and AUC were 
preferentially included and normalized for the drug dose, as an exposure dose instead of a 
calculated or estimated delivered or inhaled dose, to facilitate inter-API comparison. 
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Application of particle size reduction to inhaled poorly water soluble agents 
provided inconsistent effects on pulmonary absorption.  Micronized drug formulations 
had plasma tmax values generally less than 2 hours (120 minutes) with some decreases to 
less than 0.5 hours (30 minutes) and were influenced by the API.  Although blood 
collection procedures limit the earliest reported values, micronized drugs can be rank 
ordered with the earliest reported value as budesonide (0.13 to 0.58 hours) < 
beclomethasone 17-monopropionate (0.17 to 2.5 hours) < triamcinolone acetonide (0.25 
to 1.75 hours) < amphotericin B (0.5 to 3.5 hours) < fluticasone propionate (0.9 to  
1.88 hours).  The minimal tmax values correlate with aqueous solubilities of the APIs  
(R2 = 0.70), suggesting the rate of drug absorption from the lungs, as suggested by tmax 
values, is limited by the intrinsic solubility of the API when micronized.  However, when 
the particle size is reduced into the nanometer range, plasma tmax values decreased to 
0.051 to 0.19 hours for nano-budesonide but were 2.0 hours for URF itraconazole and  
5.4 hours for SFL itraconazole.  Although insufficient data was available to draw 
conclusions for tmax values for nano-sized poorly water soluble APIs, inhalation of 
nanoparticles could introduce additional and more variable mechanisms of absorption 
than affecting micron-sized inhaled drugs (4, 16).  The pulmonary administration of 
alcohol and propylene glycol based beclomethasone 17- monopropionate and 
cyclosporine solutions generally achieved rapid plasma tmax values.  Dissolved fentanyl in 
a propellant mixture also demonstrated very rapid drug absorption with low tmax values 
following inhalation.  Incorporation of solubilizing excipients also reduced the tmax value 
as evidenced in the inclusion of cyclodextrin with FK224, surfactants with amphotericin 
B and itraconazole, and encapsulation of fentanyl, cyclosporine, and amphotericin B into 
liposomes.  The formulation-based inclusion of solubility enhancing excipients did 
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appear to improve the rate of drug absorption following inhalation as has been 
demonstrated for poorly water soluble APIs in other routes of drug delivery (15, 86, 116, 
117). 
 
The relationships between drug solubility and solubilization were more complex 
for dose normalized tissue and systemic drug Cmax and AUC values than for tmax values.  
This could be due to the fact that pharmacokinetic parameters were adjusted based on the 
total inhalation exposure dose and not actual deposited doses.  The inter-study and intra-
study differences in pulmonary deposition based on utilization of different delivery 
systems, formulations, study populations and species, and physiologic properties 
following inhalation could not be corrected in the dose normalization due to insufficient 
and methodologically varied deposition and aerosol aerodynamic information provided 
by the many authors (16, 118, 119).  Additionally, systemic effects were inappropriate to 
consider in parameter normalization due precisely to the objective of the study to 
investigate the influence of solubility and solubilization parameters on pulmonary 
absorption of poorly water soluble APIs.  However, normalizing non-compartmental 
pharmacokinetic parameters based on exposure doses did provide a uniform adjustment 
for all APIs across varied methodologies and allow for inter-API evaluation.   
 
The most noticeable relationship is the scope of drug concentrations in the 
systemic circulation following pulmonary absorption, i.e. inhaled corticosteroids and 
inhaled amphotericin B had dose normalized concentrations in the ng mL-1 mg-1 range 
(equivalent to pg mL-1 µg-1) while the other APIs had a 1000-fold increase in 
concentration in the µg mL-1 mg-1 range.  Although this could be an artifact from dose 
normalization of pharmacokinetic parameters, inhaled corticosteroids and amphotericin B 
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have very low drug distribution to the plasma from the lungs and suggest mechanistic 
differences in pulmonary absorption between different APIs.  Additional studies are 
required to control for possible differences in pulmonary deposition and investigate 
mechanisms of absorption for these agents from the lung.   
 
The differences in tissue and systemic drug concentration scales did not affect 
trends in drug concentration and drug exposure based on formulation-based solubilization 
adjustments.  Alcoholic solutions prompted higher normalized Cmax and AUC values, 
suggesting enhanced drug absorption following inhalation, than propylene glycol 
solutions.  Therefore, the pulmonary administration of pre-dissolved poorly water soluble 
API does not equate to equivalent rates or extents of drug absorption.  Studies have 
suggested that ethanol could function as a permeation enhancer or disrupt the 
hydrodynamic balance in tissues to promote drug absorption (107, 120).   
 
Inhalation of nano-scale formulations caused divergent pharmacokinetic findings 
for nano-budesonide compared to nano-structured compositions of itraconazole and 
cyclosporine.  Inhaled suspensions of nano-budesonide promoted rapid and markedly 
elevated systemic drug concentrations but with an equivalent dose normalized AUC, 
suggesting an improved rate of drug absorption without altering the extent of drug 
absorption.  However, for inhaled nano-structured itraconazole and cyclosporine, rapid 
and extensive tissue concentrations were observed but with very little systemic drug 
absorption.  For those APIs, the rate and extent of systemic drug absorption from the 
lungs was decreased.  The inhaled itraconazole and cyclosporine particles could 
experience non-absorptive clearance mechanism from the lung tissue, possible alveolar 
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macrophages or the lymphatic system, that could segregate drug from the systemic 
circulation (17, 121).   
 
Cyclodextrin also promoted high normalized Cmax and AUC values following 
inhalation suggesting similar mechanisms of improved drug absorption as other routes of 
delivery (109, 122, 123).  However, nebulized liposomal formulations promoted 
relatively low systemic drug concentrations for cyclosporine and fentanyl but elevated 
concentrations for amphotericin B.  Although amphotericin B has been shown to bind to 
systemically circulating liposomes and cause a high but pharmacologically inactive 
systemic concentration following IV administration (124), the pulmonary administration 
of liposomes was suggested to cause enhanced drug retention in the lung and act as a 
form of drug depot for prolonged action (111, 112).  Supplemental AUC values for 
inhaled liposomal poorly water soluble APIs could resolve this effect.  
 
Although the pharmacokinetic evaluation of select inhaled poorly water soluble 
APIs demonstrated many drug-dependent and as of yet unexplored effects, drug 
physicochemical and formulation-based solubility enhancement did affect drug 
absorption form the lungs.  Additional insights will be gained as researchers continue to 
investigate the delivery of drugs to the lungs and explore the factors that relate drug 
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Chapter 2: Characterization and Pharmacokinetic Analysis of 
Aerosolized Aqueous Voriconazole Solution 
 
2.1. INTRODUCTION 
Invasive fungal infections are increasing in prevalence in immunocompromised 
patients due to decreased immunity resulting from drug therapy, organ transplantation, 
and/or various disease states (1).  The distribution of causative organisms for invasive 
fungal infections has been changing with an increase in the prevalence of Aspergillus spp. 
and other invasive molds (2).  Systemic fungal infections caused by Aspergillus spp. are 
primarily lung infections due to the inhalation of conidia.  The resulting infection, 
Invasive Aspergillosis (IA), is the cause of serious damage to lung tissue due to invasive 
hyphal growth (3).  Dissemination of IA can also occur to other organ systems and 
correlates with a poorer prognosis (4).  Despite the best therapeutic options, mortality 
rates for IA remain high (4, 5). 
 
The primary therapy for the treatment of IA is the systemic administration of 
voriconazole and has led to improved patient outcomes compared to other treatments (6, 
7).  Voriconazole is a triazole antifungal with broad antifungal activity against numerous 
pathogenic fungi in addition to its activity against Aspergillus spp. (8, 9).  Voriconazole 
has also been reported to distribute to the lungs as measured by tissue and epithelial 
lining fluid concentrations following systemic administration (10, 11).  The commercial 
voriconazole product, Vfend®, is available as an oral tablet or intravenous formulation.  
The intravenous product is formulated with Captisol®, sulfobutyl ether-β-cyclodextrin, to 
form a solubilized drug-cyclodextrin complex due to very slight voriconazole solubility 
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in water (12).  Voriconazole has reported side effects of visual disturbances, hepatic 
toxicity, and dermatologic reactions as well as serious cytochrome P450 mediated drug 
interactions (8, 10).  Adverse events causing discontinuation of therapy occurred in up to 
6% of patients and were primarily due to elevations in liver function tests or rash.  Other 
systemically administered antifungals can be selected as salvage therapy or in patients 
intolerant to voriconazole but have the potential for other serious side effects as well as 
drug interactions (6, 13, 14). 
 
The potential side effect profile and drug interactions associated with systemic 
antifungal administration might be reduced by targeting drug delivery to the lungs, the 
primary site of IA.  Targeted lung delivery of antifungals can also lead to high drug 
concentrations at the site of infection to improve clinical outcomes.  Two antifungals, 
amphotericin B and itraconazole, have been inhaled with reported pharmacokinetic and 
outcome measures (13, 15-23).  Inhaled amphotericin B formulations include drug 
solubilized with deoxycholate, drug encapsulated in liposomes, and drug-lipid complexed 
suspensions.  Inhaled itraconazole was formulated as crystalline or amorphous nano-
particulate suspensions. 
 
Inhaled amphotericin B has a better but non-optimal side effect profile and 
significantly improved outcomes compared to the systemically administered formulations 
(13, 15, 17, 23).  However, the pharmacokinetic profiles of inhaled compared to 
intravenous amphotericin B are substantially different.  Lung concentrations of 
amphotericin B following intravenous administration are initially undetectable followed 
by low levels despite extensive tissue distribution following multiple doses (24-28).   
Inhaled amphotericin B has led to much higher lung tissue concentrations but 
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undetectable plasma levels (16, 29, 30).  The high drug concentrations in the lung tissue 
following amphotericin B inhalation was hypothesized to result in significant outcomes 
in human patients and animal models of IA compared to intravenous drug administration 
(15, 17).   
 
Inhaled nano-particulate itraconazole was also well tolerated with normal 
histological findings and an absence of inflammatory mediators following a chronic, 
multi-dose study in animals (22).  The pharmacokinetic profile of different inhaled 
formulations following a single inhaled dose demonstrated high and prolonged 
itraconazole concentrations in the lungs with maximal lung levels achieved 30 to 60 
minutes after the completion of nebulization while serum concentrations remained low 
and peaked after 2 to 5.35 hours in animals (20, 21, 31).  The ratio of lung-to-serum AUC 
values was 25 to 50 and Cmax ratios ranged from approximately 10 to 100, indicating low 
drug partitioning out of the lungs.  Following multiple doses, lung concentrations 
remained substantially higher than serum concentrations (21).  Inhaled itraconazole 
demonstrated significantly improved outcomes compared to oral itraconazole and control 
groups in animal models of IA and was suggested to be due to sufficient drug 
concentrations in the lungs to inhibit invasive fungal growth at a fraction of the oral dose 
(18, 19). 
 
Both inhaled amphotericin B and inhaled particulate itraconazole demonstrated 
substantial drug retention in the lungs, improved survival in animal models of IA, and 
suggested positive clinical outcomes were associated with favorable lung 
pharmacokinetic profiles.  Gavalda and colleagues reported improved survival in an 
animal model of IA when both inhaled and intravenous antifungal was administered 
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concurrently compared to inhaled or intravenous drug administered separately (15).  This 
report suggests near-therapeutic plasma concentrations combined with very high 
concentrations of antifungal in the lung could improve patient outcomes.  However, 
neither inhaled amphotericin B nor inhaled itraconazole produce blood concentrations 
that are close to therapeutic levels.  Therefore, targeted delivery of an antifungal to the 
lungs with distribution to the blood producing high drug concentrations in both lung 
tissue and blood can potentially improve clinical outcomes and be a significant 
improvement in antifungal therapeutic options. 
 
The poor distribution of amphotericin B and itraconazole to the systemic 
circulation following inhalation could be due, in part, to the very low aqueous solubilities 
of those compounds.  Inhalation of a solubilized antifungal, the voriconazole-
cyclodextrin inclusion complex as Vfend® IV, could lead to better lung concentrations 
than reported following systemic drug administration as well as systemic drug 
distribution.  In this study, it is hypothesized that an aqueous solution of voriconazole 
solubilized with sulfobutyl ether-β-cyclodextrin, when inhaled as a single-dose, would 
produce high lung drug concentrations as well as allow rapid distribution from the lungs 
to the plasma.  Furthermore, following multiple doses, inhaled voriconazole solutions 
would also produce elevated and consistent trough concentrations in lungs and plasma.  
Although solubilized voriconazole should distribute to the systemic circulation following 
inhalation, reductions in the incidence of hepatotoxicity, visual abnormalities, and 
dermatologic reactions could still occur due to a lower drug burden and dose sparing 
compared to systemic drug administration. 
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2.2. MATERIALS AND METHODS 
2.2.1. Materials 
Vfend® IV (Pfizer Inc., New York, NY, USA) (Lot # A22278 and A26697), 
voriconazole standard (Lot number E010000674), and sulfobutyl ether-β-cyclodextrin, 
Captisol® (Lot # NC-04A-05009) were generously supplied by CyDex Pharmaceuticals, 
Inc. (Lenexa, KS).  Sterile water for injection (SWFI) (Lot # 60-252-DK, Hospira, Inc.) 
and normal saline (Lot # 58-464-DK) were purchased from Cardinal Health (Dublin, 
OH).  Sodium tetraborate decahydrate (Batch # 057K0070), boric acid (Batch # 
097K0063), and sodium acetate trihydrate (Batch # 117K0153) were purchased from 
Sigma-Aldrich, Inc. (St. Louis, MO).  Acetic acid (Lot # 72270) was purchased from 
Sigma-Aldrich Laborchemikalien GmbH (Seelze, Germany).  HPLC grade ethyl acetate 
(Lot # PU0674) was purchased from Spectrum Chemical Manuf. Corp. (Gardena, CA).  
HPLC grade acetonitrile (Lot # 082967) was purchased from Fisher Scientific (Fair 
Lawn, NJ).  HPLC grade methanol (Lot # 47360) was purchased from EMD Chemicals 
Inc. (Gibbstown, NJ).  Water was obtained from an in-house Milli-Q UV Plus water 
purification system from the Millipore Corp. (Billerica, MA).   
 
2.2.2. Characterization of In Vitro Properties of Voriconazole Solutions 
Vfend® IV was reconstituted with SWFI as instructed in the prescribing 
information to a 10 mg/mL voriconazole concentration, which also contained sulfobutyl 
ether-β-cyclodextrin at 160 mg/mL.  Additional dilutions were prepared with SWFI to 
voriconazole concentrations from 2.5 to 10 mg/mL .  The osmolality of voriconazole 
solutions were tested (n=10 per concentration) using a µOsmette Micro Osmometer 
(Precision Systems Inc., Natick, MA).  The pH of the 6.25 mg/mL voriconazole dilution 
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was determined using an Orion 350 PerpHecT® Advanced Benchtop pH Meter (Thermo 
Fisher Scientific, Waltham, MA). 
 
2.2.3. Particle Size Analysis Using a Cascade Impactor  
Voriconazole solutions were diluted to 6.25 mg/mL voriconazole and aerosolized 
using an Aeroneb® Pro micro pump nebulizer (Nektar Therapeutics, San Carlos, CA) for 
20 minutes.  Aerodynamic droplet size distributions were determined using a USP 
Apparatus 1 non-viable eight-stage cascade impactor (Thermo-Anderson, Symrna, GA) 
to quantify total emitted dose (TED) from the nebulizer output, mass median 
aerodynamic diameter (MMAD), geometric standard deviation (GSD), and percentage 
droplets with an aerodynamic diameter less than 4.7 µm (defined as the percentage fine 
particle fraction or FPF).  The characterization of aerodynamic droplet size distribution 
was conducted through modifications to the guidelines described in USP 30 Section 601: 
Aerosols, Nasal Sprays, Metered-dose Inhalers, and Dry Powder Inhalers (32).  
 
2.2.4. Single-dose Pharmacokinetic Analysis 
Male outbred ICR (Institute for Cancer Research) mice were purchased from 
Harlan Sprague Dawley, Inc. (Indianapolis, IN) and housed with free access to water and 
food.  Prior to dosing, mice were acclimatized to the nose-only dosing animal restraints.  
Mice received a single inhaled dose of 5 mL aqueous voriconazole solution at  
6.25 mg/mL voriconazole using a nose-only dosing apparatus with a drug exposure time 
of 20 minutes.  Single-dose pharmacokinetic profiles were determined in two groups of 
mice: a high flow-rate group (5 L/min air flow, 32 g average mouse mass) and low flow-
rate group (1 L/min, 22 g average mouse mass).   Two or more mice were euthanized by 
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carbon dioxide narcosis at each time point (high flow-rate: 5, 10, 20, 30, 60, 90, 150, 240, 
360, 720, and 1440 minutes or low flow-rate mice: 10, 30, 60, 240, 360, and 480 
minutes).  Whole blood was collected by cardiac puncture into heparinized vials and 
centrifuged at 9000 RPM for 15 minutes to obtain plasma.  Whole lungs were also 
collected following exsanguination.  Plasma samples and whole lungs were frozen and 
stored at -20°C until assayed.  Lungs were thawed and homogenized with 1mL of water 
using an Omni GLH homogenizer (Omni International, Marietta, GA).  Plasma samples 
and lung homogenates were analyzed individually for each animal sampled for 
voriconazole concentration by reverse-phase high-performance liquid chromatography 
(HPLC).  Concentration values were then averaged and used to determine the 
concentration versus time profiles.  All animals were handled and maintained in 
accordance with The University of Texas at Austin Institution Animal Care and Use 
Committee (IACUC) guidelines and in accordance with the American Association for 
Accreditation of Laboratory Animal Care guidelines. 
 
2.2.5. Multi-dose Pharmacokinetic Analysis 
Male ICR mice weighing, on average, 22.5 g, were administered inhaled 
voriconazole twice daily using a nose-only dosing apparatus as described above.  Doses 
were administered for 12 consecutive days beginning each day at 08:00 and 16:00 hours.  
Airflow through the dosing apparatus was constant at 1 L/min throughout the study.  The 
dosing apparatus was disassembled and cleaned between each use.  Randomly selected 
groups of 6 mice were sacrificed by carbon dioxide narcosis on days 3, 5, 10, and 12.  For 
trough concentration determination, lung and plasma samples were collected immediately 
before the next scheduled morning dose on days 3, 5, 10, and 12 (16 hours after the last 
dose).  For determination of peak voriconazole concentrations (Cmax), lung and plasma 
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samples were collected 30 minutes after the completion of the 10th dose on day 5 of 
administration.  Lung and plasma samples were handled and processed as described in 
the single-dose methodological description. 
 
2.2.6. Chromatographic Analysis 
Calibration standards, plasma, and homogenized lung samples were analyzed 
using similar methods to those previously published (33, 34).  Briefly, voriconazole was 
extracted from plasma samples through the addition of acetonitrile, centrifugation, and 
supernatant extraction.  The supernatant liquid was evaporated under a gentle stream of 
nitrogen and residual solids, including voriconazole, were re-dispersed with mobile phase 
and analyzed spectrophotometrically.  For lung homogenate, 0.2M borate buffer (pH 9.0) 
was added followed by three liquid-phase extractions with ethyl acetate.  The liquid from 
collected supernatant fractions were then evaporated under a gentle stream of nitrogen.  
Any residual solids, including voriconazole, were re-dispersed with mobile phase, 
centrifuged, and then analyzed spectrophotometrically.  Each voriconazole sample was 
analyzed using a Waters Breeze liquid chromatograph (Waters Corporation, Milford, 
MA) or Shimadzu LC-10 liquid chromatograph (Shimadzu Corporation, Columbia, MD) 
equipped with a heated (35°C) Jupiter® C18 (150 mm x 4.6 mm, 5 µm) with a Universal 
security guard (Widepore C18) guard column (Phenomenex, Torrance, CA).  The sample 
volume was 50 µL with a UV detection wavelength of 254 nm.  The mobile phase 
consisted of a 50:50 mixture of 0.01M pH 5.0 sodium acetate buffer and methanol at  
1.0 mL/min.   
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2.2.7. Pharmacokinetic Analysis 
Observed pharmacokinetic parameters were evaluated from the voriconazole 
concentration versus time profiles in plasma and lung tissue using independent non-
compartmental models.  The peak concentration (Cmax) and the time to achieve the Cmax 
(tmax) were determined.  In addition, the area under the curve (AUC) in lung tissue and 
plasma up to 6 hours after the completion of drug exposure was calculated using the 
trapezoidal rule. 
 
2.2.8. Statistical Analysis 
Maximal concentrations in lung tissue and plasma were compared for statistical 
analysis by the t-test.  Single dose Cmax values were compared by a paired t-test with a  
P-value of <0.05 for significance.  Multiple dose Cmax values were compared using a  
t-test assuming unequal variance with a P-value of <0.05 for significance. 
 
2.3. RESULTS  
2.3.1. In Vitro Solution Characterization 
The osmolality of aqueous solutions of voriconazole and sulfobutyl ether-β-
cyclodextrin were correlated with solute concentrations.  The osmolality for voriconazole 
solutions that contained sulfobutyl ether-β-cyclodextrin between 40 and 160 mg/mL were 
109.3 to 507.7 mOsm/kg, respectively.  A solution containing 6.25 mg/mL voriconazole 
and 100mg/mL sulfobutyl ether-β-cyclodextrin was isotonic with an osmolality of  
293.2 mOsm/kg (Figure 2.1).  The pH of the 6.25 mg/mL voriconazole solution ranged 
from 6.4 to 6.8. 
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2.3.2. Particle Size Analysis 
The aerodynamic particle size distribution of nebulized 6.25 mg/mL voriconazole 
solution was determined independently in duplicate using an 8-stage non-viable cascade 
impactor with a spacer and an air-flow rate of 28.3 L/min.  Sufficient voriconazole 
solution was added to the nebulizer medication reservoir such that volume remained after 
a 20 minute nebulization.  The average TED, FPF, MMAD, and GSD were  
25.51 ± 6.25 mg, 71.7 ± 2.62 %, 2.98 ± 0.06 µm, and 2.20 ± 0.13, respectively.   
 
2.3.3. Single Dose Pharmacokinetic Studies 
Following a single inhaled dose of voriconazole, the observed tmax values ranged 
from 10 to 30 minutes in lung tissue and 20 to 30 minutes in plasma (Table 2.1).  
Voriconazole concentrations in lung tissue were low to undetectable 6 to 8 hours after a 
single dose while plasma levels remained quantifiable for up to 24 hours after the 
completion of nebulization.  In mice that received nebulized voriconazole at an air flow 
rate of 5 L/min, peak lung concentrations were 1.6 µg/g wet lung weight with an AUC0-6 
value of 205.3 µg min/g wet lung weight (Figurte 2.2A).  A peak plasma concentration of 
1.2 µg/mL and AUC0-6 of 136.4 µg min/mL were achieved in this high air flow rate 
group (Figure 2.2B).  In contrast, markedly, though not statically significant (P > 0.05), 
higher peak lung concentration, 11.0 µg/g, and a AUC0-6 value, 2408.0 µg min/g, were 
achieved in mice that were exposed to nebulized voriconazole at a slower air flow rate of 
1 L/min.  Similarly, a higher peak plasma concentration, 7.1 µg/mL, and AUC0-6 value,  
1549.8 µg min/mL, were also achieved in this low air flow rate group. 
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2.3.4. Multiple Dose Pharmacokinetic Studies 
In the multiple dose pharmacokinetic study, 5 mL of 6.25 mg/mL voriconazole 
solution was administered twice daily, beginning at 08:00 and 16:00, for 12 days to mice 
at the low air flow rate, 1 L/min.  Trough lung and plasma samples were taken 
immediately before the 08:00 dose on days 3, 5, 10, and 12.  Peak lung and plasma 
samples were taken 30 minutes following the completion of the 08:00 dose on day 5.  
After 5 days of drug administration, peak voriconazole lung and plasma concentrations 
were 6.73 µg/g wet lung weight and 2.32 µg/mL, respectively.  Peak plasma 
concentrations were significantly lower (P < 0.05) following multiple doses than 
following a single inhaled dose.  Peak lung concentrations were not statistically 
significant for single and multiple doses.  Trough lung concentrations of voriconazole 
were not detectable through day 5 but reached 0.11 to 0.19 µg/g wet lung weight on days 
10 and 12, respectively.  In contrast, trough plasma voriconazole concentrations were 
quantifiable on each day of sampling and ranged from 0.18 to 0.32 µg/mL (Table 2.2).   
 
2.4. DISCUSSION 
The lungs are the primary site of IA due to inhalation of fungal conidia resulting 
in a focal fungal infection in the lungs that can disseminate to other systems.  The site of 
an IA infection within the lungs is typically in deep alveolar spaces with possible sites of 
intra-cavity aspergillomas and vascular invasions.  Although typical humans are not at 
risk for IA due to competent immune systems and effective clearance of inhaled spores, 
immunocompromised patients are at elevated risk for IA and are the focus of 
prophylactic and treatment regimens with systemic antifungal administration (6, 35).  
Systemically administered antifungals must distribute to the lungs to be effective 
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therapeutic options but have high reported rates of mortality, in part, due to poor tissue 
penetration (7, 9, 10, 14, 28, 36, 37).  Targeted antifungal delivery has been reported to 
cause high drug concentrations at the site of infection in the lung and lead to improved 
outcomes (20, 21, 29-31, 38).  The studies to date, have also demonstrated targeted 
antifungal delivery to the lungs has not led to distribution of drug to the plasma.  
Interestingly, Gavalda et al., found that a combination of inhaled and intravenous 
amphotericin B led to improved survival in a rat model of IA.  Therefore, having high 
antifungal concentrations in lung tissue and plasma can potentially lead to improved 
outcomes in IA.  The current study found that an aerosolized aqueous solution of 
voriconazole solubilized with sulfobutyl ether-β-cyclodextrin was compatible with 
inhalation and led to high concentrations in the lung tissue as well as plasma following 
single and multiple doses in a murine pharmacokinetic model of inhalation.   
 
Inhaled aerosols must be compatible with biological membranes of the respiratory 
tract to avoid reactive and inflammatory airway side effects, including cough, dyspnea, 
and irritation (39, 40).  Our results demonstrated that an aqueous solution of voriconazole 
solubilized with sulfobutyl ether-β-cyclodextrin was compatible with aerosol 
administration.  The 6.25 mg/mL voriconazole dilution had an acceptable pH and was the 
only tested concentration within the isotonic range (Figure 2.1).  When this concentration 
was aerosolized using an Aeroneb® Pro vibrating mesh nebulizer system, the in vitro 
aerodynamic particle size characteristics of MMAD and FPF, 2.98µm and 71.7%, 
respectively, suggest that the nebulized droplets have a particle size distribution 
appropriate for inspiration to the deep lung.   
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Following a single inhaled dose of voriconazole, quantifiable voriconazole 
concentrations were observed in mice that received low and high doses as determined by 
the varied air-flow rate from 1 to 5 L/min.  At 5 L/min airflow through the dosing 
chamber, a dilute cloud of voriconazole-containing nebulized droplets was present in the 
dosing chamber which led to a low dose.  Conversely, a more concentrated and stagnant 
cloud of voriconazole-containing droplets was present at 1 L/min airflow rate through the 
chamber which led to a higher dose of voriconazole in those mice.  This dose difference 
led to a 7-fold increase in Cmax values and 11-fold increase in AUC0-6 in lung tissue and 
plasma for mice in the dosing chamber with the slow air flow rate (Table 2.1).  Although 
peak concentrations and drug exposure were affected by the inhaled dose, voriconazole 
distribution from the lungs to the plasma was unaffected.  Possible drug ingestion due to 
mucociliary clearance is not a contributing factor to plasma voriconazole concentrations 
due to hyper-metabolism in mice following oral administration (41).  An approximation 
of a partition coefficient, based on the lung to plasma ratios of Cmax and AUC0-6, ranged 
from 1.4-1.6 indicating good absorption and distribution of voriconazole across lung 
mucosal surfaces.  In addition, the observed tmax values were observed after 10 to  
30 minutes in lung tissue and 20 to 30 minutes in plasma after the completion of dosing 
for all mice tested.  Additionally, voriconazole concentrations in lung tissue were low to 
undetectable 6 to 8 hours while plasma levels remained quantifiable for up to 24 hours 
after the completion of nebulization.  Therefore, voriconazole was rapidly absorbed and 
distributed to the central plasma with minimal drug retained in lung tissue. 
 
Inhaled voriconazole achieved maximal concentrations within 30 minutes in both 
lung tissue and plasma.  The maximal lung tissue concentration was 1.4 times greater 
than the maximal plasma concentration value.  The rapid distribution of voriconazole 
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from lung tissue to plasma as well as the extent of distribution differed substantially from 
previous reports of inhaled antifungal agents.  Specifically, amphotericin B has negligible 
distribution from lung tissue after inhalation.  Following nebulized suspensions of pure 
amphotericin B, very low serum concentrations were achieved with a tmax of 30 minutes 
(29).  Inhaled deoxycholate solutions of amphotericin B produced undetectable plasma 
concentrations up to 24 hours after the dose (27, 30).  Additionally, retention of inhaled 
amphotericin B in lung tissue has been reported to be 15 to 22 days following a single 
inhaled dose (38).  For itraconazole, inhaled suspensions of nanoparticulate formulations 
had lung tmax values of 0.5 to 1 hour after the dose but with delayed plasma tmax values of 
2 to 5.4 hours (20, 21, 31).  For inhaled itraconazole, the reported AUC values were 25 to 
50 times greater in lung tissue than in the plasma.  Similarly, peak itraconazole 
concentrations were 12 to 100 greater for lung tissue than plasma.  These comparisons 
indicate negligible distribution of particulate itraconazole from the lungs to the plasma.   
 
The sulfobutyl ether-β-cyclodextrin excipient in inhaled voriconazole solutions 
prompted the differences in voriconazole distribution compared to inhaled particulate and 
solubilized amphotericin B as well as inhaled particulate itraconazole.  Cyclodextrins 
have been reported to cause rapid tmax and high Cmax concentrations as well as improved 
bioavailability of intratracheally administered aerosols or solutions compared to 
equipotent alternative formulations or routes of administration (42-44).  Although Roffey 
et al. used a 10 mg/kg IV and 30 mg/kg oral dose, direct comparison to pharmacokinetic 
parameters observed following a single inhaled dose were not directly possible due to 
dose uncertainties following inhalation in this study (45).  Additionally, voriconazole 
displays non-linear pharmacokinetics in humans and animals which could account for the 
marked differences observed following inhalation of different doses due to high and low 
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air flow rate through the dosing chamber.  However, the observed Cmax, tmax, and AUC 
values following a single inhaled dose at 1 L/min air flow rate through the dosing 
chamber were similar to those reported in mice following intravenous drug 
administration.  Therefore, inhaled voriconazole solubilized with sulfobutyl ether-β-
cyclodextrin produced plasma pharmacokinetic parameters similar to intravenous drug 
administration with additional high lung tissue concentrations. 
 
The multi-dose voriconazole pharmacokinetic profile cannot be extrapolated from 
a single-dose profile due to non-linear pharmacokinetics resulting from saturable hepatic 
metabolic pathways (8).  Additionally the multi-dose pharmacokinetic profile is 
complicated in mice due to altered plasma pharmacokinetic profiles following multiple 
intravenous and oral doses when compared to a single dose (45).  The peak plasma 
voriconazole concentration after 5 days of multiple doses, 2.32 ± 1.52 µg/mL (Table 2.2), 
was significantly lower than that observed following a single dose, 7.9 ± 0.68 µg/mL 
(Table 2.1).  The peak plasma voriconazole concentration was also lower than the 
concentration associated with toxicity in human studies (6 to 7 µg/mL) and should 
therefore correlate with acceptable dose tolerability and side effect profiles following 
multiple doses (46).  However, trough plasma voriconazole concentrations had no 
discernable trend between day 3 and 12 with concentrations ranging from 0.18 to  
0.32 µg/mL (Table 2.2).  The trough plasma concentrations observed in this study were 
affected, in part, by the altered dosing interval and were lower than 1 µg/mL, the trough 
concentration correlated with improved efficacy in humans (47).  Additionally, the 
influence of altered drug metabolism on plasma concentrations following multiple 
inhaled doses is uncertain based on this study.   
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Changes in voriconazole metabolism were not investigated in this current study.  
There is a very low prevalence of drug metabolizing enzymes in lung tissue (48, 49).  
Mice livers are also of insufficient size for quantative determination of hepatic metabolic 
enzyme evaluation.  Therefore, altered metabolism was unlikely to affect voriconazole 
lung pharmacokinetic parameters following multiple doses but could account for changes 
in plasma voriconazole concentrations.  Specifically, the single-dose pharmacokinetic 
profile of inhaled voriconazole suggested drug accumulation in the lung tissue and 
plasma would be insignificant following multiple doses.  Negligible but quantifiable drug 
accumulation was evidenced in lung tissue through 12 days of dosing with undetectable 
trough concentrations on day 5 that increased to values of 0.19 µg/g wet lung weight on 
day 12 (Table 2.2).  The peak lung voriconazole concentration on day 5 was  
6.73 ± 3.64 µg/g wet lung weight was not significantly different than the observed value 
following a single dose (Table 2.1).  However, peak plasma voriconazole concentrations 
were significantly lower following multiple doses compared to a single inhaled dose and 
could be influenced by altered metabolism. 
 
Mice were selected as the pharmacokinetic model for inhaled voriconazole 
despite several limitations.  Additionally, reports using the Aeroneb® Pro vibrating mesh 
nebulizer have correlated acceptable in vitro aerosol characteristics with low lung 
deposition in humans (50, 51).  Published studies have demonstrated lower lung 
deposition of inhaled aerosols in rodents compared to humans due to allometric 
differences between species (52-54).  Voriconazole is also hyper-metabolized in mice and 
rats when administered orally and intravenously (45).  Investigators have successfully 
elevated voriconazole serum concentrations and improved murine survival in a model of 
fungal infection through the inhibition of voriconazole metabolism by grapefruit juice 
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administration (41, 55).  In the present study, no enzymatic inhibition was undertaken.  
Despite the limitations of low lung deposition and hyper-metabolism, pharmacokinetic 
profiles of voriconazole in lung tissue and plasma following single and multiple doses 
demonstrated high drug concentrations as well as elevated drug exposure levels.   
 
2.5. CONCLUSIONS 
An inhaled aqueous solution of voriconazole and sulfobutyl ether-β-cyclodextrin 
is capable of producing clinically relevant lung tissue and plasma concentrations.  Rapid 
and extensive drug distribution from the lung tissue into the blood was observed leading 
to potential advantages over contemporary reports of inhaled antifungals.  Solubilization 
of voriconazole by complexation with sulfobutyl ether-β-cyclodextrin potentially 
contributed to the observed pharmacokinetic properties.  High lung tissue as well as 
plasma concentrations were observed following single and multiple inhaled doses.  
Further studies are needed to demonstrate the influence of dosing interval on 
voriconazole concentrations following multiple inhaled doses.  However, inhaled 
voriconazole presents a potentially beneficial improvement in therapeutic options for the 
treatment of IA. 
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Invasive aspergillosis is a significant cause of morbidity and mortality in heavily 
immuncompromised patients, including those with hematologic malignancies, 
hematopoietic stem cell transplant recipients, and those undergoing solid organ 
transplantation (1, 2).  In many large cancer and transplant centers, the incidence of this 
opportunistic infectious disease has risen over the last two decades (3, 4). Invasive 
aspergillosis is also associated with significant increases in hospital costs as well as 
therapy complications in patients with multiple comorbidities, including delays in anti-
cancer chemotherapeutic regimens (5).  Although the early initiation of appropriate 
antifungal therapy may be effective in the treatment of this disease, establishing a 
diagnosis early in the course of therapy is often difficult (6).  Thus, preventative 
strategies against invasive fungal infections, including the administration of antifungal 
prophylaxis, is often used in high risk patient populations (7, 8). 
 
 Antifungal prophylaxis has been shown in some clinical trials to reduce 
the incidence of invasive mycoses and improve survival rates in high-risk patient groups 
(9-11).  Indeed, prophylactic administration of agents with activity against Aspergillus 
species, i.e. itraconazole, posaconazole, and voriconazole, has been shown to reduce the 
occurrence of invasive fungal infections, including invasive aspergillosis, in allogeneic 
stem cell transplant recipients (9, 10, 12-14).  However, the systemic administration of 
antifungals may predispose patients to the adverse effects of these agents and potentially 
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deleterious drug interactions (15).  Orally administered itraconazole is hampered by the 
low and erratic bioavailability of the oral capsule formulation and gastrointestinal side 
effects associated with the oral solution (9, 10).  Posaconazole and voriconazole are both 
associated with significant pharmacokinetic variability, and low plasma concentrations of 
both agents have been associated with therapy failures (16, 17). 
 
 Attention has begun to focus on the pulmonary delivery of antifungals for 
the prevention of invasive aspergillosis as inhalation of Aspergillus conidia into the lungs 
is the initial step in the pathogenesis of this opportunistic infection.  Targeted pulmonary 
antifungal delivery may lead to high local concentrations within the lungs, the primary 
site of entry and infection, while avoiding some toxicities associated with systemic 
administration. Preclinical work using animal models has demonstrated this to be a 
potentially useful strategy (18-21).  Clinically, aerosolization of amphotericin B lipid 
complex has been shown to be safe in lung transplant recipients and is gaining favor in 
many transplant centers (22, 23).  In addition, a recent study demonstrated that inhaled 
liposomal amphotericin B was effective in preventing invasive pulmonary aspergillosis in 
patients with hematologic malignancies (24). Previous work by our group has also 
demonstrated that aerosolized nanostructure formulations of the poorly water soluble 
agent itraconazole are effective as prophylaxis in murine models in invasive pulmonary 
aspergillosis (20, 21). 
 
 Voriconazole is a triazole antifungal with potent activity against 
Aspergillus species and has been shown to be effective as primary treatment in patients 
with proven or probable invasive aspergillosis (25).  It is currently available both as an 
oral and parenteral formulation, the latter containing the excipient sulfobutyl ether-β-
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cyclodextrin sodium as a solubilizing agent in aqueous solution.  The objective of this 
study was to assess the utility of aerosolized voriconazole as prophylaxis against invasive 
pulmonary aspergillosis caused by Aspergillus fumigatus.  We hypothesized that an 
inhaled aqueous solution of voriconazole derived from the commercially available 
intravenous formulation would prevent invasive disease and improve survival in an 
established murine model of invasive aspergillosis.  Secondary endpoints in this study 
included reductions in pulmonary fungal burden and the degree of invasive disease and 
lung injury as assessed by histopathology. 
 
3.2. MATERIALS AND METHODS 
3.2.1. Isolate 
Conidia were harvested from Aspergillus fumigatus clinical isolate 293 (AF 293) 
cultures grown on potato dextrose agar (Hardy Diagnostics, Santa Maria, CA) by 
washing and scraping agar surfaces with 0.1% Tween 80 in sterile physiological saline 
and filtering through sterile glass wool. Conidia were re-suspended to achieve a final 
inoculum of ~1 x 109 conidia/mL, as confirmed by hemocytometer counts and serial 
plating.  
 
3.2.2. Animal Model 
An established murine model of invasive pulmonary aspergillosis was used as 
previously described (26, 27). Female ICR mice (Harlan Sprague Dawley, Inc., 
Indianapolis, IN) were immunosuppressed by intraperitoneal cyclophosphamide (250 
mg/kg) and subcutaneous cortisone acetate (250 mg/kg) two days prior to inoculation. 
Both cyclophosphamide (200 mg/kg intraperitoneal) and cortisone acetate (250 mg/kg 
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subcutaneously) were re-administered on day 3 post-inoculation, and mice received 
antibiotic prophylaxis with ceftazidime 50mg/kg/day. This study was approved by the 
Institutional Animal Care Use Committee at the University of Texas Health Science 
Center at San Antonio, and all animals were handled in accordance with the American 
Association for Accreditation of Laboratory Animal Care (28). 
To simulate pulmonary pathogenesis, mice were placed inside an acrylic chamber, 
and A. fumigatus conidia were introduced by aerosolizing the conidial suspension with a 
small particle nebulizer (Hudson Micro Mist, Hudson RCI, Temecula, CA) driven by 
compressed air (29). A standard exposure time of 1 hour was used to allow for complete 
aerosolization of the conidial suspension. Starting inocula were assessed by colony 
forming unit (CFU) enumeration from mice one hour post-inoculation. 
 
3.2.3. Antifungal Therapy 
Mice were randomly assigned to three treatment groups: inhaled voriconazole  
(5 mL of 6.25 mg/mL of the commercially available voriconazole IV formulation 
containing 100 mg/mL of sulfobutyl ether-β-cyclodextrin sodium via 20 minute 
aerosolization twice daily; Pfizer, Inc., New York, NY), amphotericin B deoxycholate  
(1 mg/kg interperitoneally daily; Apothecon, Princeton, NJ), or aerosolized sulfobutyl 
ether-β-cyclodextrin sodium as control (5mL of 100 mg/mL solution via 20 minute 
aerosolization twice daily; Captisol®, CyDex  Pharmaceuticals, Inc., Lenexa, KS).  
Voriconazole and control mice received aerosolized solutions in a nose-only dosing 
chamber by a Aeroneb® Pro micropump nebulizer system with air-flow through the 
chamber at 1 L/min.  Prophylaxis was begun two days prior to pulmonary inoculation and 
continued for a total of 10 days (day 7 post-inoculation). Amphotericin B was initiated on 
day 1 following inoculation and continued until day 7 post-inoculation.  Mice were 
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monitored for an additional 5 days following discontinuation of antifungals. Animals that 
appeared moribund prior to the end of the study were euthanized by halothane and death 
was recorded as occurring the next day. Twelve mice from each group were randomly 
selected and euthanized on day 8 and the lung tissue harvested for fungal burden analysis. 
Additional mice were randomly selected from each group and euthanized on day 8 and 
day 12 for histopathology. 
 
3.2.4. Pulmonary Fungal Burden 
Lungs were homogenized in sterile saline (total volume 2 mL) supplemented with 
gentamicin and chloramphenicol using a tissue homogenizer (Polytron Dispensing and 
Mixing Technology PT 2100, Kinematica, Cincinnati, OH). Serial dilutions were 
prepared in sterile saline and plated in duplicate onto potato dextrose agar. Following 24 
hours of incubation at 37°C, colonies were enumerated and colony forming units (CFU) 
per gram of lung tissue for each animal were calculated. 
Pulmonary fungal burden was also quantified by real-time quantitative 
polymerase chain reaction (qPCR) as previously described (30, 31). Briefly, DNA was 
extracted from 90 mL of lung homogenate with the use of a commercially available kit 
(DNeasy Tissue Kit, Qiagen, Valencia, CA) according to the manufacturer’s instructions. 
DNA samples were analyzed in duplicate with the use of the ABI PRISM 7300 sequence-
detection system (Applied Biosystems, Foster City, CA) with primers and dual-labeled 
fluorescent hybridization probes specific for the A. fumigatus 1,3-β-glucan synthase 
(FKS) gene (GenBank accession number U79728) (32). The threshold cycle (Ct) of each 
sample was interpolated from a six-point standard curve generated by spiking naive 
mouse lungs with known amounts of conidia (102 to 107). The resulting data was 
expressed as conidial equivalents (CE). 
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3.2.5. Histopathological Evaluation 
Changes in lung histopathology were evaluated among the different groups on 
days 8 and 12 post-inoculation. Following sacrifice, 10% v/v formaldehyde was instilled 
into the lungs via the trachea. Lungs were harvested and placed into 10% v/v 
formaldehyde. The lungs were then processed and embedding into paraffin wax. Coronal 
sections of the entire lung were obtained at a thickness of 4-6 µm and mounted on slides. 
Sections were stained with hematoxylin and eosin and viewed by light microscopy. 
 
3.2.6. Statistics 
Survival was plotted by Kaplan-Meier analysis, and differences in median 
survival and percent survival between prophylaxis groups were analyzed by the log-rank 
test and chi-square test, respectively, using Prism software version 5 (GraphPad, San 
Diego, CA). Differences in fungal burden endpoints (CFU/g and CE) were assessed for 
significance by analysis of variance with Tukey’s post-test for multiple comparisons. A 




Mice that received aerosolized voriconazole had a survival advantage compared 
to controls and those that received amphotericin B. As shown in Figure 3.1, survival 
while receiving antifungal therapy was 92% for aerosolized voriconazole and was 
significantly greater than that of control (aerosolized sulfobutyl ether-β-cyclodextrin 
sodium, 25%; p <0.05) and amphotericin B (31%; p <0.05).  This survival benefit 
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continued once therapy was discontinued with 67% of animals that received aerosolized 
voriconazole surviving until day 12 post-inoculation, compared to 17% that received 
control (aerosolized sulfobutyl ether-β-cyclodextrin sodium; p <0.05) and 23% that 
received amphotericin B (p <0.05).  No significant difference was observed in survival 
between animals that received control and amphotericin B. The median survival time for 
mice that received aerosolized voriconazole (>12 days) was also significantly longer than 
those that received control and amphotericin B deoxycholate, 7.5 and 7 days, respectively 
(p <0.01). 
 
3.3.2. Pulmonary Fungal Burden 
Although survival was improved in animals that received aerosolized 
voriconazole, this benefit could not be explained by reductions in pulmonary fungal 
burden.  Analysis of lung fungal burden demonstrated no significant differences between 
the treatment groups as measured by both CFU enumeration or qPCR tests (Table 3.1). 
The median lung fungal burden 1 hour post-inoculation was 3.99  log10 CFU/g.  For all 
evaluated lungs, including mice from days 8 and 12 post-inoculation, median fungal 
burden values were 4.43 log10 CFU/g for controls, 4.14 log10 CFU/g for animals that 
received aerosolized voriconazole, and 4.33 log10 CFU/g for those that received 
amphotericin B.  Similar results were also observed when measured by quantitative PCR.  
Conidial equivalent values were higher than CFU counts, however, no significant 




Although no differences in tissue fungal burden were observed, marked 
differences in lung histopathology were found among the different treatment groups 
(Figure 3.2). Animals that received control (aerosolized sulfobutyl ether-β-cyclodextrin 
sodium) or amphotericin B were noted to have more severe invasive disease and gross 
abnormalities within the lungs compared to those that received aerosolized voriconazole.  
Specifically, lungs from control and amphotericin B animals had more necrotic lesions 
within the small airways, including epithelial disruption, congestion, necrosis, 
angioinvasion, and vascular lesions on day 8 post-inoculation. The extent of pulmonary 
lesions in mice that received amphotericin B was more variable than those that received 
control or aerosolized voriconazole indicating inconsistent in vivo activity.  Mice that 
received aerosolized voriconazole had fewer signs of invasive disease and markedly 
improved histological findings at this time point. Similar findings among the antifungal 
groups were also noted on day 12 post-inoculation, supporting the survival results 
demonstrating that the protective effects of voriconazole were not lost once therapy was 
discontinued.  The differences in histopathology between voriconazole and control could 
not be explained by the use of sulfobutyl ether-β-cyclodextrin sodium as the control as 
this solubilization agent was aerosolized to both groups.  In addition, preliminary safety 
studies have shown both aerosolized voriconazole and sulfobutyl ether-β-cyclodextrin 
sodium to be well-tolerated with no lung injury or inflammatory changes on histology in 
uninfected mice that have received twice daily dosing for multiple days (data not shown). 
 
3.4. DISCUSSION 
The lungs are the primarily site of inoculation and invasive disease in invasive 
pulmonary aspergillosis (33, 34). Invasive hyphal growth and subsequent angioinvasion 
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allow dissemination of the organism and invasive disease in other organs, which is 
associated with a poor prognosis and high mortality despite antifungal therapy in severly 
immunocompromised patients (35).  Because of the high morbidity and mortality 
associated with invasive aspergillosis, and difficulties in establishing a diagnosis early in 
the course of disease, many centers utilize preventative strategies, including the 
administration of antifungal as prophylaxis in patients at high risk.   
 
Antifungal prophylaxis has been shown in clinical trials to reduce the incidence of 
invasive fungal infections and improve survival.  Two open-label studies have reported 
reductions in the incidence of invasive fungal infections in patients who received 
itraconazole prophylaxis compared to those who received fluconazole (9, 10).  These 
differences were due to fewer invasive mould infections (primarily invasive aspergillosis) 
in those randomized to itraconazole.   Recently, posaconazole has been shown to be 
effective in reducing the incidence of invasive fungal infections and invasive fungal 
infection-related mortality in patients receiving autologous or allogeneic stem cell 
transplants, and those with neutropenia secondary to chemotherapy (12, 13).  Preliminary 
results from a study comparing voriconazole to fluconazole as prophylaxis in allogeneic 
blood and marrow transplant recipients also demonstrated a trend towards fewer invasive 
infections caused by Aspergillus species in those randomized to voriconazole (14).  
However, the systemic exposure of patients to antifungal agents is not without risks as 
patients are predisposed to the adverse effects and clinically significant drug interactions 
associated with these agents.  The usefulness of orally administered itraconazole solution 
is hampered by significant gastrointestinal side effects, which were reported to occur in 
up to 25% of patients in the prophylaxis studies and were a major reason for high patient 
attrition rates (9, 10).  In addition, oral formulations of itraconazole and posaconazole are 
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hampered by limited and erratic bioavailability that may limit prophylactic efficacy.   A 
small subset analysis of allogeneic stem cell transplant patients who received 
posaconazole as antifungal prophylaxis reported lower plasma concentrations in patients 
who developed invasive fungal infections compared to those who did not (17).  Similarly, 
variable pharmacokinetics and therapeutic failures with low plasma concentrations have 
been reported for voriconazole with systemic administration (36-38).  
 
Targeted drug delivery to the lungs as antifungal prophylaxis is one strategy that 
is being investigated to overcome the obstacles associated with systemic administration 
of these agents.  Animal studies have reported improved survival with aerosolized 
administration of amphotericin B deoxycholate and lipid formulations of this polyene 
(18, 19, 39).  Inhaled amphotericin B has also been shown to be safe and effective as 
prophylaxis in lung transplant recipients and patients with hematologic malignancies 
(24), and this strategy  has begun to gain favor in transplant centers (7, 23, 40-43).  
However, decreased in vitro activity and clinical failures have been reported with the use 
of amphotericin B against infections caused by non-fumigatus Aspergillus species, 
including A. flavus and A. terreus (44-46).    
 
Previous studies by our group have demonstrated that aerosolized administration 
of azoles may be effective as prophylaxis against invasive pulmonary aspergillosis. In a 
non-neutropenic model of invasive pulmonary aspergillosis caused by Aspergillus flavus, 
a survival rates were significantly improved in mice administered inhaled suspensions of 
nanoparticulate crystalline and amorphous formulations of itraconazole compared to 
controls and orally administered itraconazole solution (47).  Similarly, survival was also 
improved in mice administered nanoparticulate amorphous itraconazole compared to 
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controls in mice with invasive pulmonary aspergillosis caused by A. fumigatus with the 
same neutropenic model used in the current study (27). 
 
In the current study, significant improvements in overall survival rates and 
median survival times were observed in mice that received inhaled aqueous voriconazole 
compared to controls and animals administered amphotericin B deoxycholate as 
treatment.  In addition, marked improvements in lung histopathology were observed in 
animals the received inhaled voriconazole compared to the other therapy groups.  These 
results suggest that aerosolized voriconazole may be an effective strategy for targeted 
delivery of antifungal prophylaxis to the primary site of infection of this opportunistic 
infection.  These results are encouraging as we adapted the commercially available 
intravenous formulation with adjustments to ensure that the osmolality (293.2 mOsm/kg) 
and pH (6.4 to 6.8) were within physiologically acceptable ranges for pulmonary delivery 
(48).  
 
These encouraging results for inhaled voriconazole are obfuscated by no 
significant decreases in pulmonary fungal burden measurements among any of the 
antifungal groups compared to controls.  This lack of a reduction in pulmonary fungal 
burden has been observed in previous work by our and in other studies that have 
evaluated triazoles for invasive aspergillosis (21, 49, 50).  As fungal burden was 
measured by colony-unit enumeration and quantitative PCR, it is unclear how well these 
methods differentiate between invasive hyphae versus ungerminated conidia colonizing 
the airways following inoculation within an aerosol chamber.  However, the 
histopathology results observed in this study suggest that the improved survival may be 
attributed to reductions in invasive disease following aerosolized delivery of 
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voriconazole.  Another limitation of our study is that the survival rates in mice that 
received amphotericin B deoxycholate as treatment were low.  However, the survival 
results in this study are consistent with those previously reported after four days of 
treatment at the same dose (1 mg/kg/day) (51).  Furthermore, survival rates have only 
reached 50% when the dose of amphotericin B deoxycholate has been increased to 3 
mg/kg/day or high dose liposomal amphotercin B (10 mg/kg/day) has been used in this 
animal model (52).  It is unclear how well amphotericin B formulations would perform if 
administered as prophylaxis or by aerosolization in this neutropenic murine model. 
 
3.5. CONCLUSIONS 
In conclusion, inhaled voriconazole was effective as prophylaxis in a neutropenic 
murine of invasive pulmonary aspergillosis.  This was evident by improvements in 
survival and lung histopathology in mice administered voriconazole by aerosolization 
compared to controls and those treated with amphotericin B deoxycholate.  Thus, inhaled 
voriconazole represents a potential improvement in antifungal prophylaxis.  Additional 
studies are warranted to evaluate the efficacy and tolerability of inhaled voriconazole and 
further justify its therapeutic implementation.  
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Chapter 4: Dose Tolerability of Chronically Inhaled Voriconazole 
Solution in Rodents 
 
4.1. INTRODUCTION 
Invasive pulmonary aspergillosis (IPA) is an opportunistic infection that primarily 
affects immuncompromised individuals.  The populations with the highest infection rates 
include patients with hematologic malignancies, hematopoietic stem cell transplant 
recipients, and those undergoing solid organ transplantation (1, 2).  The causative 
epidemiology of IPA is also changing to more serious Aspergillus spp. with mortality 
rates up to 75% in some cases and substantial healthcare costs per case (3-6).  The serious 
effects of IPA have prompted investigations to improve therapeutic options for this 
disease (7, 8).   
 
In 2002, Herbrecht and colleagues published the results from a multi-center 
randomized controlled clinical trial that established voriconazole as the first-line 
therapeutic option in the treatment of IPA (9, 10).  The study compared the then standard 
of care, intravenous (IV) amphotericin B deoxycholate, with intravenous voriconazole 
with the option to switch patients to oral (PO) voriconazole.  The authors reported 12 
week survival rates of 70.8% and 59.7% for voriconazole and amphotericin B treated 
patients, respectively.  Although this study changed the treatment paradigm for IPA, the 
mortality rates remain high, prompting researchers to investigate different treatment 
modalities and approaches to the therapeutic management of IPA (4, 6).  Targeted 
antifungal delivery to the lung was theorized to cause high drug concentrations at the 
primary site of infection leading to increased efficacy and better patient outcomes but 
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with lower systemic exposure and subsequent decreased rates of adverse events 
associated with the antifungal agent.   
 
One of the promising therapeutic approaches included the prophylactic inhalation 
of antifungals, including aerosolized amphotericin B formulations, in patients at high risk 
for IPA (11-14).  Although no product is approved for inhalation therapy, the various 
formulations of amphotericin B have been investigated by nebulization, including the 
deoxycholate (Fungizone®), lipid complex (Abelcet®), or liposomal (Ambisome®) 
forms.  These different formulations, nebulizers, and regimens have led to inconsistent 
reports of prophylactic efficacy and patient tolerability leading to no unified standard for 
aerosolized amphotericin B prophylaxis (15).  Typically, systemically administered 
amphotericin B has severe dose limiting adverse effects, including electrolyte 
abnormalities, nephrotoxicity, and infusion-related toxicities (16).  Inhaled amphotericin 
B has low incidence of these systemic events due to extensive retention of the drug in the 
lung tissue with very little distribution to the systemic circulation (12, 17).  Adverse 
events associated with inhaled amphotericin B include nausea and vomiting, dysgeusia 
and taste perversion, dysphagia, coughing and bronchospasm, and decreases in 
respiratory function with lower incidence rates associated with lipid formulations of 
amphotericin B (18).  Discontinuation of amphotericin B prophylaxis due to poor patient 
tolerability has been reported in up to 25% of patients receiving the deoxycholate 
formulation with lower rates for the lipid formulations.  
 
Pre-clinical testing of aerosolized itraconazole in animal models have been 
investigated and reviewed in efforts to reduce complications and inconsistencies 
associated with inhaled amphotericin B (8, 19-21).  These researchers administered nano-
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suspensions of engineered crystalline and amorphous itraconazole particles to mice to 
establish pharmacokinetic and efficacy profiles for inhaled nanoparticulate itraconazole.  
Itraconazole was retained in lung tissue for several hours with very little drug distributing 
to the blood after administration with favorable pharmacokinetic parameters (21-23).   In 
addition, 12-day survival rates in mice infected with A. flavus and A. fumigatus treated 
daily with inhalations of itraconazole were significantly better than a positive control and 
were 50-80% and 35%, respectively (24, 25).  Inhaled nanoparticulate itraconazole was 
also well tolerated by evaluation of histopathological lung tissue sections (26). 
 
Although nanoparticulate itraconazole suspensions had encouraging results, 
voriconazole is the first-line therapeutic agent for the treatment of IPA due to improved 
survival benefits and with an expanded antifungal activity compared to itraconazole (27).  
Voriconazole is generally well tolerated with major adverse events that include abnormal 
vision, fever and chills, rash, nausea and vomiting, and headache (28).  Hepatotoxicity as 
measured by elevations in liver function tests, have also been correlated with peak plasma 
concentrations (29).  Systemic administration of voriconazole has led to variable 
pharmacokinetic properties and poor lung tissue distribution resulting in-part from non-
linear pharmacokinetics in adults resultant from saturable metabolism (28, 30, 31).  
Through targeted drug delivery to the lungs, inhaled voriconazole could offer higher 
tissue concentrations than possible following systemic drug delivery and lead to 
improvements over both inhaled amphotericin B and itraconazole as prophylaxis against 
IPA.   
 
The IV form of voriconazole, a powder for injection (Vfend® IV), contains 
voriconazole with sodium sulfobutyl ether-β-cyclodextrin in an inclusion complex to 
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improve the aqueous solubility of the poorly water soluble active agent.  High lung tissue 
and plasma concentrations with a lung tissue to plasma concentration ratio of 1.4 to 1 
were observed in a single and multiple dose pharmacokinetic study of inhaled 
voriconazole in mice (32).  In addition, this inhaled formulation of voriconazole as 
prophylaxis resulted in improved survival in a murine model of IPA (33).  In these 
studies, phenotypic evaluation of murine behavior and outward appearance suggested 
inhaled voriconazole was well tolerated.  The purpose of this study was to perform a 
more thorough analysis was performed with inhaled voriconazole administered twice 
daily (BID) to assess for hepatic, electrolyte, renal, or erythrocyte or histiocyte 
abnormalities as suggested in the prescribing information for Vfend® IV (34).  Organs 
were also evaluated for histopathological changes at the site of administration and 
absorption as well as metabolism and elimination.  It is hypothesized that inhaled 
voriconazole is well tolerated and comparable to a negative inhaled control group.  
  
4.2. MATERIALS AND METHODS 
4.2.1. Materials 
Vfend® IV (Pfizer Inc., New York, NY, USA), voriconazole, and sulfobutyl 
ether-β-cyclodextrin, Captisol®  were generously supplied by CyDex Pharmaceuticals, 
Inc. (Lenexa, KS).  The following items were purchased from the respective suppliers: 
sterile water for injection (SWFI) and normal saline from Cardinal Health (Dublin, OH); 
sodium tetraborate decahydrate, boric acid, sodium acetate trihydrate, and neutral 
buffered formalin 10% solution from Sigma-Aldrich, Inc. (St. Louis, MO); acetic acid 
from Sigma-Aldrich Laborchemikalien GmbH (Seelze, Germany); heparin sodium 
injection, USP from Baxter Healthcare Corporation (Deerfield, IL); Lavender-topped 
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(LT) BD Microtainer® Tubes with K2E (K2EDTA) and Red-topped (RT) BD 
Microtainer® No additive Tubes from Becton, Dickinson and Company (Franklin Lakes, 
NJ); and HPLC grade solvents including ethyl acetate from Spectrum Chemical Manuf. 
Corp. (Gardena, CA); acetonitrile from Fisher Scientific (Fair Lawn, NJ); and methanol 
from EMD Chemicals Inc. (Gibbstown, NJ).   
 
4.2.2. Study Design 
Male and female Sprague-Dawley rats, Harlan Sprague Dawley, Inc. 
(Indianapolis, IN), with an average mass of 250 g at the beginning of the study, were 
caged separately with free access to food and water.  Prior to dosing, animals that would 
receive any treatment were acclimatized for up to 20 minutes twice daily over 3 days to 
rodent nose-only restraint systems (Battelle Toxicology Northwest, Richland, WA).  All 
animals were handled and maintained in accordance with The University of Texas at 
Austin Institution Animal Care and Use Committee (IACUC) guidelines and in 
accordance with the American Association for Accreditation of Laboratory Animal Care 
guidelines.   
 
An isotonic drug solution was prepared with Vfend® IV reconstituted and diluted 
with SWFI to a voriconazole concentration of 6.25 mg/mL as described previously (32).  
For dose tolerability analysis, 45 male and 45 female rats were randomly divided into 
three treatment groups: High-dose (HD) that received 5 mL of drug solution nebulized 
over 20 minutes; Low-dose (LD) that received 2.5 mL of drug solution nebulized over  
20 minutes; and Control (C) that received 5 mL of normal saline over 20 minutes.  
Another group of 20 rats, designated No Treatment (NT), received no treatment but were 
housed with free access to food and water and used for establishment of normal 
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laboratory value ranges for statistical comparison.  A separate group of 8 male rats was 
used for pharmacokinetic evaluation of peak and trough voriconazole concentrations in 
lung tissue and plasma on day 3.  Treatments were administered using an in-line 
Aeroneb® Pro micro pump nebulizer from Aerogen, Inc. (Mountain View, CA) with a 
nose-only dosing chamber with an air-flow rate of 1 L/min through the chamber.  
Treatments lasted for up to 20 minutes and all solutions were nebulized to dryness.  
Treatments were administered BID beginning at 08:00 and 16:00 and continued for up to 
21 days with no additional treatments through day 28.  Animals were sacrificed on days 
7, 14, 21, and 28 by isoflurane narcosis.  NT animals were euthanized on day 28 after 
having received no treatments by isoflurane narcosis.  Animals designated for 
pharmacokinetic analysis on day 3 were euthanized by CO2 narcosis.  Euthanasia was 
ensured by desanguination via cardiac puncture followed by thoracotomy.   
 
4.2.3. Plasma and Tissue Extraction for Pharmacokinetic Analysis 
On day 3, whole blood collected via cardiac puncture was placed into heparinized 
vials and centrifuged at 9000 RPM for 15 minutes using a Microfuge® 18 
Microcentrifuge (Beckman Coulter, Fullerton, CA).  Plasma was collected into clean 
vials and frozen at -20°C until analysis.  Lungs were excised and cleaned from external 
lymphatic, connective, and airway tissue, placed in a clean vial, and frozen at -20°C until 
analysis. 
Calibration standards, plasma, and homogenized lung samples were analyzed 
using similar methods to those previously published (32, 35, 36).  Briefly, voriconazole 
was extracted from plasma samples through the addition of acetonitrile, centrifugation, 
and supernatant extraction with fluconazole as an internal standard.  The supernatant 
liquid was evaporated under a gentle stream of nitrogen and residual solids, including 
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voriconazole, were re-dispersed with mobile phase and analyzed spectrophotometrically.  
For lung analysis, lung tissue was homogenized with 2 mL of normal saline per gram wet 
lung weight, 0.2M borate buffer (pH 9.0) was added, followed by three liquid-phase 
extractions with ethyl acetate.  The liquid from collected supernatant fractions were then 
evaporated under a gentle stream of nitrogen.  Any residual solids, including 
voriconazole, were reconstituted in 200 µl of acetonitrile and centrifuged.  A 4000 Q 
TRAP mass spectrometer (Applied Biosystems, Foster City, CA) coupled with an online 
HPLC (Shimadzu, Columbia, MD) was used to analyze the samples.  10 µl samples were 
injected into Shimadzu Prominence UFLC system equipped with an Restek C18  
(4.6 x 50mm, 5 µm, 110 Å) column and eluted with mobile phase A (water with 0.1% 
formic acid) and B (acetonitrile with 0.1% formic acid) by a gradient of 20%B for  
0.5 min, then 20%-50%B over 0.5 min, followed by 50%B for 3 min, at a flow rate of  
1 ml/min.  Sample was directly eluted from the column into the electrospray ion (ESI) 
source of 4000 QTRAP.   The heated nebulizer of 4000 QTRAP was set at 700°C, the 
declustering potential (DP) at 40.  The Multiple Reaction Monitoring (MRM) scan 
experiment with unit resolution for Q1 and low resolution for Q3 was used to quantify 
voriconazole content.  The MRM transitions were set as follow, Q1=350.2, Q3=127.4, 
CE=40.  The limit of detection for voriconazole was 5 pg. 
 
4.2.4. Blood and Tissue Processing and Testing 
Following euthanasia and cardiac puncture for HD, LD, C, and NT groups, whole 
blood was collected into lavender and red-topped sample tubes.  Lavender tubes were 
gently inverted 10 times and stored under refrigeration until a complete blood count with 
differential (CBC w/ dif.) blood test could be performed within 24 hours from sample 
collection (IDEXX Laboratories, Inc., Westbrook, ME).  Whole blood in red topped 
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tubes was allowed to coagulate and centrifuged at 3000 RPM for 15 minutes with a 
Microfuge® 18 Microcentrifuge.  Serum was collected into clean vials and stored at 4°C 
until serum chemistry analysis could be performed within 24 hours from sample 
collection by IDEXX Laboratories.  Whole blood was also collected into heparinized 
tubes and centrifuged at 9000 RPM for 15 minutes.  On days 14 and 21, excess whole 
blood was collected into heparinized vials and processed in the same manner as described 
previously for trough voriconazole plasma concentration determination.  Serum 
chemistry samples had the following individual tests performed per sample: alkaline 
phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
albumin, total bilirubin, total protein, globulin, blood urea nitrogen (BUN), creatinine, 
cholesterol, glucose, calcium, phosphorous, chloride, potassium, and sodium.  The CBC 
w/diff test included analysis of the following parameters: white blood cell count (WBC), 
red blood cell count (RBC), hemoglobin (Hgb), hematocrit (Hct), and platelet count.  
 
Following thoracotomy, lungs, liver, kidneys, and spleen were removed from each 
animal.  Prior to preserving in formalin, the lungs were inflated with 10% buffered 
formalin and tied shut with silk suture, the liver was dissected into three parts, and the 
kidneys were longitudinally bisected.  Following processing, tissues were preserved 
separately in 40-50mL of 10% buffered formalin for at least 96 hours prior to fixing and 
sectioning.  The post-dissection processing steps ensured penetration of the preservative 
into the tissues.  All tissues were randomly assigned sequential numbers and shipped to 
IDEXX Laboratories, Inc. for fixing, sectioning, and staining.  Pathologic evaluation was 
independently performed in a blinded manner by both an IDEXX pathologist and a 
pulmonary pathologist.   
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4.2.5. Quantitative Analysis of Lung Tissue 
Lung tissue slides were digitally scanned at 20x magnification using a 
ScanScope® CS (Aperio Technologies, Inc., Vista, CA), and analyzed using ImageScope 
software (Aperio Technologies, Inc., Vista, CA).  The Cimolai histopathologic 
inflammatory score was used by a blinded pulmonary pathologist to assess signs of 
inflammation in lung airways (37).  In this scoring scheme, the histologic response in the 
lung was graded based on the degree and location of inflammation with possible scores 
ranging from 0 to 26, least to most severe immunologic response.  A second quantative 
pathological evaluation of lung tissues was developed through assessment of a novel 
marker of immune response in the lungs, the Respiratory Bronchiole Index (RBI).  
Inhalation injury occurs at the respiratory bronciole-alveolar interface due to inhalation of 
particulate and solubilized irritants (38, 39).  Therefore, ten randomly chosen respiratory 
ducts, the site of transition from the respiratory bronchiole to the alveolar space, were 
marked on the digitized images of all lung sections where two blinded investigators 
independently counted the number of pulmonary macrophages present at respiratory 
bronchiole alveolar ducts sites per slide under 20x magnification.  The individual scores 
were then normalized and averaged between evaluators to provide the RBI.  Validation of 
the RBI was not performed against tissues with known or controlled alveolar macrophage 
responses, but values were instead used to statistically compare lung tissue between 
treatment groups. 
 
4.2.6. Statistical Analysis 
Statistical analysis of results was performed using JMP®-7 (e-academy Inc., 
Ottawa, Ontario, Canada).  Results from blood work were evaluated by analysis of 
variance (ANOVA) with Dunnett’s Control test for the NT group with a p-value ≤0.05 
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for significance.  RBI scores were also compared between treatment groups using JMP®-




Peak plasma samples were collected 30 minutes after completion of nebulization 
due to previous pharmacokinetic findings in mice (32).  Following BID dosing for 3 days, 
peak voriconazole concentrations in lung tissue were 0.85 ± 0.63 µg/g wet lung weight 
for the high dose group and 0.37 ± 0.01 µg/g wet lung weight for the low dose group with 
corresponding peak plasma concentrations of 0.58 ± 0.30 and 0.09 ± 0.06 µg/mL, 
respectively (Table 1).  Trough voriconazole concentrations taken on day 3 immediately 
prior to the 08:00 dose were likewise 0.042 ± 0.002 and 0.044 ± 0.004 µg/g wet lung 
weight in lung tissue for high and low dose groups and 0.01 ± 0.004 and  
0.010 ± 0.003 µg/mL in corresponding plasma samples.  After additional days of dosing, 
trough plasma samples were 0.02 and 0.03 µg/mL for high and low dose groups on day 
14 and remained consistent with day 21 trough concentrations of 0.03 ± 0.01 and  
0.03 ± 0.003 µg/mL for high and low dose groups. 
 
4.3.2. Serum Chemistries and Complete Blood Counts 
When all laboratory values were analyzed by treatment groups, statistically 
significant increases were observed for components of the hepatic function test compared 
to the NT group, including ALP, albumin, and total bilirubin (Table 2A-D).  However, 
these increases were observed for both inhaled normal saline control and active treatment 
groups and would not be deemed clinically significant.  Similar patterns of statistical 
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significance but clinical irrelevance were found for decreases in gamma globulin, BUN, 
phosphorous, and WBC as well as with elevations in calcium, phosphorous, sodium, 
chloride, and platelet count.  Sub-group evaluation by day of analysis and animal gender 
provided similar patterns of sporadic statistical but not clinical significance with the 
absence of trends, except for consistent decreases in RBC count and corresponding drops 
in Hct from day 21 to day 28 for C, LD, and HD treatment groups (data not shown). 
 
4.3.3. Histopathology 
Qualitative pathological descriptions of liver, kidney, and spleen sections 
suggested that inhalation of high or low dose voriconazole produced no histological 
differences as compared to inhaled normal saline control (data not shown).  However, 
pathological descriptions of lung tissue suggested inhaled voriconazole promoted an 
increase in alveolar and respiratory duct macrophages. However, no inflammatory cell 
infiltrate of neutrophils, eosinophils or lymphoctyes were noted.  The lungs were also 
absent of pathological changes indicative of ulceration of the airway, interstitial changes, 
or edema (Figure 2).  Application of the Cimolai scoring system on lung tissues failed to 
differentiate between treatment groups with scores of 0 to 1, on a 0 to 26 scale.  
Therefore, quantative analysis of lung histiocytosis was performed through use of the 
RBI, which demonstrated significant elevations for both LD and HD groups compared to 
C group animals for days 7, 14, 21, and 28.  In addition, RBI values between LD and HD 




The poor prognosis of IPA has prompted investigation of targeted antifungal 
delivery to the lungs via nebulization.  Positive results following initial animal 
experimentation with inhaled amphotericin B led investigators to early clinical trials with 
varying results (40, 41).  Although initial clinical utilization of inhaled amphotericin B 
were generally well tolerated with acceptable lung physiological changes given the 
severity of IPA, large numbers of patients experienced therapy limiting cough, dyspnea, 
and/or nausea and vomiting (42, 43).  Animal studies also suggested positive clinical 
outcomes could exist for aerosolized suspension of nano-structured itraconazole (24-26).  
Both aerosolized amphotericin B and itraconazole reported high lung tissue 
concentrations with very low systemic drug distribution following inhalation.  In one 
study, high tissue concentrations but low systemic drug distribution following targeted 
antifungal delivery was supplemented with systemic administration of the antifungal and 
suggested improved survival as treatment in a rodent model of IPA (44).  The 
contributory effect of an inhaled and targeted antifungal with systemic drug distribution 
could improve survival through prevention of fungal dissemination from alveolar spaces 
into the pulmonary capillaries as observed following inhalation only (45). 
 
Correlations have been suggested between plasma drug concentrations and 
adverse events as well as efficacy against IPA for voriconazole in humans (35, 46).  
However, substantial intra-patient as well as intra-species variability in absorption, 
distribution, and metabolism associated with oral and intravenous voriconazole limit the 
utility of human-defined peak or trough voriconazole concentrations associated with 
efficacy and toxicity with the pharmacokinetic findings in this study (47-50).  Thus, the 
dose of inhaled voriconazole used in the HD group, equivalent to a 31.25 mg exposure 
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dose, was efficacious in an immunosuppressed murine model of IPA with 67% survival 
over 12 days.  Although voriconazole concentrations were not assessed in infected 
animals, peak and trough plasma concentrations following multiple doses in healthy mice 
were 2.32 and 0.28 µg/mL, respectively, that were lower than those associated with 
efficacy in humans (51).  These same healthy mice had peak lung concentrations of 6.73 
µg/g wet lung weight following multiple doses which likely contributed to improved 
murine survival (32, 33).  In the present study, HD group rats had an equivalent peak 
tissue to plasma concentration ratio, 1.5 to 1, following 3 days of BID dosing while a 
higher ratio was observed in LD group rats, 4.1 to 1, with corresponding trough 
concentration ratios of 3.8 to 1 and 4.0 to 1.  These varied partition factors based on 
concentration ratios between tissue and plasma are likely due to altered voriconazole 
metabolism as demonstrated by induction of voriconazole metabolism following oral and 
IV doses in rodents (49, 52).  Nevertheless, moderate trough plasma voriconazole 
accumulation was observed following BID dosing for up to 21 days, necessitating further 
pharmacokinetic analysis of voriconazole in lung tissue and plasma following inhalation 
to verify metabolic induction-based pharmacokinetic variations.   
 
Despite possible changes in voriconazole pharmacokinetics following multiple 
inhalations in a rodent model, drug distribution to the plasma was markedly improved 
compared to reports of drug distribution following inhalation of amphotericin B and 
itraconazole in the literature (21, 23, 25, 53, 54).  The relative elevation of voriconazole 
plasma drug concentrations were likely a result of improved drug solubility due to the 
cyclodextrin in the formulation leading to improved drug absorption in the lungs (55-58).  
Although the toxicological profile of inhaled sulfobutyl ether-β-cyclodextrin has not been 
publicly disclosed, limited data with similar cyclodextrin agents have been shown to be 
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safe and well tolerated following inhalation (59, 60).  Specifically, Evrard et al. 
demonstrated inhaled cyclodextrins were well tolerated through evaluation of pulmonary 
epithelium for histological signs of inflammation, morphology and cellular distribution of 
histiocytes in bronchoalveolar lavage fluid (BAL), bronchial hyperresponsiveness, kidney 
histology, and BUN values.  Thus, the differences between treatment and control groups 
likely represent responses to inhaled voriconazole and not the cyclodextrin.   
 
Elevated hepatic function values (Table 2A) were observed in all treatment 
groups and represent artifacts resulting from the method of euthanasia and duration of 
hypoxia prior to cardiac puncture and blood sampling (61, 62).  In addition, observed 
hyperglycemia (Table 2C), although not statistically significant between NT and 
treatment groups (HD, LD, and C groups), may be linked to stress imposed through 
chronic handling and manipulation during animal dosing as well as the use of isoflurane 
in euthanasia (63-65).  Numerous laboratory test values were statistically significant 
between NT and treatment groups but without clinical significance either due to 
comparable differences between C and LD or HD groups; e.g. ALP, albumin, bilirubin, 
globulin, sodium (Table 2A-C); or isolated differences in one group without evidence of 
trends between groups or throughout treatment; e.g. BUN, creatinine, calcium, 
phosphorous, WBC, Hgb, and platelet count (Table 2B-D). 
 
Qualitative pathological evaluation of liver, kidney, and spleen tissue samples 
demonstrated no difference between treatment groups as well as no differences for sub-
group analysis based on sample day or gender between HD or LD groups and the control 
group.  Pathologist descriptions of lung tissues, however, suggested inhaled voriconazole 
high dose and low dose groups could have increased frequency of histiocytes in the 
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respiratory ducts compared to the inhaled normal saline control group.  However, no 
histologic changes in the airway or interstitial space were noted.  Additionally, no 
inflammatory response (e.g. migration of neutrophils, eosinophils, or lymphocytes) was 
seen at any time point in either the C or HD and LD groups.  Thus, pathologic description 
of the lungs following inhaled voriconazole suggest isolated elevations in alveolar 
macrophages that would resolve following cessation of therapy (20, 66).   
 
Quantative evaluation of lung tissue inflammation through the Cimolai scoring 
system, as previously utilized (26), was not able to differentiate between treatment groups 
with values of 0 for all groups.  Specifically, voriconazole treated lungs had no signs of 
airway inflammation, peri-vascular inflammation, or signs of pneumonia that are 
weighted heavily in the Cimolai Score.  Therefore, the RBI, was developed to assess the 
presence of observed alveolar macrophages at some respiratory bronchiole-alveolar 
spaces.  Alveolar macrophages, a non-specific first-line host defense response to inhaled 
foreign molecules at the respiratory duct, represented an objective comparison of 
histiocyte presence at the most-likely site for deep-lung tissue damage or irritation.  
Significant elevations in the RBI were observed for HD and LD groups compared to the 
control group for all days tested (Figure 1).  No significant difference was observed 
between HD and LD groups.  However, substantial inter- and intra-animal variability was 
observed in the RBI and could be due to regional differences in drug deposition following 
inhalation within the lung (Figure 2).  Although not employed previously as a quantative 
measure, the RBI should return to baseline levels after a longer recovery period due to a 
delay in alveolar macrophage elimination kinetics following a stimulus (67).  Additional 






Inhaled aqueous solutions of inhaled voriconazole were well tolerated following 
multiple doses in rats.  The pharmacokinetic profile in rats following multiple inhalations 
demonstrated good drug absorption into the systemic circulation from the lungs due to 
the sulfobutyl ether-β-cyclodextrin present in the formulation.  Some abnormal laboratory 
test values were statistically significant but did not correlate with clinically importance 
with hepatotoxicity and hyperglycemia being artifacts associated with methodological 
procedures in the study.  Pathological evaluation of liver, kidney, and spleen tissues 
demonstrated good inhaled drug tolerability but with acute elevations in alveolar 
macrophages present at the respiratory duct associated with inhaled voriconazole. 
Additional studies are needed to further characterize pharmacokinetic and laboratory test 
parameters and lung histopathology changes before utilization in patient populations.  
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Chapter 5: Pharmacokinetic Profile of Inhaled Voriconazole Following 
Single and Multiple Doses in Rodents 
 
5.1. INTRODUCTION 
Voriconazole, a triazole antifungal, is a derivative of fluconazole but with a 
broader spectrum of antifungal activity prompting increased drug utilization in the 
empiric management of fungal infection (1).  The extended spectrum of voriconazole is 
due to complete inhibition of fungal cytochrome P450 (CYP) mediated ergosterol 
biosynthesis leading to cell membrane disruption rather than partial inhibition with 
fluconazole (2).  Voriconazole was also demonstrated to be superior to amphotericin B, 
the gold standard in antifungal agents, in the treatment of a systemic fungal infection, 
invasive pulmonary aspergillosis (IPA) (3).  Systemic fungal infections, including IPA, 
are a serious source of patient mortality in immunocompromised patients, including those 
with hematologic malignancies as well as hematopoietic stem cell and solid organ 
transplant patients (4, 5).  This is due to dissemination of fungal hyphae via the 
circulatory system following inhalation and germination of fungal conidia in the lung that 
bypass the normal immunologic responses (6-8).  Therefore, pharmacologic utilization of 
voriconazole for the management of systemic fungal infections currently relies on drug 
distribution to infected lung tissue to prevent fungal growth and dissemination.   
 
Many systemically administered antifungals have low or variable drug penetration 
into infected organs and tissues leading to poor patient outcomes (9, 10).  Some of this 
variability is due to methodological discrepancies regarding evaluation of drug 
distribution to lung tissue and lung fluid with some advocating the sampling of 
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bronchoalveolar lavage fluid or pulmonary secretions as appropriate proxy markers for 
alveolar drug concentration (11, 12).  Another source of inconsistency is due to inter-
individual as well as intra-individual variability for plasma voriconazole concentrations 
following multiple systemic doses (13).  This plasma pharmacokinetic variability has 
been associated with differences in drug absorption following oral administration, genetic 
polymorphisms in the primary metabolizing isoenzyme for voriconazole, CYP2C19, as 
well as non-linear pharmacokinetics in adult human patients due to saturable drug 
elimination.  Children, in contrast, demonstrate linear pharmacokinetics following 
systemic administration due to increased weight-normalized elimination capacities (14).  
Species variability has also been reported in rodent, lagomorph, canine, and equine 
animal studies with reported metabolic induction reported by 7 days after single daily 
oral and intravenous doses (15, 16).  In rodents specifically, pre-hepatic voriconazole 
metabolism also accounted for very low and variable oral drug bioavailability (17).  
Thus, the clinical utility of reported drug distribution to lung tissue, fluids, or cells 
following systemically administered triazole antifungals is ambiguous.  To overcome this 
clinical uncertainty of tissue drug concentrations, investigators have correlated 
pharmacodynamic efficacy with systemic pharmacokinetic measurements.  They have 
advocated optimal voriconazole efficacy in humans with associated random plasma levels 
greater than 2 µg/mL (18) and trough plasma levels greater than 1 µg/mL (19) with wider 
concentration  ranges in the reported literature (20).  
 
The current therapeutic utilization of voriconazole necessitates the balance of 
therapeutic trough drug concentrations with adverse events associated with elevated 
systemic drug exposure, including visual abnormalities, CNS toxicity, and potential 
hepatotoxicity with associated abnormalities in hepatic function laboratory tests (20-22).  
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Researchers have suggested targeted drug delivery to the lungs via inhalation could 
balance these two optimal criteria for antifungal therapy: therapeutic tissue 
concentrations with low systemic drug exposure (23, 24).  Indeed, numerous transplant 
centers utilize prophylactic regimens of aerosolized amphotericin B in patients with an 
elevated risk for IPA (25-29).  The pharmacokinetic profile of inhaled amphotericin B 
demonstrated high lung concentrations with negligible drug distribution to the systemic 
circulation while conversely, systemically administered amphotericin B demonstrated 
poor distribution to the lung tissue (30-33).  However, a combination of inhaled and IV 
amphotericin B has demonstrated improved efficacy than targeted delivery alone as 
treatment in a rodent model of IPA suggesting anti-disseminative effects of both high 
tissue and moderate plasma concentrations (34).   
 
Similar improvements in efficacy were reported in a murine model of IPA 
following inhalation of aqueous voriconazole solution with a companion pharmacokinetic 
profile in healthy mice that described high peak tissue and plasma concentrations 
following single and multiple doses (35, 36).  Substantial and rapid drug distribution to 
the systemic circulation following inhalation was attributed to drug solubilization by 
sulfobutyl ether-β-cyclodextrin promoting improved drug absorption across alveolar 
membranes.  Despite, low trough lung and plasma concentrations reported following 
multiple doses administered twice daily (BID at 08:00 and 16:00), inhaled voriconazole 
produced 67% survival over 12 days and was significantly improved compared to 
systemically administered amphotericin B.  The current study was designed to expand the 
pharmacokinetic understanding of inhaled aqueous solutions of voriconazole following a 
single dose as well as multiple doses administered every 12 hours (Q12H) in mice and 
compare rat and mice pharmacokinetic parameters through evaluation of peak and trough 
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concentrations following Q12H dosing in anticipation of future studies in human 
subjects.  It is hypothesized that a compartmental model of drug absorption from the 
lungs would characterize inhaled voriconazole pharmacokinetics with the elevation of 
trough voriconazole concentrations through adjustment of the dosing interval to Q12H 
from dosing at 08:00 and 16:00 (BID).  
 
5.2. MATERIALS AND METHODS 
5.2.1. Materials 
Vfend® IV, Pfizer Inc. (New York, NY), voriconazole, and sulfobutyl ether-β-
cyclodextrin, Captisol®, were generously supplied by CyDex Pharmaceuticals, Inc. 
(Lenexa, KS).  Sterile water for injection (SWFI) and normal saline were purchased from 
Cardinal Health (Dublin, OH).  Sodium tetraborate decahydrate, boric acid , and sodium 
acetate trihydrate were purchased from Sigma-Aldrich, Inc. (St. Louis, MO).  Acetic acid 
was purchased from Sigma-Aldrich Laborchemikalien GmbH (Seelze, Germany).  HPLC 
grade ethyl acetate was purchased from Spectrum Chemical Manuf. Corp. (Gardena, 
CA).  HPLC grade acetonitrile was purchased from Fisher Scientific (Fair Lawn, NJ).  
HPLC grade methanol was purchased from EMD Chemicals Inc. (Gibbstown, NJ).  
Water was obtained from an in-house Milli-Q UV Plus water purification system from 
the Millipore Corp. (Billerica, MA).   
 
5.2.2. Single-dose Pharmacokinetic Analysis 
Male outbred 20g ICR (Institute for Cancer Research) mice were purchased 
(Harlan Sprague Dawley, Inc., Indianapolis, IN) and housed with free access to water and 
food.  Prior to dosing, mice were acclimatized for up to 20 minutes twice daily in nose-
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only dosing animal restraints (Battelle Toxicology Northwest, Richland, WA).  
Voriconazole solutions were prepared by reconstitution and dilution of Vfend® IV with 
SWFI to a solution containing 6.25 mg/mL voriconazole.  Mice received a single 
nebulized dose of 5 mL aqueous voriconazole solution using an Aeroneb® Pro micro 
pump nebulizer (Nektar Therapeutics, San Carlos, CA) integrated into a customized 
nose-only dosing apparatus with an airflow rate of 1L/min through the apparatus over  
20 minutes.  Mice were serially euthanized by carbon dioxide narcosis at 10 and  
30 minutes, 1, 4, 6, 8, 12, and 24 hours after the completion of nebulization.  Four mice 
were euthanized at each time point with the exception of only two mice at the 10 minute 
and 4 hour times.  The average mouse mass at the time of euthanasia was 22.5 g.  Whole 
blood was collected by cardiac puncture into heparinized vials and centrifuged at  
9000 RPM for 15 minutes to obtain plasma.  Whole lungs were also collected following 
exsanguination.  Plasma samples and whole lungs were frozen and stored at -20°C until 
assayed.  All animals were handled and maintained in accordance with The University of 
Texas at Austin Institution Animal Care and Use Committee (IACUC) guidelines and in 
accordance with the American Association for Accreditation of Laboratory Animal Care 
guidelines. 
 
5.2.3. Multi-dose Pharmacokinetic Analysis 
Male ICR mice initially weighing 20 g and male Sprague-Dawley rats initially 
weighing 250 g, (Harlan Sprague Dawley, Inc., Indianapolis, IN), were administered 
5mL of 6.25 mg/mL voriconazole with an Aeroneb® Pro nebulizer every 12 hours 
(Q12H) using a nose-only dosing apparatus as described above for 7 consecutive days.  
The dosing apparatus was disassembled and cleaned between each use.  Randomly 
selected pairs of mice and rats were sacrificed by carbon dioxide narcosis either 30 
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minutes after the completion of nebulization for peak values as determined in previous 
studies (35) or immediately before the next scheduled dose for trough values on days 0, 
3, 5, and 7.  Lung and plasma samples were handled and processed as described in the 
single-dose methodological description.  Average mouse mass at the time of euthanasia 
was 23.0 g while average rat mass was 287 g. 
 
5.2.4. Chromatographic Analysis 
Plasma and lung samples were thawed prior to analysis.  Calibration standards, 
plasma, and homogenized lung samples were analyzed using similar methods to those 
previously published (13, 35, 37).  Briefly, voriconazole was extracted from mouse 
plasma samples through the addition of acetonitrile, centrifugation, and supernatant 
extraction with fluconazole as the internal standard.  The supernatant liquid was 
evaporated under a gentle stream of nitrogen and residual solids, including voriconazole, 
were re-dispersed with mobile phase and analyzed by HPLC.  Mouse lungs were 
homogenized with 1mL of water using an Omni GLH homogenizer (Omni International, 
Marietta, GA).  0.2M borate buffer (pH 9.0) was added to mouse lung homogenate 
followed by three liquid-phase extractions with ethyl acetate.  The liquid from collected 
supernatant fractions were then evaporated under a gentle stream of nitrogen.  Any 
residual solids, including voriconazole, were re-dispersed with mobile phase, centrifuged, 
and then analyzed by HPLC.  Each voriconazole sample from a mouse source was 
analyzed using a Waters Breeze liquid chromatograph (Waters Corporation, Milford MA) 
or Shimadzu LC-10 liquid chromatograph (Shimadzu Corporation, Columbia, MD) 
equipped with a heated (35°C) Jupiter® C18 (150 mm x 4.6 mm, 5 µm) with a Universal 
security guard (Widepore C18) guard column (Phenomenex, Torrance, CA).  The sample 
volume was 50 µL with a UV detection wavelength of 254 nm.  The mobile phase 
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consisted of a 50:50 mixture of 0.01M pH 5.0 sodium acetate buffer and methanol at  
1.0 mL/min.   
 
Rat plasma and lung samples were extracted in a similar manner to mouse 
samples but homogenization was performed with 2 mL normal saline per gram lung 
tissue.  Following three ethyl acetate extractions of voriconazole from lung homogenate, 
solvent was evaporated to give residual solids that were then reconstituted in 200 µl of 
acetonitrile and centrifuged.  A 4000 Q TRAP mass spectrometer (Applied Biosystems, 
Foster City, CA) coupled with an online HPLC (Shimadzu, Columbia, MD) (LC-MS) 
was used to analyze all rat samples.  10 µl samples were injected into Shimadzu 
Prominence UFLC system equipped with an Restek C18 (4.6 x 50mm, 5 µm, 110 Å) 
column and eluted with mobile phase A (water with 0.1% formic acid) and B (acetonitrile 
with 0.1% formic acid) by a gradient of 20%B for 0.5 min, then 20%-50%B over  
0.5 min, followed by 50%B for 3 min, at a flow rate of 1 ml/min.  Sample was directly 
eluted from the column into the electrospray ion (ESI) source of 4000 QTRAP.   The 
heated nebulizer of 4000 QTRAP was set at 700°C, the declustering potential (DP) at 40.  
The Multiple Reaction Monitoring (MRM) scan experiment with unit resolution for Q1 
and low resolution for Q3 was used to quantify voriconazole content.  The MRM 
transitions were set as follow, Q1=350.2, Q3=127.4, CE=40.  The limit of detection for 
voriconazole was 5 pg.  LC-MS was utilized for analysis of rat samples due to co-elution 
of peaks with voriconazole by normal HPLC that was not observed for mouse analysis.  
Plasma and lung samples from each animal were analyzed individually for voriconazole 
concentration by HPLC or LC-MS.  Concentration values were then averaged and used to 
determine pharmacokinetic parameters and concentration versus time profiles.   
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5.2.5. Pharmacokinetic Analysis 
Observed pharmacokinetic parameters were evaluated from the voriconazole 
concentration versus time profiles in mouse plasma and lung tissue.  Non-compartmental 
pharmacokinetic analysis was used to determine peak concentration (Cmax) and the time 
to achieve the Cmax (tmax).  The trapezoidal rule was used to calculate the area under the 
concentration versus time curve (AUC0-24).  The ratio of lung AUC to plasma AUC 
values allowed calculation of a partition coefficient following inhalation of voriconazole 
(Pl/p).  A one-compartment model was fitted to lung concentration data to calculate the 
lung tissue elimination rate constant (ke) and half-life (t1/2, e) A two compartment model 
was determined by linear regression of plasma concentration versus time values with the 
method of residuals and used to evaluate absorption and elimination rate coefficients (α, 
β) and half-lives (t1/2, α, t1/2, β).  
 
5.2.6. Statistical Analysis 
Concentration values following multiple doses were compared between days 
using the Student’s t-test with a p-value of <0.05 for significance.  In addition, 
concentration values were compared on day 3 in mice following Q12H and BID dosing 
using analysis of variance (ANOVA) with a p-value <0.05 for significance. 
  
5.3. RESULTS  
5.3.1. Single Dose Pharmacokinetic Profile 
Following a single dose of 31.25 mg voriconazole administered over 20 minutes 
to 6 mice  group in a nose-only dosing chamber, the 24-hour pharmacokinetic profile was 
determined in lung tissue and plasma (Figure 1).  According to non-compartmental 
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analysis Cmax, tmax, and AUC0-24 pharmacokinetic parameters in lung tissue and plasma 
were determined as 9.98 µg/g and 6.57 µg/mL, 0.17 hours (10 minutes) in both, and  
44.4 µg hr/g and 30.2 µg hr/mL, respectively.  The ratio of lung and plasma AUC0-24 
values allowed the determination of a voriconazole partition coefficient, Pl-p, following 
inhalation of 1.47 with the assumption that excised lung density was equal to 1 g/mL.  
Compartmental analysis of voriconazole pharmacokinetics supported a two compartment 
model of drug absorption and elimination (Figure 2).  The tissue compartment, 
approximated by lung tissue concentrations and designated “1”, was the site of drug 
administration and subsequent first-order elimination for 12 hours following inhalation 
and modeled by Equation 1 (R2=0.944).  The central compartment, approximated by 
plasma concentrations and designated “2” was modeled by a first-order drug absorption 
phase up to 8 hours after drug administration followed by a first-order drug elimination 
phase.  Equations for the absorption phase (R2=0.999) and elimination phase (R2=0.989) 
were determined by the method of residuals to give A, B, α, and β modeled by Equation 
2. 




1263.034.9 μ  
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The elimination rate constant (ke) and associated half-life (t1/2, e) from the tissue 
compartment was 0.263 hr-1 and 2.63 hr.  The central compartment absorption rate 
constant (α) and half-life (t1/2, α) were 0.274 hr-1 and 2.53 hr with an elimination rate 
constant (β) and half-life (t1/2, β) of 0.057 hr-1 and 12.11 hr. 
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5.3.2. Multiple Dose Pharmacokinetic Profile 
 Peak voriconazole concentrations in mouse lung tissue and plasma trended to 
higher drug concentrations following multiple inhalations over 7 days with only the 
plasma values for days 0 and 7 showing statistical significance (Figure 3A).  Trough 
concentrations were not statistically significant and demonstrated no evidence of drug 
accumulation (Figure 3C).  In the rat, no voriconazole accumulation or other trend was 
observed in peak or trough values for lung or plasma voriconazole concentrations over  
7 days of Q12H dosing (Figure 3B, D).  However, statistically significance differences 
were observed for day 7 peak lung concentrations from all other days as well as between 
plasma trough values on days 3 and 7.  Lung concentrations remained higher than plasma 
concentrations for peak and trough values except for mouse trough voriconazole 
concentrations, where lung concentrations were below plasma levels 12 hours after 
completion of dosing and were undetectable on days 3, 5, and 7.   
 
5.4. DISCUSSION 
Targeted delivery of antifungals has the potential to improve patient outcomes 
through consistent and high tissue concentrations at the site of systemic fungal infections 
as prophylaxis or as treatment.  Although high tissue concentrations have been reported, 
inconsistent drug efficacy and poor patient tolerability remain concerns with inhaled 
amphotericin B due, in part, to variability inherent in prophylaxis trials (38-44).  
However, the poor drug distribution following inhalation of amphotericin B likely 
contributed to inconsistent efficacy.  Inhalation of solubilized voriconazole has the 
potential to produce consistent pharmacokinetic responses leading to predictable 
outcomes.  
 
Non-compartmental pharmacokinetic analysis of voriconazole following a single 
inhaled dose, demonstrated similarities in drug dose between the current study and 
previous reports from the authors (Table 1) (35).  Specifically, tmax values following a 
single dose were observed after 10 minutes compared to previously reported values of 30 
minutes.  The associated Cmax drug concentrations were very similar between studies with 
values in lung tissue 9.98 ± 0.94 µg/g and plasma 6.57 ± 3.04 µg/mL comparable to 
reported values of 11.0 ± 1.6 µg/g in the lung and 7.1 ± 0.68 µg/mL in the plasma (35).  
These values are not statistically significant and represent equivalent drug doses between 
the current and previously reported study.  In addition, the partition coefficient, Pl-p, of 
1.47 based on AUC0-24 values was within the 1.4 to 1.6 range provided in the previous 
single dose pharmacokinetic study profile based on AUC0-6 values, indicative of 
equivalent absorptive processes and thorough drug distribution to the plasma following 
inhalation.   
 
The mechanisms governing pulmonary absorption are fundamentally similar to 
other absorptive sites in the body.  Drug is able to pass through biological membranes by 
active and passive mechanisms with passive drug diffusion being the predominant force.  











dQ = rate of drug diffusion from the tissue to the plasma (µg/hr); D= 
diffusion coefficient (cm2/hr); K= lipid water partition coefficient in the membrane (unit 
less); A= surface area of the membrane (cm2); (Ct-Cp)= difference in tissue and plasma 
drug concentrations (µg/cm3); and h= membrane thickness (cm) (45).  The concentration 
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gradient for inhaled voriconazole from tissue to central compartments was low at steady 
state but provided the driving force for drug absorption based on central compartment 
sink conditions.  In addition, the large alveolar surface area and thin membranes 
physiologically present in the lungs for gas exchange also promoted a high rate of drug 
diffusion for the already solubilized voriconazole molecules (46).  Reviews have reported 
numerous models of drug absorption from the lungs utilizing in vitro, ex vivo, and in vivo 
systems (47-49).  These various methodologies have attempted to isolate component 
processes in the lungs that contribute to the overall pharmacokinetic profile following 
inhalation, including drug deposition, mechanical clearance, metabolism, diffusion, etc..  
Although insufficient information was available for the calculation of D, with the 
corresponding   in the lung, the rate of drug diffusion was a component of the physiologic 
rate of drug elimination from the lung as evaluated through the rate constant, ke.  Thus, 
the numerous rate processes were constituted into pharmacokinetic rate constants ke, α, 
and β through the application of compartmental analysis. 
 
Utilization of a one-compartment pharmacokinetic model to evaluate lung tissue 
concentrations of voriconazole through 12 hours after completion of nebulization 
described first-order drug elimination from lung tissue with an elimination half-life of 
2.53 hours (Table 1).  Exclusion of the 24 hour time point was appropriate due to 
elimination of approximately 96% of the C0 concentration after 12 hours based on the 
elimination half-life in the lung.  Similarly, two-compartmental evaluation of plasma 
concentrations correlated with absorption and elimination phases in the central 
compartment following inhalation of voriconazole.  The tissue elimination rate constant 
ke (0.263 hr-1 with 2.63 hr half-life) and central compartment absorption rate constant α 
(0.274 hr-1 with 2.53 hr half-life) were equivalent and equated to drug absorption from 
the lung tissue with negligible non-absorptive voriconazole elimination from the lungs.   
 
Elimination of drug from the central compartment was first-order and 
characterized by β equal to 0.057 hr-1 with a half-life of 12.11 hours.  This half-life was 
substantially longer than reported terminal elimination half-lives in other species, 
including 6 hours in humans, 5.5 hours in guinea pigs, and 1 hour in rabbits (15, 22).  
Previous studies in mice have not reported elimination half-lives due to very low 
bioavailability and rapid clearance mechanisms following systemic administration due to 
drug hypermetabolism (17, 50).  Thus, the observed terminal drug elimination from the 
central compartment demonstrated substantial changes in clearance and elimination 
mechanisms following the inhalation of voriconazole.  These changes were not 
influenced by prolonged drug distribution from the lungs due to a short absorption half-
life but instead could be due to non-linear pharmacokinetics resulting from capacity-
limited metabolism as observe d in humans (51).  However, plasma concentrations were 
well within reported values in rodents, lagomorphs, canines, and humans such that the 
suggested increase in murine metabolic capacity should not have been saturated (15).   
 
Despite prolonged drug elimination from the central compartment, observed 
trough voriconazole concentrations following multiple doses Q12H were lower than 
predicted using Equations 1 & 2 as well as half-life elimination from the tissue, t1/2, e, and 
central, t1/2, β, compartments.  Additionally, no evidence of drug accumulation was 
observed in lung tissue or plasma.  These findings were in accordance with reported 
values following inhaled voriconazole administered BID (35).  Plasma trough 
concentrations following BID dosing ranged from 0.18 to 0.32 µg/mL while Q12H 
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dosing increased the concentration range to 0.24 to 0.50 µg/mL but were not significantly 
different (p-value >0.05).  Trough lung concentrations following both BID and Q12H 
dosing were low to undetectable.  These similarities in trough voriconazole 
concentrations from day 0 through 7 and day 3 through 12 also suggest drug elimination 
was not affected by a marked induce in drug metabolism following inhalation as reported 
for other routes of drug administration.  Additional studies are required to elucidate 
possible mechanisms that justify a low elimination rate constant, long elimination half-
life, and non-induced drug metabolism following inhalation of voriconazole solutions. 
 
Rats received the same drug exposure as mice, 31.25 mg voriconazole nebulized 
over 20 minutes, but had much lower drug concentrations in lung tissue and plasma.  
Peak voriconazole concentrations were approximately 10 to 20 times lower in the lung 
and 10 to 30 times lower in the plasma compared to mice, while a much larger 
discrepancy was observed in trough plasma concentrations with rat values 50 to  
170 times lower than those observed in mice based on day-matched values.  Although the 
study was not designed to conduct allometric analysis of pharmacokinetic properties 
between mice and rats, peak values suggest weight-based dilutional effects were 
observed.  The discrepancies between trough values may have been due to metabolic 
differences between mice and rats as reported following systemic drug administration and 
would require further study to determine differences in metabolic capacity between the 
species (15).   
 
The lowering of drug concentration based on animal weight following inhalation 
would not be expected to translate into low concentrations in humans due to differences 
in respiratory physiology between rodents and humans.  Specifically, rodents are obligate 
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nose-breathers and have substantial aerosol droplet deposition in the nasal cavity prior to 
inhalation to the deep lung (52, 53).  Humans, in contrast, can inhale through the mouth 
and have substantially higher deposition fractions in the deep lung when normalized for 
body weight (54).  Thus, the combination of a higher inhaled dose fraction and different 
metabolic processes for voriconazole between humans and rodents should lead to 
clinically relevant drug concentrations in lung tissue as well as the systemic circulation.   
 
5.5. CONCLUSION 
Following inhalation of aerosolized aqueous voriconazole solution, 
pharmacokinetic properties were evaluated and compartmental analysis was utilized to 
determine absorption and elimination rate constants and half-lives.  The pharmacokinetic 
properties of inhaled voriconazole were different from those reported in the literature and 
represent a possible route of administration to bypass variability reported in the literature.  
Although Q12H dosing did elevate trough voriconazole concentrations, the increase was 
not statistically significant and might not correlate to a clinical difference.  Although 
additional studies are needed to further investigate pharmacokinetic processes of drug 
absorption and elimination, inhaled voriconazole represents a potentially important 
advancement in the treatment of IPA. 
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Table 1.1: Properties of Inhaled Corticosteroids 
Table 1.1A: Properties of Inhaled Fluticasone Propionate 
Delivery Device and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Fluticasone propionate 
DPI 
Administered as Flutide Diskhaler®, Glaxo Ltd 
Contained microfine fluticasone propionate blended with 
lactose 
1000 µg tmax  
Cmax  
AUC 
1.4 ± 1  
0.24 ± 0.1  
2.44 ± 0.69a  
hr  
ng mL-1 






Administered as Flovent® Diskus®, GlaxoSmithKline 
Contained microfine fluticasone propionate blended with 
lactose 




1.88 (1.4, 2.38)  
0.35 (0.3, 0.45)  
2.75 (2.25, 3.45)  
7.1 (5.6-8.5)  
hr 
ng mL-1  
ng hr mL-1 
hr 
pMDI 
Administered as Flovent®, GlaxoSmithKline  
Contained microcrystalline suspension of fluticasone 
propionate in a mixture of CFC-11 and CFC-12 with 
soya lecithin 




1.67 (1.1, 2.25)  
0.25 (0.2, 0.3)  
1.75 (1.45, 2.15)  
5.3 (4.0-6.6)  
hr 
ng mL-1 

















ng hr mL-1 
hr 
DPI 
Administered as Flovent® Diskus®, GlaxoSmithKline 
Contained microfine fluticasone propionate blended with 
lactose 

















Administered as Flixotide® Accuhaler®, 
GlaxoSmithKline (Marketed as Flovent® Diskus® in the 
US)  
Contained microfine fluticasone propionate blended with 
lactose 




0.9 (0.68, 1.20)  
0.09 (0.07, 0.10)  
0.38b (0.30, 0.47) 
8.46 (6.70, 10.7) 
hr 
ng mL-1 






Delivery Device and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Fluticasone propionate 
DPI 
Administered as Flovent® Diskus®, GlaxoSmithKline 
Contained microfine fluticasone propionate blended with 
lactose 
800 µg AUC  0.256  ng hr mL-1 
pMDI 
Administered as Flovent®, GlaxoSmithKline  
Contained microcrystalline suspension of fluticasone 
propionate in a mixture of CFC-11 and CFC-12 with 
soya lecithin 






Administered as Flixotide® Diskhaler®, 
GlaxoWellcome 
Contained microfine fluticasone propionate blended with 
lactose 






0.19 (0.14, 0.26)d 
1.58 (1.14, 2.20)d 
12.3 (7.99, 18.9)d 







Administered as Flovent® Diskus®, GlaxoSmithKline 
Contained microfine fluticasone propionate blended with 
lactose 




0.26 (0.22, 0.30)d 
2.42 (2.01, 2.91)d 
12.1 (8.76, 16.8)d 






Administered as Flovent®, GlaxoSmithKline 
Contained microcrystalline suspension of fluticasone 
propionate in a mixture of CFC-11 and CFC-12 with 
soya lecithin 




0.28 (0.20, 0.38)d 
2.18 (1.77, 2.67)d 
11.4 (8.15, 16.0)d 









Table 1.1A: Properties of Inhaled Fluticasone Propionate (continued) 
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Table 1.1B: Properties of Inhaled Budesonide 
Delivery Device and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Budesonide 











ng mL-1  




Administered as Pulmicort Turbohaler®, AstraZeneca 
Contained micronized budesonide 



















DPI with oral charcoal 
Administered as Giona® Easyhaler®, Orion Pharma 
Contained micronized budesonide blended with lactose 




0.5 ± 0.18  
1.22 ± 0.41  
3.48 ± 0.93  
3.05 ± 0.48  
hr 
ng mL-1 
ng hr mL-1 
hr 
DPI with oral charcoal 
Administered as Pulmicort Turbohaler®, AstraZeneca 
Contained micronized budesonide 




0.38 ± 0.17  
1.29 ± 0.44  
3.46 ± 1.13  
2.85 ± 0.38  
hr 
ng mL-1 







Administered as Pulmicort Turbohaler®, AstraZeneca 
Contained micronized budesonide 




0.28 (0.17, 0.4)  
1.64 (1.46, 1.98)  
4.52 (3.66, 5.68)  
0.6 (0.3-0.9)  
hr 
ng mL-1 







Administered as Pulmicort Turbohaler®, AstraZeneca 
Contained micronized budesonide 





0.13 (0.10, 0.16)  
1.46 (1.18, 1.79) 
3.28 (2.82, 3.81)  
3.47 (3.21, 3.76)  
2.63 (2.46, 2.82)  
hr 
ng mL-1 








Administered as Pulmicort Turbohaler®, AstraZeneca 
Contained micronized budesonide 





0.58 (28.9)e  
0.66 (69.8)e  





ng hr mL-1 







Table 1.1B: Properties of Inhaled Budesonide (continued) 
Delivery Device and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Budesonide 
pMDI 
Administered as Pulmicort®, AstraZeneca 
Contained micronized suspension of budesonide with 
sorbitan trioleate, CFC-11, CFC-12, and CFC-114 
800 µg C2hr  0.47g  ng mL-1 
1000 µg C2hr  0.73g  ng mL-1 Nebulized Suspension 
Administered as Pulmicort Respules®, AstraZeneca 
Contained micronized suspension of budesonide with 
disodium edetate, sodium chloride, sodium citrate, citric 
acid, polysorbate 80, and Water for Injection 






Administered as Pulmicort Respules®, AstraZeneca 
Contained micronized suspension of budesonide with 
disodium edetate, sodium chloride, sodium citrate, citric 
acid, polysorbate 80, and Water for Injection 




0.24 (0.19-0.3)  
0.66 (0.42-0.91)  




ng hr mL-1 
hr 




0.14 (0.09-0.18)  





ng hr mL-1 
hr 
Nebulized Suspension 
Administered as Nanobudesonide (Smaller particle size 
distribution than Pulmicort Respules®) 
Formulation composition not reported 




0.19 (0.1-0.27)  












Table 1.1B: Properties of Inhaled Budesonide (continued) 
Delivery Device and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Budesonide 
Nebulized Suspension 
Administered as Pulmicort Respules®, AstraZeneca 
Contained micronized suspension of budesonide with 
disodium edetate, sodium chloride, sodium citrate, citric 
acid, polysorbate 80, and Water for Injection 





0.15 ± 0.12  
0.30 ± 0.18  
0.48 ± 0.16b  
0.53 ± 0.18c  
2.42 ± 0.68  
hr 
ng mL-1 
ng hr mL-1 
ng hr mL-1 
hr 





0.075 ± 0.055  
0.11 ± 0.06  
0.066 ± 0.033b  
0.073 ± 0.024c  
1.17 ± 0.56 
hr 
ng mL-1 
ng hr mL-1 
ng hr mL-1 
hr 





0.051 ± 0.025 
0.24 ± 0.14 
0.143 ± 0.070b  
0.131 ± 0.061c  
1.31 ± 0.45 
hr  
ng mL-1  
ng hr mL-1 
ng hr mL-1 
hr 
Nebulized Suspension 
Administered as a nano-scale budesonide suspension 
Contains submicron budesonide in a sterile aqueous 
formulation containing surface modifiers sodium 
chloride, citric acid, sodium citrate, and disodium 
edentate dehydrate 
Incomplete report of formulation composition 





0.062 ± 0.025  
0.43 ± 0.25 
0.369 ± 0.161b  
0.422 ± 0.196c  
2.33 ± 0.90  
hr 
ng mL-1 
ng hr mL-1 








Table 1.1C: Properties of Inhaled Beclomethasone Dipropionate (and Beclomethasone 17-Monopropionate) 
Delivery Device and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 





0.3 (0.2, 0.5)f 
0.32g (0.18, 0.55) 
0.15g (0.09, 0.27) 
hr 
ng mL-1 
ng hr mL-1 
17-BMP 
pMDI 
Administered as Beclovent®, GlaxoWellcome 
Contained suspension of micronized beclomethasone 








1.0 (0.8, 6)f 
0.94g (0.67, 1.3) 
3.85g (2.8, 5.2) 
4.1 (3.5, 4.6)  
2.7 (2.1, 3.6)f  
hr 
ng mL-1 










0.5 (0.2, 0.5)f 
0.46g (0.25, 0.72) 
0.22g (0.13, 0.35) 
hr 
ng mL-1 
ng hr mL-1 
17-BMP 
pMDI with oral charcoal 
Administered as Beclovent®, GlaxoWellcome 
Contained suspension of micronized beclomethasone 








0.8 (0.8, 1)f 
0.71g (0.44, 1.1)  
2.4g (1.5, 3.7)  
3.5 (3, 4)  
2.3 (1.7, 5.8)f  
hr 
ng mL-1 








Administered as Becodisks ®, Allen & Hanburys 
Contained micronized beclomethasone dipropionate 
blended with lactose 
800 µg 
tmax   
Cmax   
AUC   
MRT   
t1/2   
2.5 (1.9, 3.3) 
0.33 (0.28, 0.39) 
1.7b (1.5, 2.0) 
9.1 (7.1, 11.5) 
5.3 (4.1, 7.0) 
hr 
ng mL-1 








Table 1.1C: Properties of Inhaled Beclomethasone Dipropionate (and Beclomethasone 17-Monopropionate) (continued) 
Delivery Device and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Beclomethasone dipropionate (beclomethasone 17-monopropionate) 









ng hr mL-1 









ng hr mL-1 
 17-BMP: 4.5 µm MMAD 
Nebulized Solution 
Administered as a monodisperse aerosol generated by the 
electrohydrodynamic technique  
Contained 4% beclomethasone dipropionate solubilized 










ng hr mL-1 
Human patients 






Table 1.1D: Properties of Inhaled Triamcinolone Acetonide 




























ng hr mL-1 
hr 
DPI  
Administered using the breath actuated Ultrahaler®, 
Aventis Pharma 
Contains micronized triamcinolone acetonide blended 
with lactose 







2.52 (18.55)e  
hr 
ng mL-1 







Administered as Azmacort®, Aventis Pharma 
Contained microcrystalline suspension of triamcinolone 
acetonide in CFC-12 and 1% w/w dehydrated alcohol 
800 µg tmax 
Cmax 
AUC 
   
t1/2 
1.74 (44.1)e  
0.92 (33.4)e 





ng hr mL-1 
ng hr mL-1 
hr  
pMDI with oral charcoal 
Administered as Azmacort®, Aventis Pharma 
Contained microcrystalline suspension of triamcinolone 
acetonide in CFC-12 and 1% w/w dehydrated alcohol 
800 µg tmax 
Cmax 
AUC 
   
t1/2 
0.66 (31.4)e 






ng hr mL-1 







Administered as Azmacort® HFA 225, Aventis Pharma 
Contained microcrystalline suspension of triamcinolone 
acetonide in HFA 143-a 
(uncertain formulation due to acquisitions) 
675 µg tmax 
Cmax 
AUC 









ng hr mL-1 







Table 1.1D: Properties of Inhaled Triamcinolone Acetonide (continued) 
Delivery Device and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Triamcinolone acetonide 
DPI 
Administered using Ultrahaler®, Aventis Pharma 
Contains micronized triamcinolone acetonide blended 
with lactose  
720 µg 
for DPI  
pMDI 
Administered as Azmacort® HFA 225, Aventis Pharma 
Contained microcrystalline suspension of triamcinolone 




Ratio of DPI to pMDI Cmax 
 2.44 (75)e  
Ratio of DPI to pMDI AUC 
 1.96 (77)e  
DPI 
Administered using Ultrahaler®, Aventis Pharma with 
oral charcoal 





Administered as Azmacort® HFA 225, Aventis Pharma 
with oral charcoal 
Contained microcrystalline suspension of triamcinolone 




Ratio of DPI to pMDI Cmax 
 1.56 (35)e  
Ratio of DPI to pMDI AUC 





The following caption applied for Tables 1.1A-1.1D: 
Values are the geometric mean (95% confidence interval), mean ± standard deviation, or median.  Unless otherwise specified, 
the units are as follows: tmax (hr), Cmax (ng mL-1), AUC (ng hr mL-1), t1/2 (hr), MRT (hr).  DPI = Dry Powder Inhaler, pMDI = 
Pressurized Metered-dose Inhaler, MRT = Mean Residence Time, MAT: Mean Absorption Time , TX% = Absorption time for 
X% of total absorbed dose. 
a: AUC0-12, b: AUC0-8, c: AUC0-∞ , d: 90% CI, e: values are mean (Coefficient of variation %), f: values are median (range), g: 
Not expressly reported by the authors.  Values inferred from figures, tables, and methodological descriptions. 
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Table 1.2: Properties of Inhaled Antifungals 
Table 1.2A: Properties of Inhaled Amphotericin B 
Delivery Device and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Amphotericin B 




21.0 ± 1.4 
hr  
ng mL-1 




16.8 ± 6.9 
hr  
ng mL-1 
Respirgard II® (Air-jet Nebulizer) 
Nebulized Suspension 
Administered as a nebulized suspension of pure 


















233.8 ± 138.3  
481.8 ± 204.1  
hr   
ng mL-1 
ng hr mL-1 
Nebulized Suspension 
Administered as a colloidal dispersion of AmB-d, 
Fungizone®, diluted with 5% glucose 
Contained amphotericin B, sodium deoxycholate, and 
sodium phosphates 




217.7 ± 53.8  
1,199.0 ± 163.8 
hr 
ng mL-1  






C1hr >200 to 900  ng mL-1  Nebulized Suspension 
Administered as a colloidal dispersion of AmB-d, 
Fungizone® 







 (n=5) Only 2 patients had 
detectible levels 
C1hr  >200 ng mL-1 Nebulized Suspension 
Administered as a nebulized suspension of L-AmB, 
AmBisome® 
Contains amphotericin B intercalated into a liposomal 
membrane (hydrogenated soy phosphatidylcholine, 
cholesterol, distearoylphosphatidylglycerol, α-















Table 1.2A: Properties of Inhaled Amphotericin B (continued) 




0.53 ± 0.17 





0.67 ± 0.14  





0.73 ± 0.13 




Administered as a colloidal dispersion of AmB-d, 
Fungizone® 











(Plasma, BAL, and 




Administered as a colloidal dispersion of AmB-d, 
Fungizone® 
Contained amphotericin B, sodium deoxycholate, and 
sodium phosphates 
6 mg tmax  












Administered as a colloidal dispersion of AmB-d, 
Fungizone® 




Cmax  22,050 ± 5,581 ng g-1 
Nebulized Suspension 
Administered as a nebulized suspension of L-AmB, 
AmBisome® 
Contains amphotericin B intercalated into a liposomal 
membrane (hydrogenated soy phosphatidylcholine, 
cholesterol, distearoylphosphatidylglycerol, α-









Values are the median or mean ± standard deviation.  AmB-d = Amphotericin B deoxycholate, L-AmB = Liposomal amphotericin B, 
tsample: Time after completion of dose until sample was taken (hr), Cplasma, uBAL, lBAL, lung: Concentration in the plasma, upper lung 
bronchoalveolar lavage fluid, lower lung bronchoalveolar lavage fluid, and lung tissue respectively.  a: Only 1/8 samples had a detectible 
amphotericin B concentration (value for n=1).  b: Only 2/6 samples had detectible amphotericin B concentrations (value for n=2) 
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Table 1.2B: Properties of Inhaled Itraconazole 
Delivery Device and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Itraconazole 
Nebulized Suspension 
Administered as a nebulized suspension of EPAS 
itraconazole  












µg hr g-1 
hr 
Nebulized Suspension 
Administered as a nebulized suspension of SFL 
itraconazole 












µg hr g-1 
hr 
Nebulized Suspension 
Administered as a nebulized suspension of SFL 
itraconazole 
Contains nanoparticulate itraconazole with polysorbate 


















 Lung Plasma  
tmax 0.5  hr 
Cmax 25.9 0.44 µg g-1 
AUC 70.9  µg hr g-1 
Nebulized Suspension 
Administered as a nebulized suspension of EPAS 
itraconazole 
Contains nanoparticulate itraconazole with polysorbate 
80 and poloxamer 407 
4.8 mg 
t1/2 7.2  hr 
tmax 0.5  hr 
Cmax 5.3 0.44 µg g-1 
AUC 28.0  µg hr g-1 
Nebulized Suspension 
Administered as a nebulized suspension of SFL 
itraconazole 
Contains nanoparticulate itraconazole with polysorbate 
80 and poloxamer 407 
4.8 mg 
t1/2 2.9  hr 
Aspergillus 
infected mice 
(Lung and plasma 
samples) 
(82) 
 Lung Plasma  
tmax 1.0 5.4 hr 
Cmax 13.4 0.12 µg g-1 
AUC 85.8 1.69 µg hr g-1 
Nebulized Suspension 
Administered as a nebulized suspension of SFL 
itraconazole 
Contains nanoparticulate itraconazole with polysorbate 
80 and poloxamer 407 
5.7 mg 
t1/2 5.5 hr 3.7 hr hr 
Healthy mice 




Table 1.2B: Properties of Inhaled Itraconazole (continued) 
Delivery Device and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Itraconazole 
 Lung Plasma  
tmax 0.5 2.0 hr 
Cmax 21.1 1.64 µg g-1 
AUC 149.9 5.6 µg hr g-1 
Nebulized Suspension 
Administered as a nebulized suspension of URF 
itraconazole  
Contains nanoparticulate itraconazole with mannitol and 
lecithin 
7.1 mg 
t1/2 7.4 3.6 hr 
Healthy mice 




Values are the geometric mean. 
EPAS = Evaporative precipitation into aqueous solution (crystalline nanoparticles) 
SFL = Spray freezing into liquid (amorphous nanoparticles) 
URF = Ultra-rapid freezing (amorphous nanoparticles) 
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Table 1.3: Properties of Inhaled Oligopeptides 
Table 1.3A: Properties of Inhaled Cyclosporine 
Delivery Method and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Cyclosporine 
Clung, trough 2.56 ± 1.33 µg g-1 
Cblood, trough 0.16 ± 0.08 µg mL-1 
1 mg kg-1 
L/B Ratioa 16.0 
Clung, trough 4.41 ± 1.50 µg g-1 
Cblood, trough 0.27 ± 0.10 µg mL-1 
2 mg kg-1 
L/B Ratioa 16.6 
Clung, trough 12.35 ± 8.83 µg g-1 
Cblood, trough 0.73 ± 0.22 µg mL-1 
Nebulized Solution 
Administered as a solution of cyclosporine in 100% 
alcohol (40 mg mL-1) 
No other excipients were used 
3 mg kg-1 
L/B Ratioa 17.0 
Rats having 





  Lung Blood  
tmaxc 0.5 0.5 hr 
Cmaxc >100 >2.5 µg g-1 
AUC 413.32 15.16 µg hr g-1 
3 mg kg-1 
L/B Ratiob 27.3 
tmaxc 1.0 1.0 hr 
Cmaxc >175 >3.5 µg mL-1 
AUC 477.96 27.45 µg hr mL-1 
Nebulized Solution 
Administered as a solution of cyclosporine in 100% 
alcohol (40 mg mL-1) 
No other excipients were used 
5 mg kg-1 
L/B Ratiob 17.4 
Healthy rats 
(Lung and blood 
samples) 
(95) 
  Lung Blood  
10 mg kg-1 AUC 200 253 µg hr g-1 
Nebulized Solution 
Administered as a solution of cyclosporine in 95% 
alcohol (33.3 to 83.3 mg mL-1) 
No other excipients were used 
25 mg kg-1 AUC 588 684 µg hr g-1 
Healthy rats (Lung 
and blood samples) 
(93) 
 150
Table 1.3A: Properties of Inhaled Cyclosporine (Continued) 
Delivery Method and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Cyclosporine 
Nebulized Solution 
Administered as a solution of cyclosporine in propylene 
glycol (62.5 mg mL-1) 
No other excipients were used 
300 mg tmax   
Cmax   
Ctrough   
1.0 
0.23 ± 0.13 













Administered as a solution of cyclosporine in propylene 
glycol (62.5 mg mL-1) 
No other excipients were used 




0.68 ± 0.30 
0.21 ± 0.09 
1.03 ± 0.43 
40.7 ± 17.7 
hr  
µg mL-1 









Table 1.3A: Properties of Inhaled Cyclosporine (Continued) 
Delivery Method and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Cyclosporine 
  Lung Blood  
tmax 4.6 0.1 hr 
Cmax 57 1.9 µg g-1 
AUC 386 14.2 µg hr g-1 
8.4 mg kg-1 
t1/2 2.2 10.0 hr 
tmax 0.1 0.3 hr 
Cmax 121 2.9 µg g-1 
AUC 771 48.2 µg hr g-1 
56.2 mg kg-1 
t1/2 5.2 18.5 hr 
tmax 0.1 0.6 hr 
Cmax 150 5.0 µg g-1 
AUC 1248 90.3 µg hr g-1 
112.6 mg kg-1 
t1/2 
t
5.8 20.1 hr 
Healthy rats 
(Lung and blood 
samples) 










µg hr mL-1 
hr 










µg hr mL-1 
hr 
Nebulized Solution 
Administered as a solution of cyclosporine in 
propylene glycol (62.5 mg mL-1) 
No other excipients were used 

















 Lung Blood  Nebulized Liposomal Suspension 
Administered as a dilauroylphosphatidylcholine 
(DLPC) cyclosporine multi-lamellar liposome 
Contained cyclosporine in a DLPC multi-lamellar 
liposome of dissolved in ultrapure water 
25 mg 











Table 1.3A: Properties of Inhaled Cyclosporine (Continued) 
Delivery Method and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Cyclosporine 
 Lung Blood  
tmax 0.5 0.25 hr 
Nebulized Liposomal Suspension 
Administered as a dilauroylphosphatidylcholine 
(DLPC) cyclosporine multi-lamellar liposome 
Contained cyclosporine in a DLPC multi-lamellar 
liposome of dissolved in ultrapure water 
25 mg 
Cmax 7.5c <0.3 µg g-1 
Healthy mongrel 
dogs 
(Lung and blood 
samples) 
(99) 
 Lung Blood  
tmax 1.0 3.7 hr 
Cmax 10.5 0.37 µg g-1 
AUC 144.4 9.7 µg hr g-1 
Nebulized Suspension 
Administered as a nebulized suspension of CP 
cyclosporine  
Contained nano-scale cyclosporine with polysorbate 
80 
3.5 mg kg-1 
t1/2 9.6 18.2 hr 
Healthy mice 




Values are the geometric mean or the mean ± standard deviation. 
a: L/B Ratio = Ratio of lung Cmax to blood Cmax 
b: L/B Ratio = Ratio of lung AUC to blood AUC 
c: Values not expressly reported by the authors.  Values inferred from figures, tables, and methodological descriptions. 
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Table 1.3B: Properties of Inhaled FK224 
Delivery Device and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
FK224 




1.0 ± 0.3  
0.05 ± 0.03  
0.32 ± 0.13  
hr 
µg mL-1 
µg hr mL-1 




0.25 ± 0.1  
0.17 ± 0.09  
2.15 ± 0.25  
hr 
µg mL-1 
µg hr mL-1 
FK224 : β-CD :: 1 : 7 
pMDI 
Administered as a suspension of FK224 and β-
cyclodextrin  
Contains micronized FK224/β-cyclodextrin in various 
ratios with soybean lecithin in a mixture of CFC-11, 
CFC-12, and CFC-114 




0.25 ± 0.2  
0.43 ± 0.22  
6.76 ± 0.92  
hr 
µg mL-1 




1 mg tmax 
Cmax 
AUC 
2.7 ± 1.3  
0.07 ± 0.02  




4 mg tmax 
Cmax 
AUC 
3.0 ± 0.8  
0.36 ± 0.07  





Administered as a suspension of FK224 and β-
cyclodextrin in propellant 
Contains micronized FK224/β-cyclodextrin in a 1:1 
ratio with soybean lecithin in a mixture of CFC-11, 
CFC-12, and CFC-114 
8 mg tmax 
Cmax 
AUC 
2.7 ± 0.6  
0.55 ± 0.09  




4 mg tmax 
Cmax 
AUC 
2.2 ± 1.2  
1.36 ± 0.17  





Administered using filled capsules and with a 
Spinhaler® 
Contained micronized FK224/β-cyclodextrin in a 1:1 
ratio blended with lactose  
10 mg tmax 
Cmax 
AUC 
0.7 ± 0.1  
3.66 ± 0.56  









Values are the mean ± standard deviation. 
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Table 1.4: Properties of Inhaled Fentanyl 
Delivery Device and Formulation Dose Pharmacokinetic Parameters Studied Population Reference 
Fentanyl 
2 mg tmax 
Cmax 
0.38 ± 0.11  




Administered as a mixture of free (50%) and liposome-
encapsulated (50%) fentanyl (FLEF) 
Contained free fentanyl and liposomal encapsulated 
(phospholipon 90-G and cholesterol) fentanyl in sterile 
water 










100 µg tmax 
Cmax 
AUC 
0.12 ± 0.08  
1.5 ± 1.5  
15.4 ± 5.57  
hr 
ng mL-1 
ng hr mL-1 
200 µg tmax 
Cmax 
AUC 
0.12 ± 0.12  
1.9 ± 0.9  
19.0 ± 7.90  
hr 
ng mL-1 
ng hr mL-1 
pMDI 
Administered as a fentanyl solution in propellant using a 
pMDI fitted with SmartMist™ (breath actuated adapter) 
Contained fentanyl base solution in a mixture of CFC-11 
and CFC-12 with sorbitan trioleate 
300 µg tmax 
Cmax 
AUC 
0.10 ± 0.07  
4.2 ± 2.7  
27.4 ± 24.0  
hr 
ng mL-1 






Adminsitered as fentanyl-lactose blend in Taifun® 
device 
Contained fentanyl blended with lactose carrier particle 



















Table 2.1: Single-dose Pharmacokinetic Parameters for Inhaled Voriconazole  
Parameter High-flow Rate Low-flow Rate Units 
Air Flow Rate 5.2-5.4 1 (L/min) 
Mouse Mass 31.8 21.8 (g) 
Lung Mass 0.23 0.17 (g) 
Vfend Conc. 6.23 6.9 (mg/mL) 
Lung 10 30 (min) Tmax Plasma 20 30 (min) 
Lung 1.6 ± 0.17 11.0 ± 1.6 (µg/g) Cmax Plasma 1.2 ± 0.25 7.1 ± 0.68 (µg/mL) 
Lung 205.3 2408 (µg min/g) AUC0-6 Plasma 136.4 1549.8 (µg min/mL) 
 
The inhaled dose was 5 mL of 6.25 mg/mL voriconazole solution nebulized over  
20 minutes to mice in a nose-only dosing chamber.  All values are the reported average 
except for the observed tmax.  The values for Cmax are the average ± standard deviation 
(N=2).  The AUC was calculated for concentration versus time profiles from 0-6 hours by 
the trapezoidal method.   
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(µg/g wet lung weight) (µg/mL) Day 
Peak Trough Peak Trough 
3 - -* - 0.22 ± 0.08 
5 6.73 ± 3.64 -* 2.32 ± 1.52 0.28 ± 0.14 
10 - 0.11 ± 0.09 - 0.18 ± 0.09 
12 - 0.19 ± 0.23 - 0.32 ± 0.08 
 
Inhaled voriconazole was administered at 08:00 and 16:00 for 12 days.  The inhaled dose 
was 5mL of 6.25mg/mL voriconazole solution nebulized over 20 minutes to mice in a 
nose-only dosing chamber.  Trough values were determined from samples taken 
immediately before the 08:00 dose while peak samples were taken 30 minutes after the 
08:00 dose.  Average values are reported ± standard deviation for N=6 mice per value.   




Table 3.1: Pulmonary Fungal Burden in Infected Mice 




(3.55 – 4.45) 
4.41 
(3.56 – 4.91) 
4.21 
(3.62 – 4.68) 
4.33 




(4.47 – 5.95) 
5.24 
(4.45 – 5.98) 
5.56 
(5.08 – 5.89) 
 
Pulmonary fungal burden for mice that received aerosolized voriconazole (6.25 mg/mL 
twice daily), amphotericin B deoxycholate, or control (aerosolized sulfobutyl ether-β-
cyclodextrin sodium 100 mg/mL twice daily) and challenged by pulmonary inoculation 
with A. fumigatus.  (1 hr SAC = Animals sacrificed 1 hour after inoculation) 
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Table 4.1: Multiple Dose Pharmacokinetic Profile of Inhaled Vorciconazole in Rats (BID 
Dosing) 
Voriconazole Peak Voriconazole Trough 
Day Group Lung (µg/g) Plasma (µg/ml) Lung (µg/g) 
Plasma 
(µg/ml) 
High dose 0.85 ± 0.63 0.58 ± 0.30 0.042 ± 0.002 0.011 ± 0.004 
3 
Low dose 0.38 ± 0.01 0.09 ± 0.06 0.040 ± 0.004 0.010 ± 0.003 
High dose    0.023a 
14 
Low dose    0.029a 
High dose    0.030 ± 0.011 
21 
Low dose    0.027 ± 0.003 
 
Values are the mean ± standard deviation. 
a: Value represents the observed concentration (N=1) 
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Table 4.2: Laboratory Values Following Multiple Doses of Inhaled Voriconazole in Rats 
Table 4.2A: Hepatic Function 
 NT C LD HD 
ALP (U/L) 188 ± 40 216* ± 52 218* ± 51 213* ± 41 
ALT (U/L) 80 ± 54 79 ± 53 96 ± 78 72 ± 31 
AST (U/L) 147 ± 123 132 ± 130 164 ± 160 110 ± 58 
Albumin (g/dL) 3.2 ± 0.1 3.3* ± 0.2 3.3* ± 0.2 3.3* ± 0.2 
Bilirubin (mg/dL) 0.1 ± 0 0.1* ± 0 0.1* ± 0 0.1* ± 0 
 
Table 4.2B: Renal Function 
 NT C LD HD 
Protein (g/dL) 6.2 ± 0.3 6.1 ± 0.4 6.2 ± 0.3 6.2 ± 0.4 
Globulin (g/dL) 3.1 ± 0.3 2.8* ± 0.3 2.9* ± 0.3 2.9* ± 0.3 
BUN (mg/dL) 21 ± 2 19* ± 2 21 ± 5 21 ± 3 
Creatinine (mg/dL) 0.5 ± 0 0.5 ± 0.1 0.5 ± 0.1 0.4* ± 0.1 
 
Table 4.2C: Blood Chemistry 
 NT C LD HD 
Cholesterol (mg/dL) 94 ± 10 95 ± 15 95 ± 13 93 ± 19 
Glucose (mg/dL) 319 ± 101 329 ± 143 334 ± 154 291 ± 116 
Calcium (mg/dL) 11.2 ± 0.5 11.5* ± 0.6 11.4 ± 0.6 11.3 ± 0.6 
Phosphorous (mg/dL) 9.0 ± 1.3 9.6 ± 2.1 8.9 ± 1.9 8.0* ± 1.3 
Chloride (mg/dL) 99 ± 2 100 ± 2 101* ± 2 101* ± 2 
Potassium (mg/dL) 6 ± 1 6 ± 1 7 ± 2 6 ± 1 
Sodium (mg/dL) 142 ± 2 144* ± 2 144* ± 3 145* ± 2 
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Table 4.2: Laboratory Values Following Multiple Doses of Inhaled Voriconazole in Rats 
(continued) 
Table 4.2D: CBC 
 NT C LD HD 
WBC (103/μL) 5.3 ± 2.3 4.1* ± 1.6 4.7 ± 2 5.2 ± 1.9 
RBC (106/μL) 8.2 ± 1.3 8.0 ± 0.8 7.9 ± 0.8 8.0 ± 0.7 
HGB (g/dL) 15.8 ± 2.3 14.7* ± 1.5 14.7* ± 1.2 15.0 ± 1.0 
HCT (%) 50.2 ± 7.2 49.5 ± 5.1 49.1 ± 5.3 48.2 ± 7.6 
Platelet (103/μL) 657 ± 240 767 ± 235 685 ± 264 842* ± 182 
 
Values are the mean ± standard deviation. 
NT = No Treatment Group (N=20), C = Inhaled Normal Saline Group (N=30), LD = 
Inhaled Low Dose Voriconazole Group (N=30), HD = Inhaled High Dose Voriconazole 
Group (N=30) 
 
*: Statistically significant compared to NT (p-value <0.05). 
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Table 5.1: Pharmacokientic Parameters of Voriconaozle in Lung Tissue and Plasma 




tmax 0.17 hr 0.17 hr 
Cmax    9.98 ± 0.94 µg/g 6.57 ± 3.04 µg/mL 
AUC0-24 44.4 µg hr/g 30.2 µg hr/mL 
Pl-p 1.47 
ke (lung elimination) 0.263 hr-1  
Α (plasma absorption)  0.274 hr-1 
Β (plasma elimination)  0.057 hr-1 
t1/2, e 2.63 hr  
t1/2, α  2.53 hr 






























Figure 2.1: Osmolality of Voriconazole and Cyclodextrin Solutions 
Osmolality of aqueous solutions in a fixed mass ratio of 1 to 16 of voriconazole 
and sulfobutyl ether-β-cyclodextrin.  The shaded region indicates the limits of 
isotonicity.  Error bars represent one standard deviation (N=10).  The fitted line 























































Figure 2.2: Pharmacokinetic Profile of Voriconazole in Lung Tissue and Plasma Following Inhalation 
Pharmacokinetic profile of voriconazole in lung tissue (A) and plasma (B) following a single inhaled dose of aqueous 
voriconazole solution.  The inhaled dose was 5 mL of 6.25 mg/mL voriconazole solution nebulized over 20 minutes to 
mice in a nose-only dosing chamber.  Errors bars represent one standard deviation (N=2, except N=4 for 1 hour time 
point for low flow rate group and N=1 for 10 minute time point for low-flow rate group).  Voriconazole was 
undetectable in lung tissue 6, 12, and 24 hours after the completion of nebulization. 
 
Survival curves for immunosuppressed mice that received aerosolized voriconazole (6.25 mg/mL twice daily), 
amphotericin B deoxycholate, or control (aerosolized sulfobutyl ether-β-cyclodextrin sodium 100 mg/mL twice daily) 
and challenged by pulmonary inoculation with A. fumigatus.  (A) Survival on therapy (day 7; N = 24 per study group). 
(B) Survival after therapy discontinued (N = 12 per study group). 
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Figure 3.1: Survival in Infected Mice 
 
 
Figure 3.2: Pulmonary Histopathology Images from Infected Mice 
Histopathology of lungs from mice on days 8 (A, B, and C) and 12 (E, F, and G) post-inoculation that received 
aerosolized aerosolized sulfobutyl ether-β-cyclodextrin sodium (A & D), intraperitoneal amphotericin B deoxycholate 
(B & E), or aerozolied voriconazole (C & F).  Lung sections were stained with hemotoxylin and eosin and viewed by 




Figure 4.1: Respiratory Bronchiole Index 
 
Rats received inhaled voriconazole BID for 21 days followed by a 7-day recovery 
period for a total of 28 days.  RBI = Respiratory Bronchiole Index.  *: Statistically 
significant difference compared to Control Group (p-value <0.05).  Error bars 
omitted due for clarity in interpreting the figure. 
 
 
Figure 4.2: Representative Lung Histopathology Images Following Inhalation of 
Voriconazole 
C = Control Group, LD = Low Dose Group, HD = High Dose Group.  
Representative images are of alveolar regions near the respiratory bronchiole 
duct.  Free alveolar macrophages are visible in several images and demonstrate 
the variability observed between treatment groups as well as the duration of 





























Figure 5.1: Single Dose Pharamcokinetic Profile in Lung Tissue and Plasma of Mice 
Following a Single Inhaled Dose 
Pharmacokinetic profile following a single dose of inhaled voriconazole in lung 
tissue and plasma.  Log-scaled drug concentrations are represented in units of 
µg/g wet lung weight for lung tissue (■ = Mouse Lung) and µg/mL for plasma (● 
= Mouse Plasma).  One-tailed error bars represent one standard deviation and 





1 2 ke ≈ α 
Tissue Compartment Central Compartment
 
Figure 5.2: Two-compartment Pharmacokientic Model  
Two-compartment pharmacokinetic model used to evaluate voriconazole in lung 
tissue and plasma.  Lung tissue was assumed to correspond to the tissue 
compartment (1) and was the site of drug administration.  Drug diffusion from the 
tissue compartment was assumed to be unidirectional elimination with rate 
constant ke.  Plasma was assumed to represent the central compartment (2) and 




Pharmacokinetic profiles of voriconazole in mouse and rat lung tissue and plasma following multiple doses 
administered every 12 hours.  Figure 3A represents peak drug concentrations in mice while Figure 3C represents trough 
concentrations (■ = Mouse Lung, ● = Mouse Plasma).  Figures 3B and 3D represent peak and trough voriconazole 
concentrations, respectively, in rats (□ = Rat Lung, ○ = Rat Plasma).  One-tailed error bars represent one standard 
deviation and were used for simplicity in interpreting the figure.   
Figure 5.3: Peak and Trough Lung and Plasma Voriconazole Concentrations in Mice and Rats Following Multiple Inhaled 
Doses 
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Pharmacokinetic profiles of voriconazole in mouse and rat lung tissue and plasma following multiple doses 
administered every 12 hours.  Figure 3A represents peak drug concentrations in mice while Figure 3C represents trough 
concentrations (■ = Mouse Lung, ● = Mouse Plasma).  Figures 3B and 3D represent peak and trough voriconazole 
concentrations, respectively, in rats (□ = Rat Lung, ○ = Rat Plasma).  One-tailed error bars represent one standard 
deviation and were used for simplicity in interpreting the figure.  
Figure 5.3: Peak and Trough Lung and Plasma Voriconazole Concentrations in Mice and Rats Following Multiple Inhaled 
Doses (continued) 
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The 20 minute concentration value was low likely due to saturated chamber 
humidity 
A.3. Results 
Using a 19G needle on a 5mL syringe at each port, serially withdrew 5mL 
samples of the nebulized aerosol over 2 seconds per port. 
Construction of a 6-port chamber: Contracted with the Chemistry & Biochemistry 
machine shop (WEL 2.140) to construct a 6-port chamber. 
A.2. Methods 
Previous to the studies in Chapter 2, only 4 mice had been exposed in the dosing 
chamber to the aerosolized droplets. 
A.1. History 
APPENDIX A: VALIDATION OF A 6-PORT NOSE-ONLY DOSING CHAMBER 
The 6-port chamber has low concentration variability between ports 
 
Analyzed drug concentration using UV-vis 
Slowly expelled and rinsed each syringe into and with 5mL water 
Nebulized theophylline in tap-water solution over 20 minutes. 





























Figure A.1: Validation of a 6-Port Dosing Chamber 
Error bars represent the percent relative standard deviation. 
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APPENDIX B: VISCOSITY OF VFEND® IV DILUTIONS 
B.1. History 
Very little solution was nebulized when the reconstituted Vfend® IV solution was 
nebulized (10mg/mL voriconazole concentration).  This was thought to be due to 
increased viscosity of the cyclodextrin-containing solution.   
 
B.2. Methods 
Vfend® IV was diluted with sterile water for injection to varying concentrations. 
Viscosity was measured using a Physica MCR 300 Cone on Plate Viscometer by 
Anton Paar USA Inc., Ashland, VA, at 1000RPM and 25°C. 
 
B.3. Results 
Viscosity was affected by cyclodextrin concentration within the Vfend® IV 























APPENDIX C: ORIGINAL PROCEDURE FOR HPLC QUANTIFICATION OF 
VORICONAZOLE IN BIOLOGICAL SAMPLES 
C.1. History 
Yoen Ju Son adapted published methods for voriconazole (VRC) concentration 
determination to the equipment and materials in the McConville Laboratory.  Following 
difficulty in reproducing her methods in the Williams’s Laboratory, we achieved 
correlation in voriconazole concentration determination through a clarified method. 
C.2. Procedures for Plasma Analysis 
• Thaw/defrost plasma samples 
• Spike empty Eppendorf tube (E-tube) with VRC spiking solution (mobile phase) 
• Quickly transfer 250µL of the plasma sample to E-tube 
• Vortex for 30 seconds 
• Add 400µL acetonitrile  
• Vortex for 30 seconds 
• Stored at 4°C for 10 min 
• Vortex for 10 seconds 
• Centrifuge at 15,000 rpm for 5 mins 
• Transfer supernatant to E-tube 
• Place samples in the aluminum heating block at R.T. 
• Dry under nitrogen stream (~60 min) 
• Redisperse with 250µL of mobile phase  
• Centrifuge at 15,000 rpm for 3 mins 
• Transfer supernatant to HPLC vial 
Reference: Pascual et al., Antimicrobial Agents and Chemotherapy , Jan 2007 
C.3. Procedures for Lung Tissue Analysis 
• Thaw/defrost lung samples 
• Collect ice in a large beaker 
• Add lung to glass vial  
• Add 1mL DI water 
• Homogenize the lung tissue with a homogenizer (keep vial on ice) for 3 mins 
• Spike empty Eppendorf tube (E-tube) with VRC spiking solution (mobile phase) 
• Quickly transfer 200µL of the homogenated lung to the E-tube  
• Vortex for 30 seconds 
• Add 500µL of 0.2M borate buffer (pH 9.0) 
 
• Vortex for 30 seconds 
• Stored at 4°C for 10 min 
• Vortex for 10 seconds 
• Add 500 µL of ethyl acetate 
• Vortex for 30 seconds 
• Transfer supernatant to E-tube ( Extraction- 3 times) 
• Place samples in the aluminum heating block at R.Temp. 
• Dry under nitrogen stream (~60 min) 
• Redisperse with 200µL of mobile phase  
• Centrifuge at 15,000 rpm for 3 mins 
• Transfer supernatant to HPLC vial 
Reference: Lutsar et al., Clinical Infectious Disease, 2003, 37 
C.4. HPLC Parameters 
• HPLC : Waters Breeze  
• Column: Jupiter® C18 (150mm × 4.6mm, 5µm)  
• Guard Column: Universal security guard (Widepore C18) 
• Temp: 35 °C  
• Flow rate: 1ml/min 
• Injection Vol.; 50 µL  
• Detect wavelength: UV 255 nm  
• Mobile phase (isocratic gradient): Methanol: 0.01M sodium acetate buffer1 (pH 
5.0) = 50:50 




Table C.1: Voricoanzole Peak Confirmation 
Concentration 









RSQ (R2) : 0.9999 
Slope : 55887 
Intercept: 2473.1 
 
Table C.2: Extraction Method Validation for Plasma 
Concentration 
(µg/mL) 
Recovery Ratio (%) 
(N=2) 
0.25 96.4 ± 0.00 
0.5 91.6 ± 0.02 
5 105.4 ± 0.04 
10 90.0 ± 0.00 
 
Table C.3: Extraction Method Validation for Lung Tissue 
Concentration 
(µg/mL) 
Recovery Ratio (%) 
(N=2) 
0.25 96.4 ± 0.00 
0.5 96.1 ± 0.03 
5 97.1 ± 0.03 





Figure C.1: Blank Plasma Chromatogram 
 
 





Figure C.3: Blank Lung Homogenate Chromatogram 
 
 
Figure C.4: Voriconazole Spiked Lung Homogenate Chromatograms  
 
Figure C.4A: Voriconazole Spiked Lung Homogenate (Low Concentration) 
 
 
Figure C.4B: Voriconazole Spiked Lung Homogenate (High Concentration) 
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APPENDIX D: HPLC AND LC-MS ANALYSIS METHODS FOR QUANTITATION OF 
VORICONAZOLE IN PLASMA AND LUNG HOMOGENATE 
D.1. Materials 
Voriconazole standard (Lot # E010000674) was generously supplied by CyDex 
Pharmaceuticals, Inc. (Lenexa, KS).  Fluconazole standard (Lot # 43352) was purchased 
from Hawkins, Inc. (Minneapolis, MN).  Sodium tetraborate decahydrate (Batch # 
057K0070), boric acid (Batch # 097K0063), sodium acetate trihydrate (Batch # 
117K0153), and sodium chloride solution, 0.85% (Batch # 106K6027) were purchased 
from Sigma-Aldrich, Inc. (St. Louis, MO).  Acetic acid (Lot # 72270) was purchased 
from Sigma-Aldrich Laborchemikalien GmbH (Seelze, Germany).  HPLC grade ethyl 
acetate (Lot # PU0674) was purchased from Spectrum Chemical Manuf. Corp. (Gardena, 
CA).  HPLC grade acetonitrile was purchased from Fisher Scientific (Fair Lawn, NJ).  
HPLC grade methanol was purchased from EMD Chemicals Inc. (Gibbstown, NJ).  
Water was obtained from an in-house Milli-Q UV Plus water purification system from 
the Millipore Corp. (Billerica, MA).  
 
D.2. HPLC Mobile Phase 
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Mobile phase for reverse phase high performance liquid chromatography 
consisted of a 50:50 mixture of 0.01 M pH 5.0 sodium acetate buffer and methanol.  
Equal volumes of 0.01 M pH 5.0 sodium acetate buffer and methanol were mixed 
together, passed through 0.2 µm filter, and degassed with a vacuum, sonication system.  
0.01 M pH 5.0 sodium acetate buffer was prepared by adding 0.871 g sodium acetate 
trihydrate and 200 µL acetic acid to 1 L of water.  The pH of the 0.01 M sodium acetate 
buffer was measured using a pH meter.  It was discovered on March, 19, 2008 that the 
sodium acetate buffer was prepared incorrectly.  0.871 g sodium acetate trihydrate and 
 
200 µL acetic acid was added to 2 L of water, resulting in buffer solution with a different 
ionic strength which lead to incomplete separation of the plasma peak and voriconazole 
peak during HPLC analysis. 
 
D.3. Voriconazole Extraction Method for Mouse Plasma 
Similar methods were used to those previously published [1].  Validation was 
performed by spiking voriconazole standard dissolved in mobile phase into 250 µL of 
blank plasma.  Table 1 shows the method validation for the mouse plasma samples spiked 
with voriconazole solution.  Figures 1 and 2 show the chromatrographs of blank plasma 
and plasma spiked with voriconazole solution, respectively.  Voriconazole was extracted 
from plasma samples through the addition of acetonitrile, centrifugation, and supernatant 
extraction.  250 µL of plasma was transferred to a 2 mL Eppendorf tube followed by 
vortex mixing for 30 seconds.  400 µL of acetonitrile was added to the Eppendorf tube 
followed by vortex mixing for 30 seconds.  The Eppendorf tube was stored at 4°C for 10 
minutes followed by vortex mixing for 10 seconds and centrifugation at 15,000 rpm for 5 
minutes.  The supernatant liquid was transferred to a new Eppendorf tube and evaporated 
under a gentle stream of nitrogen.  Residual solids were re-dispersed with 250 µL of 
mobile phase. 
 
D.4. Voriconazole Extraction Method for Mouse Lung Homogenate 
Similar methods were used to those previously published [2].  Lung tissue was 
thawed and homogenized with 1 mL of water for 3 minutes in an ice bath using an Omni 
GLH homogenizer from Omni International (Marietta, GA).  Validation was performed 
by spiking voriconazole standard dissolved in mobile phase into 200 µL of lung 




samples spiked with voriconazole solution.  Figures 3 and 4 show the chromatrographs of 
blank lung homogenate and lung homogenate spiked with voriconazole solution, 
respectively.  Voriconazole was extracted from lung homogenate samples through the 
addition of 0.2 M pH 9.0 borate buffer, ethyl acetate, centrifugation, and supernatant 
extraction.  0.2 M pH 9.0 borate buffer was prepared by by mixing 50 mL of 12.4 g/L 
boric acid solution with 59 mL of 19.05 g/L sodium tetraborate decahydrate solution.  
The 0.2 M borate buffer was passed through 0.2 µm filter and the pH was measured.  200 
µL of lung homogenate was transferred to a 2 mL Eppendorf tube followed by vortex 
mixing for 30 seconds.  500 µL of 0.2 M pH 9.0 borate buffer was added to the 
Eppendorf tube followed by vortex mixing for 30 seconds.  The Eppendorf tube was 
stored at 4°C for 10 minutes followed by vortex mixing for 10 seconds.  500 µL of ethyl 
acetate was added to the Eppendorf tube followed by vortex mixing for 30 seconds and 
centrifugation at 15,000 rpm for 1 minute.  The supernatant liquid was transferred to a 
new Eppendorf tube and the ethyl acetate extraction procedure was repeated two more 
times.  The total volume of extraction supernatant from the 3 iterations was 
approximately 1.4 mL. The supernatant liquid was evaporated under a gentle stream of 
nitrogen and the residual solids were re-dispersed with 200 µL of mobile phase.   
 
D.5. HPLC Analysis Method for Mouse Plasma and Lung Homogenate Samples 
Voriconazole standards were prepared by dissolving voriconazole in mobile phase 
followed by serial dilution with mobile phase.  A standard curve was generated with a 
minimum of 5 concentrations.  Each extracted and reconstituted sample was transferred 
to a polypropylene conical insert and placed in the appropriate HPLC vial.  The samples 
were analyzed using a Waters Breeze liquid chromatograph (Waters Corporation, Milford 
MA) or Shimadzu LC-10 liquid chromatograph (Shimadzu Corporation, Columbia, MD) 
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equipped with a heated (35°C) Jupiter® C18 (150 mm x 4.6 mm, 5 µm, 300 Å) with a 
security guard cartridge (Widepore C18, 4 x 3.0 mm) (Phenomenex, Torrance, CA).  The 
sample volume was 50 µL with a UV detection wavelength of 254 nm.  The mobile phase 
consisted of a 50:50 mixture of 0.01 M pH 5.0 sodium acetate buffer and methanol at a 
flowrate of 1.0 mL/minute.  The retention time for voriconazole was approximately 8 
minutes.  The lower limit of quantitation was 100 ng/mL. 
 
D.6. LC-MS Method Development for Rat Plasma and Lung Homogenate Samples 
Due to the low concentrations of voriconazole in rats following inhalation, HPLC 
with UV detection was not suitable for analysis.  The LTQ XL Linear Ion Trap Mass 
Spectrometer located in Welch 5.336 at The University of Texas at Austin was evaluated.  
The LC-MS method evaluated was a C18 column at room temperature, 100-1000 m/z, 17 
minute run, positive with PDA, 10 µL injection, and 0.5 mL/minute flowrate.  A mobile 
phase gradient of 95% water:5% acetonitrile was used for the first minute followed by 
equilibration from 95% water to 5% water over the next 4 minutes.  Metronidazole and 
ketoconazole were evaluated as internal standards.  Ketoconazole was unstable in the 
aqueous mobile phase and metronidazole was very polar so that it eluted very quickly 
with a broad peak. Neither metronidazole nor ketoconazole are suitable were suitable as 
internal standards.  The retention time for voriconazole (m/z 350) was approximately 7.6 
minutes.  The lower limit of detection (LLOD) for voriconazole was approximately 10 
ng/mL and the lower limit of quantitation (LLOQ) was approximately 50 ng/mL.  A 20 
µL injection volume could be used to yield LLOD = 5 ng/mL and LLOQ = 25 ng/mL.   
 
An inter-day and intra-day validation study on the LTQ XL Linear Ion Trap Mass 
Spectrometer showed that the amount of voriconazole detected was variable from day to 
day as well as within intraday with a sample set of approximately 20 samples.  It was 
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concluded that this mass spectrometer is unstable and not suitable for quantitation of 
voriconazole in plasma and lung homogenate samples. 
 
The Applied Biosystems 4000 Q Trap LC-MS/MS system with ESI, APCI and 
nanospray sources coupled with Shimadzu LC-20AD HPLC system located in the 
Analytical Instrumentation Facility Core (PHR 1.110) at The University of Texas at 
Austin was evaluated for quantitation of voriconazole and fluconazole (internal standard).  
The system was found to be variable from day to day but stable during an intraday study.  
The LC-MSMS method development and the analysis of the extracted samples were 
performed by Dr. Herng-Hsiang Lo in the CRED Analytical Instrumentation Facility 
Core supported by NIEHS center grant ES07784.  A 4000 Q TRAP mass spectrometer 
(Applied Biosystems, Foster City, CA) coupled with an online HPLC (Shimadzu, 
Columbia, MD) was used to analyze the samples.  Dried samples were reconstituted in 
200 µL of acetonitrile, 10 µL was injected into Shimadzu Prominence UFLC system 
equipped with an Restek C18 (4.6 x 50mm, 5 µm, 110 Å) column; both fluconazole and 
voriconazole were eluted with mobile phase A (water with 0.1% formic acid) and B 
(acetonitrile with 0.1% formic acid) by a gradient of 20% B for 0.5 minutes, then 20%-
50% B over 0.5 minutes, followed by 50% B for 3 minutes, at a flow rate of 1 
mL/minute.  Sample was directly eluted from the column into the electrospray ion (ESI) 
source of 4000 QTRAP.   The heated nebulizer of 4000 QTRAP was set at 700°C, the 
declustering potential (DP) at 40.  The Multiple Reaction Monitoring (MRM) scan 
experiment with unit resolution for Q1 and low resolution for Q3 was used to quantify 
fluconazole and voriconazole.  The MRM transitions were set as follows, fluconazole: 
Q1=307.5, Q3=238.4, collision energy (CE) =25; voriconazole: Q1=350.2, Q3=127.4, 
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CE=40.  The lower limit of detection for both fluconazole and voriconazole was 5 pg.  
The upper limit of detection for both fluconazole and voriconazole was 20 ng. 
 
D.7. Voriconazole Extraction Method for Rat Plasma and Lung Homogenate 
A study was performed to compare extraction methods for rat plasma and lung 
homogenate for mass spectrometry analysis.  Both methods described above (acetonitrile 
method and borate buffer plus ethyl acetate method) were tested for extraction of 
voriconazole and fluconazole from rat plasma.  Only the borate buffer plus ethyl acetate 
method was tested for extraction of voriconazole and fluconazole from rat lung 
homogenate.  Thawed blank rat plasma was spiked with voriconazole standard dissolved 
in acetonitrile and fluconazole standard dissolved in acetonitrile.  Lung tissue was thawed 
and homogenized with 1 mL of 0.85% sodium chloride solution for every 0.5 g of lung 
tissue for 3 minutes in an ice bath using an Omni GLH homogenizer. Lung homogenate 
was also spiked with the voriconazole and fluconazole standards dissolved in acetonitrile.  
Only one spiked quantity of each drug was tested:  40.5 ng voriconazole and 64.8 ng 
fluconazole.  The borate buffer plus ethyl acetate method was superior to the acetonitrile 
for rat plasma for both fluconazole and voriconazole.  The extraction efficiencies were 
48% compared to 18% for fluconazole and 74% compared to 50% for voriconazole.  
Similar extraction efficiencies were found for the lung homogenate:  42% for fluconazole 
and 74% for voriconazole.  Therefore, the borate buffer plus ethyl acetate method was 
chosen for extraction of voriconazole and fluconazole from both rat plasma and lung 
homogenate samples.  Since the extraction efficiencies differed for fluconazole and 
voriconzole, fluconazole could not be used as an internal extraction standard to adjust the 
quantity of voriconazole determined in unknown samples.  However, fluconazole could 
still be used as an internal LC-MSMS standard to detect erroneous results.  In order to 
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validate the quantitation of voriconazole in unknown samples, a calibration curve must be 
generated each time a sample set is run on the LC-MSMS system. 
 
Voriconazole standards and fluconazole standards were prepared by dissolving 
voriconazole or fluconazole in acetonitrile followed by serial dilution with acetonitrile. 
Lung tissue was thawed and homogenized with 1 mL of 0.85% sodium chloride solution 
for every 0.5 g of lung tissue for 3 minutes in an ice bath using an Omni GLH 
homogenizer.  A calibration curve with a minimum of 4 concentrations (2 ng, 32 ng, 130 
ng, and 520 ng) was generated by spiking voriconazole standards into 200 µL of plasma 
or lung homogenate.  Only 1 concentration of fluconazole standard (approximately 200 
ng) was spiked into the plasma and lung homogenate samples.  200 µL of plasma or lung 
homogenate was transferred to a 2 mL Eppendorf tube followed by vortex mixing for 30 
seconds.  500 µL of 0.2 M pH 9.0 borate buffer was added to the Eppendorf tube 
followed by vortex mixing for 30 seconds.  The Eppendorf tube was stored at 4°C for 10 
minutes followed by vortex mixing for 10 seconds.  500 µL of ethyl acetate was added to 
the Eppendorf tube followed by vortex mixing for 30 seconds and centrifugation at 
15,000 rpm for 1 minute.  The supernatant liquid was transferred to a new Eppendorf 
tube and the ethyl acetate extraction procedure was repeated two more times.  The total 
volume of extraction supernatant from the 3 iterations was approximately 1 mL for 
plasma and 1.4 mL for lung homogenate. The supernatant liquid was evaporated under a 
gentle stream of nitrogen and the dried samples were submitted to Dr. Herng-Hsiang Lo 
in the CRED Analytical Instrumentation Facility Core for analysis.  The standard curve 
and the calibration curve were used to quantify the amount of voriconazole present in 
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Table D.1: Extraction Method Validation for Mouse Plasma 
Spiked Concentration 
(µg/mL) 
Recovery Ratio (%) 
(N=2) 
0.25 96.4 ± 0.00 
0.5 91.6 ± 0.02 
5 105.4 ± 0.04 
10 90.0 ± 0.00 
 
 
Table D.2: Extraction Method Validation for Mouse Lung Homogenate 
Spiked Concentration 
(µg/mL) 
Recovery Ratio (%) 
(N=2) 
0.25 96.4 ± 0.00 
0.5 96.1 ± 0.03 
5 97.1 ± 0.03 





















APPENDIX E: NEBULIZATION PROCEDURES EMPLOYED IN CHAPTER 3 
E.1. Acclimatization of Mice to the Animal Restraint Tubes 
Mice will be placed in the restraint tubes to acclimatize them to the dosing 
procedure.  Specificlly, mice should be restrained in the tubes for 5 minutes.  Time in the 





Figure E.1. Schematic of the Mouse Restraint Tube 
 
E.2. Reconstitution and Dilution of Injectable Vfend 
The vials of injectable Vfend must be reconstituted and diluted prior to 
nebulization.  The Vfend should be reconstituted to a total volume of 32mL with Sterile 
Water for Injection (SWFI).  This is accomplished by reconstituting per vial instructions 
by the addition of 19mL SWFI.  Then, an additional 12mL should be added before the 
solution is nebulized.  The dilution step (addition of 12mL SWFI) should be done in a 
separate container than the manufacturer’s vial.  The final concentration of voriconazole 
should be 6.25 mg/mL.  Remaining solution after nebulization could be refrigerated and 




E.3. Preparation of the Inhaled Control Solution 
Captisol® (β-cyclodextrin sulfobutyl ethers, sodium salt) should be dissolved in 
SWFI at a concentration of 100mg/mL.  This should be done by adding sufficient SWFI 
to 5000mg Captisol to achieve a total volume of 50mL.  Store the Captisol under vacuum 
and with excess desiccant 
 
E.4. Assembly of the Nose-only Dosing Chamber 
The nose-only dosing chamber includes the following components: 
• 6-port dosing tube 
• 6 animal restraint tubes (including 6 tube restrictors and 6 mouse pushers) 
• Fan assembly 
• Power adapter and switch 
• 4 silicone seals 
• Upstream air-flow restrictor 
• Downstream exhaust tube 
• Nebulizer medication reservoir 
• Nebulizer T-type adapter 
• Nebulizer controller unit with cord 
• Nebulizer power cord and  
• The nose-only dosing chamber should be assembled as diagrammed below: 
• Fan 
• Nebulizer reservoir and t-type adapter 
• Exhaust tube 
• 6-port dosing tube 
• Animal restraint tubes 
• Nebulizer controller unit 















Figure E.2: Schematic of the Dosing Apparatus 
E.5. Dosing Procedure 
Assemble the dosing apparatus.  Turn on fan and verify air flow rate is 1mL/min.  
Place 5-6mL of the solution into the medication reservoir.  Turn on the nebulizer by 
holding down the ON/OFF button until the 30 minute light is lit.  Nebulize the solution 
for 20 minutes. 
 
When done, collect sample of residual Vfend for concentration analysis.  Dry the 
6-port dosing tube and t-type nebulizer adapter of any condensation.  Clean the 
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restraining tubes if necessary.  Sonicate nebulizer reservoir in detergent solution for 5 
minutes.  Rinse nebulizer with tap water.  Nebulize tap water for 5 minutes and then dry 
the reservoir.  If necessary, measure residual volumes of the tap water to determine 





APPENDIX F: EXPANDED METHODS EMPLOYED FOR CHAPTER 3 
F.1. Reconstitution and Dilution of Injectable Vfend 
• Add 19mL SWFI and allow to dissolve 
• Transfer to new container 
• Add additional 12mL SWFI 
• Final concentration should be 6.25mg/mL 
• Preparation of the Inhaled Control Solution 
• Weigh 5000mg Captisol 
• QS 50mL with SWFI 
 
F.2. Dosing Procedure 
• Assemble nose-only dosing chanber 
• Turn on fan and verify 1L/min flow rate 
• Add solution to medication reservoir 
• Hold down ON/OFF button until 30 minute timer is lit 
• Nebulize solution for 20 minutes 
• Collect sample of residual volume in medication reservoir 
• Clean nose-only dosing chamber from condensation if necessary 
• Sonicate medication reservoir in detergent solution for 5 minutes 
• Rinse medication reservoir in tap water 
• Nebulize tap water through medication reservoir for 5 minutes 
• If necessary, measure residual volume of tap water to assess nebulizer output 
• Reassemble the nose-only dosing chamber 
• Aerosolized Voriconazole as Prophylaxis Against Invasive Pulmonary 
Aspergillosis 
 
F.3. Animal Numbers 
Groups: 
1 hr SAC   5 
Uninfect.Control 5 
AMB (1 mg/kg) 29 (4 not immunosuppressed) 
Aero. Control  28 (4 not immunosuppressed) 
Aero. VOR  28 (4 not immunosuppressed) 




56 mice will be acclimatized to the chambers beginning on Friday, July 26 
Friday – 7 minutes 
Saturday – 14 minutes 
Sunday – 21 minutes 
 
F.4. Disposition of Groups 
F.4.1. AMB (1 mg/kg) 
*4 mice will begin receiving IP AMB on day -2 and continue until through the 
morning of day 0.  These 4 mice will not be infected or receive 
immunosuppression.  The other 25 mice in this group will begin receiving AMB 
on day +1. 
 
Day 0 (using 4 mice dosed with AMB beginning on day -2) 
2 mice will have blood drawn and placed in heparinized tubes for PK analysis 
2 mice will have BALs performed with PBS for ELISA analysis 
 
Day 8 (using 12 mice dosed with AMB beginning on day +1) 
3 mice will have lungs filled with formalin and removed for histopathology 
9 mice will have lungs removed for tissue burden analysis 
2 mice from this group will also have blood drawn and placed in heparinized 
tubes for PK analsysis, and 2 x 200 mcL aliquots from lung hemogenates 
removed for PK tissue analysis 
 
Day 12 (using 13 mice dosed with AMB beginning on day +1) 
Survival analysis 
If enough animals remain, 4 mice will have lungs filled with formalin and 
removed for histopathology, and 2 mice will have blood drawn and lungs 
removed for PK tissue analysis 
F.4.2. Control 
Day 0 (4 mice that are not immunosuppressed) 
2 mice will have blood drawn and placed in heparinized tubes for PK analysis 
2 mice will have BALs performed with PBS for ELISA analysis 
 
Day 8 (using 12 mice that are immunosuppressed and infected) 
3 mice will have lungs filled with formalin and removed for histopathology 
9 mice will have lungs removed for tissue burden analysis 
2 mice from this group will also have blood drawn and placed in heparinized 
tubes for PK analsysis, and 2 x 200 mcL aliquots from lung hemogenates 
removed for PK tissue analysis 
 




If enough animals remain, 4 mice will have lungs filled with formalin and 
removed for histopathology, and 2 mice will have blood drawn and lungs 
removed for PK tissue analysis 
F.4.3. Voriconazole 
Day 0 (4 mice that are not immunosuppressed) 
2 mice will have blood drawn and placed in heparinized tubes for PK analysis 
2 mice will have BALs performed with PBS for ELISA analysis 
 
Day 8 (using 12 mice that are immunosuppressed and infected) 
3 mice will have lungs filled with formalin and removed for histopathology 
9 mice will have lungs removed for tissue burden analysis 
2 mice from this group will also have blood drawn and placed in heparinized 
tubes for PK analsysis, and 2 x 200 mcL aliquots from lung hemogenates 
removed for PK tissue analysis 
 
Day 12 (using 12 mice that are immunosuppressed and infected) 
Survival analysis 
If enough animals remain, 4 mice will have lungs filled with formalin and 
removed for histopathology, and 2 mice will have blood drawn and lungs 









APPENDIX G: SAMPLE COLLECTION PROCEDURES EMPLOYED IN CHAPTERS 2-5 
G.1. Blood for Voriconazole Concentration Determination 
G.1.1. Material preparation 
1) Extract 0.5-1 mL of 10,000 Unit/mL heparin and place in a clean 1.5 mL 
conical vial.  This vial is designated the HEPARIN VIAL. 
2) From the HERAPIN VIAL, add 40-100 µL (1-2 drops) of heparin to a 
sufficient number of 1.5 mL conical vials.  These vials are designated 
BLOOD VIALS. 
3) From the HEPARIN VIAL, coat the necessary number of 3mL 21 G 
needles/syringes to be used for blood collection with heparin by drawing 0.1-
0.5 mL heparin into the syringe and expel the heparin back into the HEPARIN 
VIAL.  These syringes are designated HEPARINIZED SYRINGES. 
G.1.2. Sample collection 
1) Immediately after sacrifice*, collect as much blood as possible by cardiac 
puncture using HEPARINIZED SYRINGES 
a) A maximum of 1 mL of suction could be applied to the HEPARINIZED 
SYRINGE when performing cardiac puncture. 
2) Remove the needle from the HEPARINIZED SYRINGE and fill whole blood 
into BLOOD VIALS. 
3) Invert and gently shake the BLOOD VIALS in order to disperse the heparin 
throughout the whole blood. 
4) Whole blood in BLOOD VIALS should be maintained at room temperature 
until centrifugation. 
5) Whole blood in BLOOD VIALS should be centrifuged as soon as possible 
after collection 
G.1.3. Sample processing 
1) Prepare clean 1.5 mL conical vials to collect the plasma that will be obtained 
after centrifugation.  These vials are designated PLASMA VIALS. 
2) Centrifuge the whole blood in the BLOOD VIALS to obtain plasma 
a) Centrifugation of BLOOD VIALS should be performed at 9000 rpm 
(approximately 75 G) for 15 minutes using the Beckman Coulter 
Microfuge 18 centrifuge. 
3) Extract the supernatant (plasma) into PLASMA VIALS using one pipet per 
vial. 
4) Plasma in PLASMA VIALS can be frozen at -5 to -2oC until voriconazole 
quantification by HPLC. 
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G.2. Blood for CBC/Serum Chemistry 
G.2.1. Material Preperation 
1) Fill out the online forms with VetConnect.com (IDEXX) to request sample 
analysis approximately 24 hours before whole blood and tissue sample 
collection. 
a) Print the completed requisition(s) and include in samples sent for analysis. 
b) Appendix A includes a completed requisition form as an example. 
2) Immediately after sacrifice*, collect as much blood as possible by cardiac 
puncture using clean (no additive) 3 mL 21 G syringe/needles. 
a) Apply gentle suction when collecting blood to minimize hemolysis. 
i) A maximum of 1 mL of suction could be applied to the syringe when 
performing cardiac puncture. 
b) A minimum of 1 mL of whole blood is necessary to be able to run both 
CBC and serum chemistry.   
G.2.2. Sample Collection 
1) Collect as much blood as possible by cardiac puncture. 
2) For CBC Analysis on Whole Blood: 
a) Whole blood processing must be performed at room temperature. 
b) Remove the needle after blood draw and fill 250-500 µL whole blood into 
Lavender-topped (LT) tubes for CBC analysis. 
i) Anticoagulant coats the inside of the LT tubes 
c) Immediately invert the LT tube 10 times gently to ensure anticoagulation.   
i) DO NOT SHAKE. 
ii) Rat whole blood contains a very large number of platelets and will clot 
easily and rapidly.   
iii) Immediately disperse anticoagulant by gentle tube inversion after 
blood collection. 
d) Keep LT tubes at room temperature for 30 minutes before refrigeration at 
2-5oC.   
i) Do not freeze whole blood in LT tubes. 
3) For Serum Chemistry Analysis: 
a) Whole blood collected for chemistry analysis should be maintained at 
room temperature. 
b) Whole blood will ultimately be clotted and centrifuged, so anticoagulant 
should not be used. 
c) Any whole blood remaining after CBC analysis should be filled into clean 
1.5 mL conical vials. 
i) If possible, >2 mL of whole blood should be collected for serum 
chemistry analysis 




d) Store collected blood at room temperature for 15-20 minutes to allow for 
clotting (coagulation). 
e) Centrifuge coagulated blood at 2500 RPM (approximately 6 G) for 10-15 
minutes.** 
f) Transfer supernatant (serum) to Red-topped (RT) tubes for serum 
chemistry analysis. 
g) Refrigerate serum-filled RT tubes until analysis at 2-5oC. 
h) If excess serum is available after RT tubes are filled, transfer any 
remaining serum to clean 1.5 mL conical vials. 
i) Freeze excess serum at -60 to -80oC until analysis. 
G.2.3. Shipping and Handling of Whole Blood for CBC Analysis and Serum for 
Chemistry Analysis 
1) Place LT (for CBC) and RT (for chemistry) tubes in zip-lock bag(s) of an 
appropriate size. 
2) Place the completed requisition from in the appropriate zip-lock bag(s). 
3) Place the zip-lock bags, containing samples and requisitions, in the provided 
IDEXX drop box. 
4) Place a frozen ice-pack in the IDEXX drop box without samples coming in 
contact with the ice pack. 
a) The ice pack maintains a cool environment within the IDEXX drop box 
until the IDEXX courier is able to collect samples. 
b) Do not freeze CBC or serum chemistry samples. 
5) The IDEXX courier will typically pick up samples in the evening (6-7PM) as 
the last stop before samples are flown to the lab in Dallas. 
a) The courier will refrigerate samples once they are collected. 
6) Both CBC and serum chemistry samples should be run within 12 hr of 
collection. 
 
G.3. Procedure for Tissue Collection 
G.3.1. Lung Collection for Voriconazole Concentration Determination 
1) After blood is collected by cardiac puncture, extract lungs.   
2) Remove adipose and connective tissue.   
3) Place lungs in an appropriate vial and freeze until analysis. 
G.3.2. Lung, Liver, Kidney, and Spleen Collection for Histological Analysis 
1) Place 10-40 mL of 10% formalin in 50 mL sputum vials. 
a) A sufficient volume of formalin should be added to have approximately 
10-20x the organ volume. 
b) Excised organs should be immediately placed in 10% formalin 
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c) All 10% formalin, as well as organs in 10% formalin, should be stored at 
room temperature 
2) Excision and Fixing of Lungs: 
a) Fill a syringe with 3-5mL of 10% formalin 
b) Attach a filter straw to the filled 5mL syringe 
c) After blood is collected by cardiac puncture, make a small incision in the 
trachea without cutting through the trachea. 
d) Insert the tip of the filter straw into the incision in the trachea and slowly 
infuse the lungs with sufficient 10% formalin to inflate the lungs over 1 
minute 
e) With the filter straw still in place, tie the trachea shut with suture and 
withdraw the filter straw 
f) Tighten the suture sufficiently to retain 10% formalin in the lungs.   
g) The inflated whole lungs and heart should then be excised. 
h) Place the inflated lung into 10% formalin 
i) A sufficient volume of formalin should be added to have 
approximately 10-20x the organ volume. 
3) Excision and Fixing of Liver, Kidneys, and Spleen 
a) Liver should be excised and cut into smaller segments (3-5) to allow better 
penetration of 10% formalin into the tissue 
i) Liver pieces could be placed in multiple 10% formalin vials to allow 
for adequate tissue fixing 
b) Spleen should be excised and placed in 10% formalin 
c) Kidneys should be excised, cut along the coronal axis (in half), and placed 
in 10% formalin 
4) Allow organs to remain in 10% formalin for at least 24-48 hours before 
further processing. 
 
*If isoflurane is used for anesthesia prior to sacrifice, elevated glucose levels are likely to 
occur. (see Saha et al. Acute hyperglycemia induced by ketamine/xylazine 
anesthesia in rats. Exp. Biol Med (2005) 230:777-784) 
**The following formula may be used to calculate revolutions per minute (rpm) from g.  
g = (1.12 x 10-5) x r x (rpm)2 where r is the distance from the center of the 
centrifuge head to the base of the tube.   
 
G.4. Chemicals and Supplies 
Heparin Sodium Injection, USP, NDC 0641-0410-02, 10,000 UNITS/mL, 25 x 1mL 
vials, Baxter Healthcare Corporation – Henry Schein Distributor, Item #1105666 
Formalin Solution, Neutral buffered, 10%, 4L per box, Sigma Aldrich, Item #HT501128 
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Lavender-topped (LT) Tubes, BD Microtainer® Tubes with K2E (K2EDTA), 50 per 
pack, BD, Item #365974 
Red-topped (RT) Tubes, BD Microtainer® No additive Tubes, 50 per pack, BD, Item 
#365957 
Syringe – 3mL 21G1, BD Syringe, Sterile, Single Use, Latex Free, Luer-lok, (0.8 mm x 
25 mm), 100 per box, BD Medical Systems, Item #309575 





APPENDIX H: ESTABLISHMENT OF AN IN-HOUSE CONTROL FOR BLOOD WORK AND 
LABORATORY TESTING 
H.1. History 
For the experiments included in Chapter 4, elevations in critical laboratory test 
values, including those hepatic function tests and serum glucose, were noted following 
inhalation of voriconazole as well as inhaled normal saline control compared to the 
reference values provided by IDEXX laboratories and Harlan.  It was suggested that these 




10 male and 10 female Sprague-Dawley rats, Harlan Sprague Dawley, Inc. 
(Indianapolis, IN), with an average mass of 250 g at the beginning of the study, were 
caged separately with free access to food and water.  The animals were not handled or 
manipulated by the investigators.  After 28 days, the rats were transferred to the Necropsy 
Room in the ARC and allowed to return to normal resting behavior.  They were 
euthanized by isoflurane narcosis followed immediately by exsanguination by cardiac 
puncture and thoracotomy.  Whole blood was handled and processed in the same manner 
described in 4.2.4. Blood and Tissue Processing and Testing.  All animals were handled 
and maintained in accordance with The University of Texas at Austin Institution Animal 
Care and Use Committee (IACUC) guidelines and in accordance with the American 
Association for Accreditation of Laboratory Animal Care guidelines.   
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28NDM1 28 ND 1 M 1 200 70 110 3.2 5.7 2.5 0.1 0.1 22 0.5 
28NDM2 28 ND 1 M 2 234 133 271 3.4 6.2 2.8 0.1 0.1 22 0.5 
28NDF1 28 ND 2 F 1 208 274 510 3.3 5.8 2.5 0.1 0.1 23 0.5 
28NDF2 28 ND 2 F 2 243 58 78 3.3 5.7 2.4 0.1 0.1 22 0.5 
28ND3M1 28 ND 3 M 1 247 60 79 2.9 6.1 3.2 0.0 0.0 24 0.5 
28ND3M2 28 ND 3 M 2 207 62 71 3.2 6.3 3.1 0.1 0.1 24 0.5 
28ND4F1 28 ND 4 F 1 174 61 83 3.4 6.7 3.3 0.1 0.1 20 0.4 
28ND4F2 28 ND 4 F 2 127 49 73 3.2 6.9 3.7 0.1 0.1 19 0.5 
28ND5M1 28 ND 5 M 1 220 141 364 3.1 6.3 3.2 0.0 0.0 23 0.5 
28ND5M2 28 ND 5 M 2 188 125 297 3.1 6.3 3.2 0.1 0.1 23 0.4 
28ND6F1 28 ND 6 F 1 177 62 101 3.3 6.6 3.3 0.1 0.1 18 0.5 
28ND6F2 28 ND 6 F 2 156 66 159 3.0 6.3 3.3 0.1 0.1 20 0.5 
28ND7M1 28 ND 7 M 1 186 47 60 3.2 6.4 3.2 0.1 0.1 20 0.4 
28ND7M2 28 ND 7 M 2 191 48 111 3.0 6.1 3.1 0.0 0.0 20 0.5 
28ND8F1 28 ND 8 F 1 186 73 214 3.2 6.3 3.1 0.0 0.0 18 0.5 
28ND8F2 28 ND 8 F 2 139 68 74 3.1 6.1 3.0 0.1 0.1 21 0.5 
28ND9M1 28 ND 9 M 1 225 64 63 2.9 5.8 2.9 0.1 0.1 24 0.5 
28ND9M2 28 ND 9 M 2 210 48 69 3.1 5.8 2.7 0.1 0.1 20 0.5 
28ND10F1 28 ND 10 F 1 113 56 54 3.2 6.5 3.3 0.1 0.1 22 0.4 
28ND10F2 28 ND 10 F 2 121 39 108 3.3 6.5 3.2 0.1 0.1 16 0.5 
High   40 75 4.8 7.6 3 0.5   21 0.8 
IDEXX REFERENCE 
Low   30 45 3.8 5.6 1.8 0.2   15 0.2 
High 196 45 104 3.8 6.6 3 0.13   22 0.4 
HSD REFERENCE 






























































































































28NDM1 28 ND 1 M 1 84 486 12.0 9.7 98 7.2 145 1.3 44.0 0 20 + N 
28NDM2 28 ND 1 M 2 94 285 11.6 9.7 100 7.0 146 1.2 44.0 0 21 + N 
28NDF1 28 ND 2 F 1 91 361 11.3 10.3 102 9.4 141 1.3 46.0 0 15 ++ N 
28NDF2 28 ND 2 F 2 102 357 11.6 10.2 102 5.9 145 1.4 44.0 0 25 + N 
28ND3M1 28 ND 3 M 1 100 478 11.3 10.2 96 5.2 140 0.9 48.0 0 27 ++ N 
28ND3M2 28 ND 3 M 2 78 237 10.7 9.1 98 5.5 143 1.0 48.0 0 26 N N 
28ND4F1 28 ND 4 F 1 100 305 11.0 6.4 99 5.3 141 1.0 50.0 0 27 N N 
28ND4F2 28 ND 4 F 2 105 376 11.7 8.3 96 6.9 142 0.9 38.0 0 21 N N 
28ND5M1 28 ND 5 M 1 85 526 12.1 11.5 98 9.2 139 1.0 46.0 0 15 ++ N 
28ND5M2 28 ND 5 M 2 97 237 10.8 9.5 99 6.6 143 1.0 57.5 0 22 ++ N 
28ND6F1 28 ND 6 F 1 105 230 11.5 8.1 102 5.5 144 1.0 36.0 0 26 N N 
28ND6F2 28 ND 6 F 2 91 378 11.2 8.8 98 6.1 140 0.9 40.0 0 23 + N 
28ND7M1 28 ND 7 M 1 87 275 11.1 8.7 100 5.3 141 1.0 50.0 0 27 N N 
28ND7M2 28 ND 7 M 2 94 303 11.2 9.0 99 6.4 143 1.0 40.0 0 22 + N 
28ND8F1 28 ND 8 F 1 101 226 10.8 9.1 99 5.7 139 1.0 36.0 0 24 ++ N 
28ND8F2 28 ND 8 F 2 109 264 10.7 7.4 99 5.4 140 1.0 42.0 0 26 N N 
28ND9M1 28 ND 9 M 1 81 259 10.7 8.3 100 4.9 140 1.0 48.0 0 29 N N 
28ND9M2 28 ND 9 M 2 77 424 10.5 10.7 100 6.1 140 1.1 40.0 0 23 + N 
28ND10F1 28 ND 10 F 1 113 206 11.5 8.9 99 5.5 142 1.0 55.0 0 26 N N 
28ND10F2 28 ND 10 F 2 89 163 10.4 7.0 101 5.2 140 1.0 32.0 0 27 + N 
High 130 135 13 8.3   5.8 140             
IDEXX REFERENCE 
Low 40 50 5 5.3   3.7 127             
High   112 11.5 9.2 107 6.6 147             
HSD REFERENCE 







































































































28NDM1 28 ND 1 M 1 5.6 8.5 15.8 52.5 62 18.6 30.1 13 81 1 3 2 810 
28NDM2 28 ND 1 M 2 7.7 9.3 16.6 56.2 61 17.9 29.5 12 83 1 2 2 896 
28NDF1 28 ND 2 F 1 5.2 7.1 13.5 44.6 63 19.0 30.2 9 86 1 4 0 414 
28NDF2 28 ND 2 F 2 3.2 7.4 14.4 46.3 63 19.6 31.1 14 83 3 0 0 988 
28ND3M1 28 ND 3 M 1 8.9 8.5 16.1 52.4 62 19.0 30.7 16 79 2 3 1 825 
28ND3M2 28 ND 3 M 2 7.8 9.4 17.6 56.5 60 18.8 31.2 8 89 2 1 0 873 
28ND4F1 28 ND 4 F 1 4.8 8.8 16.0 51.3 58 18.2 31.2 19 79 1 1 0 490 
28ND4F2 28 ND 4 F 2 4.0 7.5 15.3 46.9 63 20.4 32.6 17 70 1 5 7 358 
28ND5M1 28 ND 5 M 1 3.9 8.9 16.4 51.8 58 18.4 31.7 15 78 5 2 0 807 
28ND5M2 28 ND 5 M 2 4.8 8.1 15.9 49.8 62 19.7 31.9 7 90 2 1 0 223 
28ND6F1 28 ND 6 F 1 1.1 5.2 9.7 32.2 63 18.8 30.1 12 74 6 5 4 A 
28ND6F2 28 ND 6 F 2 4.7 9.1 17.7 52.5 57 19.4 33.7 6 90 3 1 0 643 
28ND7M1 28 ND 7 M 1 6.4 9.0 16.7 53.9 60 18.7 31.0 14 83 2 1 1 804 
28ND7M2 28 ND 7 M 2 7.9 8.5 17.0 53.5 63 20.0 31.8 12 86 1 1 0 488 
28ND8F1 28 ND 8 F 1 5.4 9.8 19.3 59.0 60 19.8 32.7 19 77 3 1 0 352 
28ND8F2 28 ND 8 F 2 4.8 8.6 16.3 53.0 61 18.9 30.8 6 93 0 1 0 470 
28ND9M1 28 ND 9 M 1 10.2 8.7 16.0 51.2 59 18.5 31.3 11 84 4 1 1 866 
28ND9M2 28 ND 9 M 2 4.4 9.1 18.4 56.8 63 20.3 32.4 13 84 2 2 0 A 
28ND10F1 28 ND 10 F 1 4.4 8.5 16.0 52.1 62 18.9 30.7 7 85 5 1 1 870 
28ND10F2 28 ND 10 F 2 1.1 5.0 10.3 31.4 63 20.6 32.8 13 67 10 7 4 A 
High   10   48       34 85 5 6 2   
IDEXX REFERENCE 
Low   7   36       9 68 0 0 0   
High 16.1 9.0 17.4 52.4 67 21.2 35.3 25 71 5     1655 
HSD REFERENCE 



































































































































28NDM1 28 ND 1 M 1 728 4536 56 168 112 + +       
28NDM2 28 ND 1 M 2 924 6391 77 154 154   Y B   
28NDF1 28 ND 2 F 1 468 4472 52 208 0 + + Y B   
28NDF2 28 ND 2 F 2 448 2656 96 0 0    B   
28ND3M1 28 ND 3 M 1 1424 7031 178 267 89   Y    
28ND3M2 28 ND 3 M 2 624 6942 156 78 0 + +     
28ND4F1 28 ND 4 F 1 912 3792 48 48 0   Y B   
28ND4F2 28 ND 4 F 2 680 2800 40 200 280 + +   D 
28ND5M1 28 ND 5 M 1 585 3042 195 78 0   Y    
28ND5M2 28 ND 5 M 2 336 4320 96 48 0 + + Y  D 
28ND6F1 28 ND 6 F 1 132 814 66 55 44 + +  C D 
28ND6F2 28 ND 6 F 2 282 4230 141 47 0 + + Y    
28ND7M1 28 ND 7 M 1 896 5312 128 64 64   Y    
28ND7M2 28 ND 7 M 2 948 6794 79 79 0 + + Y B   
28ND8F1 28 ND 8 F 1 1026 4158 162 54 0   Y B   
28ND8F2 28 ND 8 F 2 288 4464 0 48 0 + + Y B   
28ND9M1 28 ND 9 M 1 1122 8568 408 102 102 + +     
28ND9M2 28 ND 9 M 2 572 3696 88 88 0 + +  C D 
28ND10F1 28 ND 10 F 1 308 3740 220 44 44   Y    
28ND10F2 28 ND 10 F 2 143 737 110 77 44 + +   C D 
High 5400 14100 540             IDEXX REFERENCE 
Low 100 2000 0             
High 8800 11560 980             HSD REFERENCE 
Low 0 3190 0             
                
A Decreased             
B PLATELET COUNT REFLECTS MINIMUM VALUE.      
C PLATELET ESTIMATE APPEARS TO BE <10,000      
D ***BLOOD COUNT AND PLATELET EVALUATION AFFECTED BY PRESENCE OF CLOT IN TUBE***  
 
ND = No dose (equivalent to No Treatment), F= Female, M=Male 
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